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resumo As células mononucleares do sangue (CMS) desempenham diversos e 
importantes papéis na monitorização da homeostasia do sistema 
imunitário. Assim sendo, esta subpopulação de células sanguíneas pode 
providenciar acesso a potenciais biomoléculas relevantes a nível 
fisiológico, nomeadamente proteínas. Por esta razão, as CMS 
representam uma amostra biológica promissora na investigação 
científica, particularmente na descoberta de potenciais marcadores 
biológicos de diversas doenças. 
Estudos anteriores de caracterização proteómica das CMS de indivíduos 
saudáveis falharam quer na identificação de um grande número de 
proteínas, quer na sua quantificação, de forma compatível com a 
pesquisa de potenciais biomarcadores. Portanto, este estudo teve como 
objectivo providenciar uma caracterização proteómica abrangente, bem 
como a criação de uma biblioteca SWATH. Foi igualmente avaliado se 
usando tubos CPT™ disponíveis na BD Vacutainer® para o isolamento 
das CMS, seria possível identificar um maior número de proteínas 
imunologicamente relevantes comparativamente a amostras de plasma. 
O teste de enriquecimento revelou que é possível identificar mais 
proteínas associadas ao sistema imunitário em CMS isoladas do que em 
amostras de plasma. Também se verificou que a maioria das proteínas 
quantificadas com ontologia genética “sistema imunitário” estão 
presentes em maior quantidade nas amostras de CMS. 
2D LC-MS/MS mostrou ser a melhor abordagem na análise qualitativa 
das CMS e na elaboração da biblioteca SWATH, uma vez que o número 
de proteínas identificadas e quantificadas apresentou um aumento de 
66,3% e 16,9%, respectivamente, comparativamente à 1D LC-MS/MS.  
No total foram identificadas 2071 proteínas e foi possível quantificar 922 
proteínas diferentes em seis amostras distintas. Destas, 445 proteínas 
eram comuns a todos os indivíduos. 
Em conclusão, este trabalho disponibiliza um amplo conjunto de dados 
do proteoma das CMS que será útil a estudos futuros que pretendam 
centrar-se na pesquisa de potenciais marcadores biológicos, nas CMS, 
das mais diversas patologias. Além disso, comprovou-se que o método 
de aquisição SWATH-MS é reprodutível e eficaz na quantificação das 
proteínas das CMS. 
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abstract Peripheral blood mononuclear cells (PBMCs) play quite diverse and 
important roles in monitoring immune homeostasis. Thus, these subset 
of blood cells may provide access to potential physiological relevant 
biomolecules, namely proteins. For this reason, PBMCs represent a 
promising biological sample in scientific research, particularly as a source 
of potential biological markers discovery of the most diverse diseases. 
Prior studies of proteomic characterization of PBMCs from healthy 
individuals lack either the identification of a large number of proteins or 
its quantification in a way that is compatible with the search of potential 
biomarker candidates. Therefore, this study aimed to  provide a 
comprehensive PBMCs proteome characterisation as well as to create a 
SWATH library. 
It was also evaluated if by using the BD Vacutainer® CPT™ tubes for 
PBMCs isolation, it would be possible to identify a larger number of 
immunologically relevant proteins in comparison to plasma samples. 
The enrichment test assay revealed that it is possible to identify more 
immune-related proteins from isolated PBMCs than from plasma. 
Moreover, the majority of the quantified proteins with an “immune system” 
GO term assigned is present in higher amounts in PBMCs samples. 
2D LC-MS/MS proved to be the best approach to use in qualitative 
analysis of PBMCs and in the construction of a SWATH library, since it 
resulted in an increase of both identified and quantified proteins (66.3% 
and 16.9%, respectively) in comparison to 1D LC-MS/MS.  
A total of 2071 proteins were identified and it was possible to quantify 922 
different proteins among six distinct samples. From these proteins, 445 
were commom between all individuals. 
In conclusion, this work provides a comprehensive PBMCs proteome 
dataset that will be useful in further studies that focus on the search for
potential biological markers of various pathologies in these cells.
Additionally, SWATH-MS proved to be a reproducible and effective 
acquisition method to quantify PBMCs proteins. 
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I.1. Master Thesis’ context 
Schizophrenia (SCZ) is a complex and chronic psychiatric disorder that affects 0.72% of 
world’s population1,2. Patients with SCZ exhibit quite severe and diverse symptoms (e.g. 
hallucinations, apathy, and disorganised speech, among others) that cause a considerable burden 
on patients, their families and society1, and place SCZ in the top 10 of the most disabling diseases 
worldwide3. Although SCZ is highly heritable, the genetic component does not fully explain its 
aetiology. Environmental factors such as pregnancy and delivery complications, urbanicity, and 
migration also play a role in its pathogenesis4. Due to the lack of a biochemical test that allows SCZ’s 
diagnosis, currently this process is based on an interview-based evaluation of patients’ symptoms, 
which onset can vary among patients and through the course of the disease, according to 
international guidelines (e.g. DSM and ICD)5. The subjective and empirical diagnosis is mostly due 
to SCZ’s heterogenic phenotype and the ambiguous boundaries among other mental illnesses5. The 
existing treatment includes psychosocial interventions and medication with the aim of alleviating 
some of the symptoms, reducing both the frequency and the severity of psychosis and improving 
quality of life6. Although there is a wide range of antipsychotics available for SCZ treatment, the 
selection of the best medication is also a challenge for clinicians and involves a long trial and error 
process6 in which a considerable number of patients (>70%) have to interrupt the initial treatment 
due to its inefficacy or intolerable side effects7. The identification of a biological marker (or a set of 
them) that could provide a SCZ’s molecular fingerprint may help clinicians to differentiate between 
psychiatric disorders or to distinguish between SCZ subtypes8. That is, the identification of 
differential biological markers would not only improve its diagnosis, but also the stratification of 
patients8. Moreover, it could help the establishment of treatment strategies, monitoring 
therapeutic response, predicting its progression, and eventually understanding the 
pathophysiological mechanisms underlying the disease8. Thus, the identification of a SCZ molecular 
fingerprint is a step forward in the improvement of patients’ mental health.  
The pathophysiological mechanisms involved in SCZ remain unclear9, however it is known 
that both the structure and the functioning of the brain are altered10–12. Moreover, there are several 
hypotheses involving different neurotransmission systems (e.g. dopaminergic, glutamatergic and 
cholinergic systems) that have been proposed based on decades of research13. In addition to the 
neurotransmission systems’ hypotheses, there are also strong arguments that the immune system 
is altered in SCZ and perhaps it underlies its aetiology14. GWAS revealed significant single nucleotide 
polymorphisms (SNPs) spanning the major histocompatibility complex (MHC) region on 
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chromosome 6p21.3-22.115,16; several studies found alterations in different cytokines, cytokine 
receptors and antagonists in both blood and cerebrospinal fluid (CSF)17–20, with some of the 
observed alterations being associated with different SCZ status; abnormalities in peripheral 
lymphocyte and monocyte levels21,22; some patents with SCZ showed microglia activation23; and the 
antibody production in these patients is higher when comparing to healthy controls24, specifically 
antibodies against specific brain regions, and against neurotransmitter receptors25,26 which can 
provide an important connection between immune impairments and altered neurotransmissions.  
I.2. Peripheral blood mononuclear cells  
As the name suggests, peripheral blood mononuclear cells (PBMCs) concern the blood cells 
that have a round nucleus, in contrast to those that have a multilobed nucleus. This subpopulation 
consists of lymphocytes (T lymphocytes, B lymphocytes and natural killer (NK) cells) (70-90%),  
monocytes (10-30%), and dendritic cells (≈1%)27.  
Lymphocytes consist of diverse subsets that differ in how they recognize antigens and in 
their function. T and B lymphocytes are the unique cells of the adaptive immunity. Once naive B 
cells recognise antigens by membrane-bound antibodies, they undergo a humoral immune 
response, become active, and differentiate into plasma cells that segregate antibodies of the same 
specificity as the antigen receptor. T lymphocytes form a group of functionally distinct cells 
comprising helper T cells (Th cells), cytotoxic cells (Tc cells), and regulatory T cells (Tregs). The CD4+ 
Th cells are the orchestrating cells of the immune response and play an important role helping 
phagocytic cells. Tc cells (CD8+) are responsible for killing body cells infected with virus or bacteria, 
or that are eventually damaged or dysfunctional, and the function of CD4+ Tregs is to inhibit immune 
responses (i.e. maintenance of self-tolerance). NK cells are involved in the innate immune response 
and their major function is to kill infected cells and produce interferon-gamma (IFN-γ) which 
activates macrophages to destroy phagocytised microbes. These cells can be identified by 
expression of CD56 and the absence of the T cell marker CD322,27. 
Monocytes can be divided into two classes: the so-called classic monocytes that produce 
abundant inflammatory mediators and are rapidly recruited to sites of infection or tissue injury, 
and the non-classical monocytes (NCM) that contribute to tissue repair after injury. These cells are 
identifiable by high cell surface expression of CD14 and lack of CD16 (CD14++CD16-), and 
CD14+CD16++, respectively27. 
INTRODUCTION | 5 
 
Dendritic cells (DCs) are the most specialised antigen-presenting cells and play a crucial role 
in the interphase between the innate and adaptive immune system. Classic or conventional 
dendritic cells carry antigens from the infection site to the lymph nodes and present it to the 
adaptive immune system’s cells. DCs in cooperation with the MHC class II molecules and the co-
stimulatory CD80 and CD86 molecules stimulate the naïve cells of the adaptive immune system, 
which will consequently proliferate and become active22,27. Plasmacytoid dendritic cells (pDC) are 
responsible for an early response to viral infections. This subpopulation of DCs recognize nucleic 
acids of intracellular viruses and produce soluble proteins, type I interferons, which have an 
effective antiviral activity27. 
I.2.1.  PBMCs as a source of  biomarkers  
A biomarker is a measurable feature that allows to distinguish between normal biological 
processes, pathological processes or pharmacologic responses to a therapeutic intervention28. This 
feature can be a gene, RNA, protein, its post-translational modifications (PTM), lipid or metabolite, 
what means that practically any human body molecule is a potential biomarker candidate (PBC) as 
long as it can be associated with a disease8,29. However, some authors suggest that PBCs pursuit 
should focus on proteins, once they are the true effectors of physiological functions8, and it is also 
claimed that the proteome is more related to the phenotype of an organism than genes are30. As a 
pathological state modifies the protein levels of a normal physiological state the study of such 
alterations can provide new insights into the pathophysiological pathways underlying a given 
disease8. Therefore, proteomics is an extremely valuable tool to study different diseases and to 
search for PBC, namely SCZ31,32, since it can provide a molecular characterisation of a given sample 
(e.g. cells or tissues) in a large-scale and in a high-throughput manner33. Indeed, this approach has 
been providing molecular signatures of this illness34,35. However, to my knowledge, these two 
studies have not yet been applied in clinical practice, probably because they did not provide a high-
quality biomarker. Moreover, these studies used a target proteomic approach, more specifically an 
immunoassay. This approach limits the discovery of biomarkers since the study was performed 
against proteins for which the immunoassay was developed. Using a non-targeted approach such 
as shotgun proteomics it is possible to identify thousands of proteins and thus to provide a better 
biological fingerprinting for SCZ, however with a more complex and time-consuming data analysis36. 
In PBCs discovery, it is important to know not only what to look for (e.g. proteins, 
metabolites, etc.) but also where to look for, that is, what type of sample use as a source of PBCs. 
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Plasma has been widely used in PBCs discovery since it is easily obtained from living patients in 
large amounts37. Its proteome comprises 22 highly abundant proteins (e.g. albumin, 
immunoglobulins, among others) that make up 99% of total protein abundance in plasma. This  
wide dynamic range in protein abundance (greater than 10 orders of magnitude) makes it 
impossible to detect low abundant proteins without a depletion step of the most abundant 
proteins38, and low abundant proteins might be the key to understand pathophysiological pathways 
of some diseases (e.g. psychiatric disorders)39. As PBMCs play different and important roles in the 
immune system, monitoring and responding in an inflammatory manner, they provide access to 
potential physiological relevant biomolecules40,41. Moreover, PBMCs are also easily and rapidly 
isolated from whole blood (WB), which means that they can be obtained through a low-invasive 
method of collection (i.e. blood drawing) without the interference of human plasma due to the 
presence of highly abundant proteins38. For this reason, PBMCs have been used in scientific 
research to study the most diverse diseases such as stroke42, amyotrophic lateral sclerosis43 and 
psychiatric disorders32,44,45. Therefore, PBMCs may be a source of PBC for diagnosis and monitoring 
of many diseases, representing an alternative to plasma samples. Regarding psychiatric disorders, 
specifically SCZ, the first thing that comes to mind when thinking of biomarkers source is living brain 
tissue, but the use of this biopsies in scientific research is impracticable, thus post-mortem brain 
tissue has been widely used in SCZ studies46. However, artefacts arising from chronic medication, 
the cause of death and the post-mortem interval47,48 may hinder the interpretation of the obtained 
results, once the observed alterations might be due to the disease itself or a consequence of the 
chronic therapy. Therefore, the use of peripheral samples (e.g. blood, urine and others) provides a 
valuable alternative once it can be obtained from living patients, through the course of the disease, 
and in large amounts44,49. Furthermore, searching for biomarkers on blood allows the use of a 
standardized low invasive sample collection procedure49. Different studies have been conducted to 
find out if CNS alterations can actually be observed in the blood stream and it was discovered that 
brain is integrated in fundamental biological functions of the whole body which is confirmed by 
modifications in blood molecular composition50. Different authors compared the gene expression 
in blood and in brain, and found out that blood gene expression is significantly identical to that of 
CNS tissues51,52, namely approximately 50% of the so-called SCZ susceptibility genes are shared by 
these tissues51. Particularly, PBMCs can be a valuable source of biomarkers for SCZ40,45,52 and since 
they represent an important cellular component of the immune system, they can provide a suitable 
model to study SCZ-related immune impairments44. Indeed, Gladkevich et al. argue that 
lymphocytes, a PBMCs subpopulation, may actually be a neuronal probe in the investigations of 
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CNS pathology in psychiatric disorders, once they play a fundamental role in the interactions 
between CNS and the immune system. Such affirmation is supported by three observations: i) 
impaired lymphocyte functions in psychiatric diseases; ii) expression of neuroactive proteins in 
lymphocytes; and iii) similarities of hormonal effects on the CNS processes and lymphocytes 
physiology45.  
In biomarker discovery, it is essential to know not only which proteins are present in a given 
sample, but also its expression levels that is, it is crucial to quantify the difference among different 
samples (i.e. disease vs. control samples). Therefore, besides the qualitative protein analysis, it is 
equally important if not more, a quantitative analysis of the identified proteins53. After the 
identification of a PBC (or a set), it is mandatory to validate it in repeated studies and in a large 
number of samples so that it can be used in clinical environment. Immuno-based assays, such as 
Western blot and enzyme-linked immunosorbent assay (ELISA) are the most frequently used 
techniques, but both methods require the availability of specific antibodies. Another possibility is 
to perform a mass spectrometry (MS)-based technique, selective reaction monitoring (SRM), which 
allows an accurate measurement of the relative or absolute concentration of the previous identified 
PBC31.  
I.3. Proteomics 
In 1995 Wilkins et al. proposed the concept of proteome defining it as “the entire PROTEin 
complement expressed by the geneOME, or by a cell or tissue type”54,55 and consequently emerged 
a new field of science: proteomics. As the word suggests, proteomics is the study of the proteome, 
that is the study of different protein characteristics (i.e. expression level, PTMs and others) on a 
large scale to characterise biological processes (e.g. diseases)56,57. 
Nowadays, there are two fundamental approaches used in proteomics: bottom-up and top-
down. Bottom-up proteomics (also known as shotgun proteomics) requires simple or complex 
protein mixtures to be digested, the resulting peptides are then separated by liquid 
chromatography (LC) and analysed by MS (Figure I.1.). In top-down strategy, intact proteins are 
directly analysed by MS and subjected to fragmentation in the mass spectrometer. In both 
approaches proteins are identified by comparing the mass spectra obtained with theoretical 
spectra based on protein databases53.  
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Since biomarkers discovery is based on proteomic differences between samples (i.e. control 
and disease samples), besides proteins identification it is also extremely important to perform a 
quantitative approach53. Protein quantification can be performed by label-free strategies, such as 
SRM and SWATH59. Both approaches require previous generation of reference spectral maps to 
perform quantification however, SRM is based on a target data acquisition whereas SWATH is based 
on an untargeted data acquisition and targeted data extraction59. Another way to quantify proteins 
by MS is to label the samples. Techniques like ICAT, iTRAQ, SILAC and H218O labelling can be 
employed yet, all of these methods are quite expensive due to the use of isotopic reagents, or 
require protein labelling during protein synthesis (SILAC) not amenable for use with human 
samples53. 
I.3.1.  Sample preparation  
In proteomics, the most important step is sample preparation as it determines the coverage 
of the target proteome achieved. As protein classes differ between different types of tissues/cells 
it is mandatory to adjust the extraction protocol to the tissue/cells in the study31.  
 
Figure I.1. Generic MS-based 
proteomics experiment. The classic 
proteomics approach consists of five 
stages. In stage 1, the proteins to be 
analysed are isolated from cell lysate 
or tissue, which usually includes a 
final step of one-dimensional gel 
electrophoresis. After that, the 
proteins are enzymatically digested, 
typically with trypsin (stage 2). The 
resulting peptide mixture is 
separated by high-performance 
liquid chromatography and its 
molecular weight determined by 
mass spectrometry (stage 3). In 
stage 4, the software generates a 
prioritized list of the peptides for 
fragmentation in a series of tandem 
mass spectrometric (MS/MS) 
experiments. Finally, the resulting 
spectra are matched against protein 
sequence databases so it is possible 
to identify the peptides and thus the 
proteins (stage 5). Adapted from58. 
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The protein concentration range in a complex biological sample typical exceeds the 
dynamic range of any currently available analytical method,  therefore it is useful to decrease its 
complexity by prefractionation of the sample, or to perform an enrichment step of the target 
proteins60. In this master’s thesis project, the BD Vacutainer® cell preparation tube (CPT™) will be 
used in order to sub fractionate blood and isolate PBMCs. As described by the manufacturer, CPT™ 
is an evacuated tube that allows both the collection of WB and the separation of PBMCs in a single 
centrifugation step. The tube contains sodium citrate as anticoagulant, a FICOLL™ Hypaque™ 
density solution, and a polyester gel barrier. During centrifugation, the gel fraction moves and forms 
a barrier separating PBMCs and plasma from denser blood cells (erythrocytes and granulocytes). 
The use of this simplified procedure is an advantage for inexperienced operators in Ficoll density 
gradient handling and results in improved consistency among different operators61.  
After prefractionation, the cells must be disrupted either by mechanical or chemical 
methods so then the proteins can be solubilised60. If proteins are not properly extracted and 
solubilised, they will not be identified nor quantified, hence this step may compromise the whole 
experiment31. Protein solubilisation may involve the use of detergents (e.g. SDS, Triton X-100 or 
CHAPS) which disrupt hydrophobic interactions, reducing agents (e.g. DTT or TCEP) to break 
disulphide bonds between cysteine residues, and protease inhibitors (e.g. PMSF or EDTA) to 
prevent protein degradation60. 
In shotgun proteomics approach, there are two main strategies that can be used to simplify 
a complex biological sample and obtain a peptide solution proper to MS analysis: in-gel and in-
solution digestion62. The so-called in-gel digestion consists in the separation of proteins by gel 
electrophoreses (usually SDS-PAGE) to decrease sample’s complexity53. After that, the gel-trapped 
proteins must be digested, usually with trypsin, an enzyme that cleaves the C-terminal side of lysine 
and arginine residues63. The other strategy consists in performing protein extraction with strong 
chaotropic reagents (e.g. urea and thiourea), precipitate them and then digest proteins under 
denaturing conditions (in-solution digestion)62. 
I.3.2.  LC-MS/MS 
Liquid chromatography coupled with tandem mass spectrometry (LC-MS/MS) has 
increasingly become the method of choice in proteomic studies31. Chromatography is a powerful 
tool for the separation of different compounds in a complex mixture, but it clearly lacks unequivocal 
identification of such molecules, even when retention times are different. On the other hand, mass 
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spectrometry allows the identification of many compounds with a high degree of confidence, 
although analysing a complex mixture by MS can be problematic, especially in the identification of 
molecules present in low concentration. Thus the combination of LC, which allows the separation 
of peptides reducing sample complexity, with the identification potential of mass spectrometry is 
extremely advantageous, mostly because different compounds with close retention times can have 
different mass spectra making it  possible to distinguish and identify them64. 
As the system that was used in the development of this project is a high-performance liquid 
chromatograph coupled to a hybrid quadrupole time-of-flight (QqTOF) mass spectrometer with an 
electrospray ionization source, only features related to this instrument will be discussed in the 
following sections. 
I.3.2.1.  High-Performance Liquid Chromatography  
High-performance liquid chromatography (HPLC) is currently established as the leading 
technique for the separation and purification of a wide range of molecules including peptides and 
proteins. The success of HPLC is due to a vast number of inherent characteristics related to 
reproducibility, simplicity of selectivity manipulation, and usually high recoveries65. 
In a chromatographic separation, the compounds present in a complex mixture are 
resolved according to their interaction with the stationary phase and depending on the extent of 
the interaction, it takes different times for them to move from the initial position to the detector. 
To ensure a constant flow rate and therefore a reproducible chromatography, the mobile phase is 
a liquid delivered under high pressure (usually up to 400 bar), whereas the stationary phase is 
packed into a column capable of withstanding the high pressures64.  
Reversed-phase chromatography (RPC) is perhaps the most commonly used method for 
peptides separation. This category of chromatography depends on the hydrophobic interaction of 
the solute molecule from the mobile phase to the immobilized hydrophobic ligands attached to the 
stationary phase (i.e. the sorbent). The sorbent consists of a functional group (usually n-alkyl 
groups, such as C18 molecules which is widely used for the fractionation of peptides) bound to silica 
from which the solutes are eluted with a gradient of increasing concentrations of an organic solvent 
(e.g. acetonitrile) containing an ionic modifier (e.g. formic acid)65.  
Proteomic analysis of peptide mixtures from complex biological samples largely exceeds 
the capacity of 1D chromatography, making it necessary to adopt multidimensional separation 
approaches, once increasing peptides separation results is the identification of more peptides and 
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consequently more proteins66. Several approaches can be applied to improve proteome coverage 
however, RPC at high pH coupled with RPC at low pH has proved to give best orthogonality over 
other 2D-LC combinations (e.g. SCX with pH gradient followed by RPC at low pH)67. 
I.3.2.2.  Mass Spectrometry  
Mass spectrometry is an analytic technique that allows both qualitative and quantitative 
information of a molecule, by separation of ions according to their mass-to-charge (m/z) ratio. The 
principle of MS analysis consists of three major steps: i) ionization of the molecules that are 
converted into gas-phase ions; ii) resolving ions according to their m/z ratio; and iii) detection of 
the ions, which consists in the conversion of the registration of the number of ions at each m/z 
value into a mass spectrum (i.e. a plot of ions relative abundance versus m/z ratio). In proteomic 
approaches there are two main classes of ions detected in MS experiments, molecular ions, which 
contain the entire analyte molecule, and fragment ions, which contain a portion of the structure. 
The molecular weight of an analyte is determined by the m/z of a molecular ion – if z is known – 
while some structural information can be determined by the fragmentation spectra58,64.  
In Figure I.2. it is shown the basic components of a mass spectrometer, which includes a 
sample inlet (e.g. a liquid chromatograph or a direct insertion probe), an ion source, a mass 
analyser,  a detector,  the instrument control, data and vacuum systems. The mass spectrometer 
must operate under vacuum conditions so that the generated ions reach the detector, because the 
 
Figure I.2. Basic components of a mass spectrometer. The mass analyser, the detector and some parts of the ion 
source are kept under vacuum conditions. The instrument control system monitors and controls the whole instrument. 
The produced data are recorded by the data system. Adapted from63.  
Inlet Ion source Mass 
analyser 
Detector 
Data system 
 
Instrument 
control 
system 
Vacuum system 
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average distance travelled by an ion between collisions (i.e. the mean free path) at atmospheric 
pressure is about 10-8 m. Reducing the pressure results in an increased mean free path around 10 
m, and so the ions reach the mass spectrometer detector64. 
I.3.2.2.1.  Ionization  
There are different methods that allow the ionization of molecules including electron 
ionization (EI), chemical ionization (CI), fast-atom bombardment (FAB), electrospray (ESI), MALDI, 
and others. However, ESI (Figure I.3.) is the most suitable ionization method for LC-MS analysis of 
peptides64. This method consists in an acidic, aqueous solution containing the peptides to be 
sprayed through a metallic capillary to which a potential difference (2-5kV) is applied. This results 
in the production of a Taylor cone from which droplets of the solution are sputtered. Protons from 
the acidic conditions confer a positive charge to the droplets, causing them to move from the 
needle towards the instrument, which is negatively charged in relation to the needle. The size of 
the charged droplets decreases by desolvation, which is assisted by a continuous counter flow of a 
drying gas, usually nitrogen, that goes in the opposite direction to that of the droplets. As a result, 
the repulsive forces between equal charges on the surface of the droplets overcome the cohesive 
forces of surface tension and a Coulombic explosion occurs, producing charged microdroplets. This 
process is repeated until ions of the peptides are desorbed into the gas-phase, where they can be 
directed into the mass spectrometer by appropriate electric fields63,64. 
 
Figure I.3. A generalized view of the electrospray ionization process. Sputtered charged droplets from a Taylor cone 
are desolved by a continuous flow of N2, leading to the formation of ions that enter the mass spectrometer. Adapted 
from63. 
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I.3.2.2.2.  Mass Analyser  
The mass analyser determines the m/z of the generated ions and there is a variety of mass 
analysers available, mainly quadrupole, ion trap, orbitrap, time-of-flight (TOF), magnetic sector, and 
Fourier transform ion cyclotron resonance (FT-ICR). Parameters such as resolution, accuracy, 
precision, speed of data acquisition, sensitivity, and m/z range of the mass analyser should be taken 
into account when choosing the instrument. Regarding the above mentioned features, quadrupole, 
ion trap, orbitrap and TOF mass analysers are the most frequently used in high-throughput 
proteomics experiments because they outperform the other mass analysers63.  
Quadrupole analysers are composed of four rods (poles) arranged as two sets of two 
electrically connected rods (Figure I.4.). A combination of radiofrequency (RF) and direct current 
(DC) is applied to each pair of rods. At a specific value of RF and DC, ions of a particular m/z follow 
a stable trajectory from the beginning of the mass analyser until the end of the mass analyser, while 
ions with other m/z have unstable trajectories and do not reach the end of the mass analyser. If a 
detector is available after the quadrupole, the mass spectrum is acquired by varying the RF and DC 
voltages such that an increasing m/z is selected to pass through the quadrupole and reach the 
detector. This analyser can also be set up to contain and transmit ions of all m/z by applying an RF-
only field63,64. 
 
Figure I.4. Schematic representation of a quadrupole 
mass analyser. Four poles are arranged in two sets of 
opposing rods. An electric field with RF and DC 
components is applied in one set of rods, and according to 
the symmetric equation in the second set of rods. Ions of 
a given m/z follow a stable trajectory and reach the end of 
the mass analyser (blue), while ions with other m/z values 
do not reach the end of the mass analyser (red). Adapted 
from63. 
As the name suggests, a TOF analyser (Figure I.5.) measures the time required for an ion to 
travel the length of the flight tube. A fixed amount of kinetic energy is given to an ion by acceleration 
in an electric field that is generated by the application of a high voltage (typically between +20 kV 
and +30 kV for positive ions such as peptides). After acceleration, the ion enters a field-free region, 
travelling at a velocity that is inversely proportional to the square root of its mass. This means that 
ions with low m/z travel faster than ions with a higher m/z63. The initial velocities of the ions as they 
are accelerated may differ and therefore the resolution of the TOF analyser is compromised. It is 
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possible to reduce the effects of such initial energy spread using longer flight tubes and higher 
accelerating voltages. Another method is to use an ion reflector (also referred as a reflectron). It 
consists of an ion mirror that reverses the flight path of the ion in order to focus ions with the same 
m/z but different velocities. Ions with the same m/z but different velocities penetrate the reflectron 
to different levels (i.e. higher velocity ions penetrate farther than lower velocity ions), adjusting 
velocity differences63.  
 
 
 
 
Figure I.5. Schematic representation of a reflector 
time-of-flight instrument. Ions are accelerated to 
high kinetic energy and are separated along a flight 
tube because of their different velocities. The ions 
are reflected in a reflectron, which compensates 
for slight differences in kinetic energy, and reach 
the detector that amplifies and counts the ions. 
Adapted from58. 
I.3.2.2.3.  Tandem Mass Spectrometry  
Tandem mass spectrometry (MS/MS) is a two-step mass analysis. A first analyser is used to 
isolate an ion with a specific m/z that is then fragmented and the m/z of the fragment ions (also 
known as product ions) is determined in a second stage of mass analysis (Figure I.6.). The acquired 
MS/MS spectrum is thus a record of m/z values and relative intensities of all the resulting fragment 
ions generated from an isolated precursor ion. It is the information derived from the product ions 
spectra that allows structure characterization of an analyte63. Collision-induced dissociation (CID) is 
the most common process to fragment ions. The mass-selected ion in the first analyser is 
transmitted to a high-pressure region (i.e. collision cell) where it undergoes a number of collisions 
with the neutral gas molecules (usually nitrogen or a noble gas) contained in that region. When the 
ion collides with the gas molecules part of the kinetic energy of the ion is converted into internal 
energy. It turns into an unstable ion inducing fragmentation reactions and the resulting fragment 
ions are analysed in the second stage of mass analysis63. 
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A QqTOF instrument (Figure I.7.) is widely used in protein identification. The first mass 
analyser is a quadrupole and the second mass analyser is a TOF. The collision cell is surrounded by 
lens system so that it is possible for collisions to occur while it contains and transmits ions of all m/z 
to the second stage of mass analysis. In this type of tandem mass spectrometer both mass and 
product ion spectra are recorded by the TOF analyser63.  
The tandem mass spectrometer can operate in different scan modes. In the standard mode 
of mass analysis, the first mass analyser and the collision cell transmit all ions that are analysed in 
the second mass analyser. To determine the amino acid sequence of a peptide a product ion scan 
is performed: the chosen ion is mass-selected in the first mass analyser and fragmented in the 
collision cell. The generated ions are scanned in the second mass analyser63.  
 
Figure I.6. Tandem mass spectrometry experiment. A precursor ion is selected in the first mass analyser and 
fragmented by collision with a neutral gas. The fragment ions are analysed in the second stage of mass analysis to 
produce a product ion spectrum. Adapted from63. 
 
 
 
 
 
 
 
Figure I.7. Schematic representation of a 
hybrid quadrupole-time-of-flight instrument. 
Ions of a certain m/z are selected in a first 
section (Q1), fragmented in a collision cell (q2), 
and the fragments are separated in a reflector 
TOF. Adapted from58. 
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I.3.2.2.4.  SWATH-MS 
As mentioned above, protein quantification by MS can be done either by label or label-free 
methods53,59. In this project, a recently developed method of label-free quantification designated 
as SWATH (sequential window acquisition of all theoretical fragmentation spectra) was used. This 
approach requires the use of a fast-scanning, high resolution QqTOF mass spectrometer (TripleTOF 
5600TM, AB Sciex®) and combines high specificity of the data-independent acquisition (DIA) method 
with a novel targeted data extraction strategy59,68. 
SWATH consists in the selection of overlapped sequential precursor ion mass windows of a 
specific width covering an m/z range (Figure I.8.). The precursor ions selected are then fragmented 
and the ensemble of these fragment ion spectra as complex fragment ion maps is recorded. The 
peptides are converted into a high-resolution digital map consisting of fragment ion spectra, which 
derived from the fragmentation of all precursor ions present in the sample in a determined m/z 
ratio at a certain time. The use of such scans increases the complexity of the analysis of the acquired 
data sets, once the link between the fragment ions and the precursors from which they derive is 
lost59,68.  
The acquired fragment ion maps are queried for the presence and quantity of specific 
peptides of interest, using a priori information contained in reference spectral libraries (i.e. the 
fragment ion signals, their relative intensities, retention time, etc.)68. The quantification is based on 
the peak areas of extracted ion chromatograms (XIC), which are computationally reconstituted 
from the merged spectra on the basis of both experimental and in silico generated spectral 
information69. 
 
Figure I.8. Schematic representation of SWATH-MS acquisition. In this data-independent acquisition method data are 
acquired by repeatedly scan through sequential precursor ion mass windows of 25 Da width in a quadrupole mass 
analyser (Q1). The selected ions are then fragmented in the collision cell (q2) and transmitted to the TOF analyser where 
the fragment ions are measured. The quantification is achieved through the peak areas of XICs of each precursor ion. 
Adapted from59. 
 
INTRODUCTION | 17 
 
I.3.3.  Bioinformatics  
Proteomics studies generate large data sets so manual interpretation of the acquired 
spectra is not practicable. Thus, it requires the use of software tools that compares experimental 
spectra with theoretical ones, generated by protein sequences stored in protein databases as well 
as by in silico digestions, to find a match. The software overlaps experimental and theoretical 
spectra and gives a score based on the similarity of the spectra. This results in a sorted list of the 
candidate proteins. The score awarded must take into account several features such as 
dissimilarities in the peak position due to internal or calibration errors, modified amino acids, 
expected peak intensities, noise, contaminants, missing peaks and others. There are different score 
schemes used in various algorithms, resulting in different software available to protein assignment 
(e.g. Mascot, SEQUEST, ProteinPilot, etc.), that resort to protein databases (e.g. UniProt, NCBI, 
etc.)70,71. 
Once identified and quantified the altered proteins it is crucial to proceed to their biological 
interpretation. The Gene Ontology (GO) project provides controlled and structured vocabulary (i.e. 
ontologies) and classifications to describe key domains of molecular and cellular biology that can 
be used in the annotation of genes, gene products, and sequences. GO classifies gene products 
according to three categories: i) molecular function, which describes activities that occur at the 
molecular level (e.g. kinase activity); ii) biological process, which describes series of biological 
events accomplished by one or more organized assemblies of molecular functions (e.g. cell 
proliferation);  and iii) cellular component, which describes subcellular locations and 
macromolecule complexes (e.g. nucleus)72. GO vocabulary is widely used in enrichment analysis 
(i.e. the identification of GO terms that are significantly over or under represented in a given set of 
proteins) and there are different tools available to carry out this analysis including, Gene Ontology 
enRIchment anaLysis and visuaLizAtion tool (GOrilla)73, GoMiner74, Database for Annotation 
Visualization and Integrated Discovery (DAVID)75, AmiGO76, etc. Another useful bioinformatic tool 
for biological interpretation is the Protein Analysis Through Evolutionary Relationships (PANTHER) 
classification system which provides proteins classification according to their function77. 
I.3.4.  Proteomic studies  of PBMCs 
The search of “peripheral blood mononuclear cells” AND “proteomics” terms on PubMed 
database turned into 106 results. The majority of the studies are related to different diseases (e.g. 
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stroke42, amyotrophic lateral sclerosis43, and systemic lupus erythematosus78 among others) and 
only four aimed to characterise PBMCs’ proteome of healthy individuals. One of these studies 
yielded 174 proteins identified by MS/MS analysis of 246 two-dimension electrophoresis (2-DE) gel 
spots79. Maccarrone et al. used a shotgun-MS approach resulting in the identification of about 1090 
proteins, but only approximately 685 were identified by at least two non-redundant peptides with 
maximum false identification rate set to 5%80. In the latest study the authors tried different LC-
MS/MS analyses with or without strong cation exchange chromatography (SCX) fractionation, 
reaching a total of 49 different runs, that leaded to the identification of 4129 protein groups40. In 
this article, the authors claim that the stablished method is proper to significantly extend the 
molecular markers of specific activation states of PBMCs however, it is not compatible with PBC 
discovery since the amount of protein needed per sample (300 µg) may not be possible to obtain. 
Moreover, running a sample in 49 different methods drastically increases both the time and the 
costs of the analysis. Haudek-Prinz et al. characterised the proteome signature of inflammatory 
activated PBMCs by 2D-PAGE or SDS-PAGE followed LC-MS/MS analysis, comprising 1497 
proteins41. Furthermore, when looking to references of articles from related topics another one was 
found. In this study the authors identified 1168 proteins, from which 678 were identified by 
shotgun-MS and 490 by LC-MS/MS preceded by 2-DE81. 
Regarding proteomic studies of PBMCs of schizophrenic patients, 65 results were obtained 
after searching on PubMed database the terms “peripheral blood mononuclear cells” AND 
“schizophrenia”. Of these, only twelve articles were related to proteins study and three of those 
studies aimed to uncover the effects of antipsychotic medication on PBMC82–84. From the remaining 
nine, eight of them intended to verify the levels of specific proteins and were based on 
immunoassays (e.g. ELISA, Western blot, and others)85–92. In the remaining study a shotgun 
proteomic approach was used resulting in the identification of 185 cytosolic proteins by LC-
MS/MS93. 
It is clear that prior studies of PBMCs proteomic characterisation, from both healthy 
controls and schizophrenic patients, lack either in the identification of a large set of proteins or in 
its quantification. This highlights the need for a wider proteomic characterisation of PBMCs 
proteome. Such improvement would result in a better understanding of the normal physiological 
protein state of these cells, so it can be later compared to that of different patients, namely patients 
with SCZ, and thus contribute to a deeper knowledge of the immune impairments in patients with 
SCZ. 
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I.4. Flow cytometry 
Flow cytometry is a technique that measures optical and fluorescence properties of 
particles (e.g. single cells, nuclei, chromosomes, and other particles that can be suspended in a 
fluid) flowing in a liquid stream through a beam of light94,95. The characteristics measured (e.g. 
relative size, internal complexity, and relative fluorescence intensity) are determined by an optical-
to-electronic coupling system that records how the particle scatters incident light (typically from a 
laser) and emits fluorescence94. A flow cytometer (Figure I.10.) is made of four main elements: i) a 
fluid system to transport particles in a stream to the focused light beam; ii) an optical system that 
consists of light to illuminate the particles in the sample stream and optical filters to direct the 
resulting light signals to the appropriate detectors; iii) an electric system to detect light signals and 
converting it to electronic signals that are proportional to light intensity, and iv) a computer for 
data recording and analysis94,96. Once inside the flow cytometer, the sample is drawn into a stream 
created by a surrounding sheath fluid that creates laminar flow, allowing the particles in suspension 
to pass individually through an analysis point. At the analysis point, a beam of monochromatic light 
intersects the particles that emit light in all directions, and then the light is collected via optics that 
direct the light to a series of filters and dichroic mirrors that isolate particular wavelength bands. 
The light signals are detected by photomultiplier tubes and converted to electronic signals that are 
recorded and analysed in a computer. The resulting data is commonly displayed in univariate 
histogram or 2D dot-plot formats (to show correlation between two parameters)94–96. 
Blood cells, namely PBMCs, express certain surface proteins that can be used in its 
immunophenotyping. These proteins are known as cluster of differentiation (CD) and allow 
distinguishing between different blood cells. This powerful technology has increasingly become the 
method of choice for the analysis of cellular phenotype and function of the immune system. 
Typically, in immune phenotyping, antibodies conjugated to fluorescent dyes bind specific proteins 
on cell surface. As labelled cells pass through the light source, fluorescent molecules are exited and 
when returning to the stationary state the emitted fluorescence is recorded95. The use of multiple 
fluorochromes (with similar excitation wavelengths and different emission wavelengths) allows 
several cell properties to be measured simultaneously. This peculiarity permits the characterization 
of subsets of cells in a complex mixture (e.g. blood) in a way that is not possible using bulk assays 
(e.g. Western blot and ELISA)95,97. 
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Figure I.10. Schematic representation of a flow cytometer. A particle suspension is hydrodynamically focused with 
sheath fluid to intersect a laser. Signals are collected by a forward angle light scatter detector, a side-scatter detector 
(1), and multiple fluorescence emission detectors (2– 4). The signals are amplified and converted to digital form for 
analysis and display on a computer screen. 
 
 
 
 
 
 
 
 
 
II. Objectives 
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PBMCs correspond to an important part of the immune system that play different and 
important roles in monitoring immune homeostasis. Therefore, these subset of blood cells may 
provide access to potential physiological relevant biomolecules, particularly proteins. Moreover 
they are easily isolated from WB, which in turn can be obtained through a non-invasive method and 
in large amounts. For this reason, PBMCs represent a promising biological sample in scientific 
research, namely as a source of PBC discovery of the most diverse diseases. 
Prior studies of proteomic characterization of PBMCs from healthy individuals lack either 
the identification of a large set of proteins or the quantification of those proteins in a way that is 
compatible with the seach of PBCs. Thus, the aim of this master’s thesis project is to provide a 
comprehensive proteome characterisation of PBMCs contributing to improve the existing 
databases and the creation of a SWATH library. In addition, it will be assessed if there is an 
enrichment of immune system proteins in isolated PBMCs comparing to plasma, and it is also 
suggested the analysis of the main PBMCs subpopulations by flow cytometry to supplement the 
biological information obtained by the proteomic screening.  
In order to achieve it, the following tasks are proposed: i) comparing PBMCs and plasma 
proteomes, ii) identifying PBMCs proteins by LC-MS/MS and creating a SWATH library, and iii) 
analysing PBMCs subpopulations by flow cytometry. 
 
 
 
 
 
 
 
 
 
 
 
 
 
III. Methods & Materials 
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III.1. Samples collection and processing  
III .1.1.  Samples for  the enr ichment test  
To evaluate if there is an enrichment of immune system proteins in isolated PBMCs three 
different samples were analysed: PBMCs, plasma depleted from PBMCs, and plasma still with 
PBMCs (P+C). Blood from healthy volunteers was collected into 8 ml Vacutainer® CPT™ (BD) 
containing sodium citrate as anticoagulant and the CPTs were processed according to the 
manufacturer’s instructions. After blood drawing and gently inversion of the CPTs, the tubes were 
centrifuged at 1650×g for 30 minutes (Centrifuge 5810 R, Eppendorf) at RT within two hours of 
blood collection. CPTs were gently inverted and the mixture of PBMCs and plasma was transferred 
into a centrifuge tube (VWR). From the mixture of PBMCs with plasma 500 µL were collected into 
a microcentrifuge tube (Eppendorf) and precipitated with trichloroacetic acid (TCA) (P+C samples). 
The remaining mixture was centrifuged at 1650×g for 30 minutes (Centrifuge 5810 R, Eppendorf) at 
RT. The supernatant was collected and proteins were precipitated with TCA (plasma samples). The 
cell pellet (PBMCs samples) was washed with PBS and centrifuge at 300×g for 5 minutes (the 
process was repeated). All samples were resuspended in Laemmli Sample Buffer (Bio-Rad). 
Protein concentration was determined using the 2-D Quant Kit (GE Healthcare). The assay 
was performed according to the manufacturer protocol using bovine serum albumin (BSA) as a 
standard. 
III .1.2.  Samples for  qualitative and quantitative analys is  
Blood from healthy volunteers was collected into 8 ml Vacutainer® CPT™ (BD) containing 
sodium citrate as anticoagulant and the CPTs were processed according to the manufacturer’s 
instructions. After blood drawing and gently inversion of the CPTs, the tubes were centrifuged at 
1650×g for 30 minutes (Centrifuge 5810 R, Eppendorf) at RT within two hours of blood collection. 
PBMCs were collected from the processed CPT by drawing off PBMCs layer with a pipette. Lastly, 
the PBMCs were washed with PBS and centrifuge at 300×g for 5 minutes (the process was 
repeated), precipitated with methanol (VWR) and the pellet was resuspended in Laemmli Sample 
Buffer (Bio-Rad) and sonicated on a SONICS Vibracell 130 W using a 2 mm probe at 20% of 
amplitude for 30 seconds (1 second on 1 second off cycle). Protein concentration was determined 
as described above. 
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III.2. Samples preparation for LC-MS/MS 
For the library identification (IDA acquisition) 20 μg of protein of each biological replicate 
of every single sample (PBMCs, P+C and plasma), were pooled together, and for the SWATH analysis 
100 μg of each sample was used (2.1 μg of GFP was added all to samples). All samples were 
denatured with Laemmli Sample Buffer (Bio-Rad) and boiled at 95˚C during 5 min followed by 
addition of 2 μL of acrylamide [40% acrylamide/bis solution (Bio-Rad)] per 30 μL of sample to 
alkylate cysteine residues. The samples were loaded in a 4-20% Mini-PROTEAN® TGX™ Precast Gel 
(Bio-Rad) and electrophoretically resolved at 110 V for 15 min using a Mini-PROTEAN® Tetra 
Electrophoresis System (Bio-Rad).  
Proteins were visualised with Colloidal Coomassie Brilliant Blue G-250 (Bio-Rad) staining. 
Shortly, the gel was rinsed with double deionized water (ddH2O) and immersed in the staining 
solution [10% (v/v) of an 80% solution of phosphoric acid, 10% (w/v) ammonium sulphate, 20% 
(v/v) methanol] to which Coomassie was added98. 
Each gel lane was sliced into 9 bands of equal size using a disposable GridCutter (2 mm × 7 
mm lanes, 25 rows, 1 column). The bands of each lane were grouped three by three, sliced into 
smaller pieces, and transferred to microcentrifuge tubes with 1 mL of ultrapure water (VWR) to 
prevent band pieces to dry. The gel pieces were destained with a destaining solution (50 mM 
ammonium bicarbonate, 30% acetonitrile (ACN)) by shaking in a thermomixer (Comfort, Eppendorf) 
at 850 rpm for 15 min at 25˚C. This step was repeated until no Coomassie staining was observed 
and then the gel pieces were washed with ddH2O in a thermomixer at 850 rpm for 15 min at 25˚C. 
After water removal, the gel pieces were dehydrated on a Concentrator Plus (Eppendorf) at 60˚C 
for 1 hour. A trypsin (Roche) solution (0.01 mg/mL in 10 mM ammonium bicarbonate) was added 
to each tube until all dried pieces were covered and left for 15 min, on ice, to rehydrate the gel 
pieces. After this period 20 μL of 10 mM ammonium bicarbonate were added and in-gel digestion 
was performed in the dark, overnight at RT. After the digestion, the tryptic solution from gel pieces 
was collected to low binding microcentrifuge tubes (LoBind®, Eppendorf). The peptides were 
extracted from gel pieces by sequential addition of solutions with an increase concentration of ACN 
(30%, 50%, and 98%, respectively) in 1% FA. After the addition of each solution, the tubes were 
shaken in the thermomixer (Comfort, Eppendorf) at 1050 rpm for 15 min and the solution was 
collected to the tube containing the previous fraction. At this stage, peptides extracted from 
different bands were pooled together into one peptide mixture per sample, whereas peptides from 
pool samples were kept separated. The peptide mixtures were concentrated on the Concentrator 
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Plus (Eppendorf) at 60˚C. Peptides were resuspended to a final volume of 100 μL in a solution of 2% 
ACN and 1% FA, and sonicated on a SONICS Vibracell 750 W using a cup-horn at 20% of amplitude 
for 2 min (1 second on 1 second off cycle). 
The extracted peptides were desalted using C18 Bond Elut OMIX solid phase extraction 
pipette tips (Agilent technology). Briefly, the tip column was hydrated with 200 μL of 50% ACN and 
equilibrated with 300 μL of 2% ACN with 1% FA. The peptides were loaded into the column five 
times followed a wash step with 100 μL of 2% ACN with 1% FA (the washed is saved until LC-MS/MS 
analysis of the peptides). Peptides were then eluted to a low binding microcentrifuge tubes 
(LoBind®, Eppendorf) with 400 μL of 70% ACN and 0.1% FA and the eluates were concentrated using 
the Concentrator Plus (Eppendorf) at 60°C. The peptide mixtures were resuspended to 30 μL in a 
solution of 2% ACN and 0.1% FA, spiked with iRTs peptides (Biognosys AG), and sonicated on a 
SONICS Vibracell 750 W using a cup-horn at 20% of amplitude for 2 min (1 second on 1 second off 
cycle). After centrifugation at 14,000×g for 5 minutes (MiniSpin® plus, Eppendorf) the supernatants 
were transferred into vials for posterior LC-MS/MS analysis. 
III.3. LC-MS/MS data acquisition 
Tryptic peptides were analysed on a TripleTOF 5600™ mass spectrometer (AB Sciex®) in two 
different acquisition modes: IDA and SWATH. Peptides (from the enrichment test’s samples and for 
the SWATH analysis) were analysed by LC-MS/MS both in IDA and SWATH acquisition modes.  
The peptide mixtures were separated by LC (NanoLC Ultra 2D, Eksigent) on a ChromXP™ 
C18 reverse phase column (300 μm ID × 15 cm length, 3 μm particles, 120 Å pore size, Eksigent) at 
5 μL/min with a linear gradient of 2% to 30% ACN in 0.1% FA for 45 min. Peptides were eluted into 
the mass spectrometer using an ESI source (DuoSpray™ Source, AB Sciex®) in positive mode. 
IDA experiments were performed for each fraction (10 μL) to create the identification 
library. The mass spectrometer was set for IDA scanning full spectra (350-1250 m/z) for 25 ms, 
followed by up to 20 MS/MS scans (100-1500 m/z for 100 ms each). Candidate ions with a charge 
state between +2 and +5 and counts above a minimum threshold of 70 counts per second were 
isolated for fragmentation and one MS/MS spectrum was collected before adding those ions to the 
exclusion list for 20 seconds (mass spectrometer operated by Analyst® TF 1.6, AB Sciex®). Rolling 
collision energy was used with a collision energy spread of five. For the exclusion analysis, an 
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exclusion list (EL) with previous identified peptides was created and LC-MS/MS analysis was 
performed as described above excluding those peptides in the new acquisition. 
Ten μL of each sample were used for quantitative analysis by acquisition in SWATH mode. 
The SWATH setup was essentially as in Gillet et al.68, with the same chromatographic conditions 
used as in the IDA analysis described above. For SWATH-MS–based experiments, the mass 
spectrometer was operated in a looped product ion mode. The instrument was specifically tuned 
to allow a quadrupole resolution of 25 m/z mass selection. Using an isolation width of 26 m/z 
(containing 1 m/z for the window overlap), a set of 30 overlapping windows was constructed 
covering the precursor mass range of 350–1100 m/z. A 50 ms survey scan (350-1250 m/z) was 
acquired at the beginning of each cycle for instrument calibration and SWATH MS/MS spectra were 
collected from 100–1500 m/z for 100 ms resulting in a cycle time of 3.25 sec from the precursors 
ranging from 350 to 1100 m/z. The collision energy for each window was determined according to 
the calculation for a charge 2+ ion centred upon the window with a collision energy spread of 15. 
III.4. Sample preparation for 2D LC-MS/MS 
For 2D LC-MS/MS analysis, samples were prepared as described in III.2. with minor 
modifications: 300 μg of protein was used for library identification (IDA acquisition), and after 
peptide extraction and concentration on a Concentrator Plus (Eppendorf) at 60˚C , they were 
resuspended to a final volume of 90 μL in 72 mM TEAB for posterior 2D-LC-MS/MS analysis. 
III.5. 2D LC-MS/MS data acquisition 
Peptides were analysed by 2D LC-MS/MS, with a high pH RPC as first dimension and then 
analyzed by LC-MS as described above. The first dimension chromatography was performed in 
Ultimate™ 3000 LC, LC packing, Dionex with a C18 Acclaim® Polar Advantage II column (2.1 × 150 
mm length, 3 μm particles, 120 Å pore size, Dionex), using 72 mM TEAB pH 8.5 as mobile phase A 
and 72 mM TEAB in ACN pH 8.5 as mobile phase B at 150 μL/min. The peptides were fractionated 
by a multistep gradient: 0-32 min linear gradient to 45% B, 32-34 min linear gradient from 45% to 
100% B, 34-40 100% B, 40-41 min linear gradient from 100% to 0% B, and 41-45 min 0% B.  
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The 28 collected fractions throughout the chromatographic run were joined into 8 samples 
(Figure IV.10.), evaporated, resuspended to 30 μL in a solution of 2% ACN and 0.1% FA, spiked with 
iRTs peptides (Biognosys AG), and sonicated on a SONICS Vibracell 750 W using a cup-horn at 20% 
of amplitude for 2 min (1 second on 1 second off cycle). After centrifugation at 14,000×g for 5 
minutes (MiniSpin® plus, Eppendorf) the supernatants were transferred into vials for posterior LC-
MS/MS analysis, as described above. 
 III.6. Protein identification and library generation  
Protein identification for each IDA method was obtained using ProteinPilot™ software (v5, 
AB Sciex®) with the following search parameters: search against homo sapiens from SwissProt 
database (last update in May 2015); trypsin digestion; acrylamide as cysteine alkylating reagent; 
special focus option for gel based, thorough ID search effort, and 0.05 unused ProtScore (10% 
confidence score) as detected protein threshold. Data analysis was based on an independent False 
Discovery Rate (FDR) analysis using the target-decoy approach. Positive identifications were 
considered when proteins present 95% confidence (5% local FDR) with more than one peptide hit 
with individual confidence above 95%. When a protein was identified with a single peptide, an 
Unused above 1.3 was considered as positive identification or the peptide has to present an 
individual confidence above 95% and a minimum sequence tag of 3 amino acids (4 consecutive 
peaks in the MS/MS spectrum). The reverse proteins and peptides, as well as, the peptides with 
zero contribution were removed. 
A specific library of precursor masses and fragment ions was created combining all files 
from IDA experiments and used for subsequent SWATH processing. The library was obtained using 
ProteinPilot™ software (v5, AB Sciex®) with similar parameters as above, but including GFP protein 
and iRTs peptides in the database.  
III.7. SWATH data file processing  
Prior to data processing, peptides were selected automatically from the library using the 
following criteria: (i) the unique peptides for a specific targeted protein were ranked by the intensity 
of the precursor ion from the IDA analysis as estimated by the ProteinPilot™ software, and (ii) 
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peptides that contained biological modifications and/or were shared between different protein 
entries/isoforms were excluded from selection. Up to 15 peptides were chosen per protein, and 
SWATH quantitation was attempted for all proteins in library files that were identified below 1% 
global FDR from ProteinPilot™ search. In SWATH™ acquisition data, peptides are confirmed by 
finding and scoring peak groups, which are a set of fragment ions for the peptide.  
Up to 5 target fragment ions were automatically selected following the criteria described 
in Lambert et al.99: (i) fragment ions for a selected peptide were ranked according to ion intensity; 
(ii) ions higher in m/z than the y4 fragment ion for each selected peptide were ranked highest; (iii) 
ions within the SWATH isolation window were excluded from selection; (iv) if insufficient target 
ions were found, ions lower than y4 but outside of the SWATH window were chosen; and (v) if there 
were still insufficient ions, then fragment ions from within the SWATH window region were chosen.  
Peak groups were scored following the criteria described in Lambert et al.99, briefly, each 
target fragment ion was scored based on the retention time adjustment, peak width overlap, peak 
intensity ratio, correct isotopic state, m/z error and MS/MS score. The individual peak group scores 
were combination of all subscores (scores from fragment ions) and the peak group with the best 
score was taken forward. Peak group confidence threshold was determined based on a FDR analysis 
using the target-decoy approach and 1% extraction FDR threshold was used for all the analyses. 
Peptide features (i.e. peptides in a given charge state) that met the 1% FDR threshold in all the 
replicates were retained, and the peak areas of the target fragment ions of those peptides were 
extracted across the experiment using a extracted-ion chromatogram (XIC) window  of  5 min with 
a 0.02 Da width. 
Protein levels were estimated by summing all the transitions from all the peptides for a 
given protein (adapted from100). The protein levels were normalized for the most stable internal 
standards spiked into the samples.  
III.8. Bioinformatics  
The BioVenn diagram tool101 (http://www.cmbi.ru.nl/cdd/biovenn/) from Centre for 
Molecular and Biomolecular Informatics was used to compare the number of proteins that are 
shared or unique between different samples. The lists containing the proteins from the desired 
samples to be compared were uploaded and the tool generates area-proportional Venn diagrams 
of the inserted proteins and a text file containing the accession numbers of the analysed proteins 
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as well as the distribution of these proteins within the different samples. As this software only 
analyse a maximum of three data sets at the same time, VENNTURE tool102 
(http://www.irp.nia.nih.gov/branches/lci/nia_bioinformatics_software.html) was used to obtain a 
Venn diagram of six datasets. This software provides the distribution of the proteins within the 
different samples, as well as non-proportional Venn diagram. 
PANTHER Classification System77 (http://www.pantherdb.org/tools/) was performed for 
the lists of identified and quantified proteins. This tool creates map lists of cellular component, 
biological process, and molecular function ontologies. All the analyses were done for Homo sapiens, 
and the results were viewed as pie charts. 
To compare the quantified proteins with an immune system process GO term among the 
three different samples (PBMCs, P+C and plasma) a heat map with standardized values was 
generated by the Graphical Proteomics Data Explorer (GProX) tool version 1.1.15103. 
In order to visualise in which metabolic pathways the identified proteins are involved in, 
the KEGG database104,105 (http://www.genome.jp/kegg/tool/map_pathway2.html) was used. This 
displays metabolic pathway maps where the proteins play roles in and highlight the uploaded 
proteins. 
III.9. Multivariate analysis  
The principal components analysis (PCA) was performed in the MarkerView™ software 
(version 1.2.1, AB Sciex) without weighting and using Pareto as the scaling method.  
III.10. Flow cytometric data acquisition and analysis  
In flow cytometric analysis both PBMCs and WB samples were used. WB samples were 
collected from healthy volunteers into 2 ml Vacutainer® Blood Collection Tube (BD) containing 
K2EDTA as anticoagulant and tubes were inverted to ensure mixing of anticoagulant with blood to 
prevent clotting. PBMCs were isolated and washed as described in section III.2. The cell pellet was 
then resuspended in 1 mL PBS and cells were counted on a COULTER® Ac·T diff2™ (Beckman 
Coulter). 
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The distribution of PBMCs and WB subsets was evaluated using the following combination 
of monoclonal antibodies: anti-HLA-DR-FITC (clone Immu-357), anti-CD45-KO (clone J.33), anti-
CD56-Pc7 (clone N901 (NKH-1)), anti-CD123-PE (clone SSDCLY107D2), anti-CD8-APC (clone B9.11), 
anti-CD33-APC (clone D3HL60.251) from Beckman Coulter; anti-CD3-PerCP-Cy5.5 (clone SK7), and 
anti-CD14-APCH7 (clone MφP9) from BD Biosciences; anti-CD20-PB (clone 2H7) from BioLegend; 
and anti-CD4-PB (clone RPA-T4) from BD Pharmingen.  
For staining purposes, samples were incubated for 15 minutes in the dark at room 
temperature in the presence of the above-mentioned monoclonal antibodies. Then, 2 ml of FACS 
lysing solution (BD) diluted 1/10 (v/v) in distilled water was added and after gentle vortex, samples 
were incubated for another 15 minutes under the same conditions as those mentioned above to 
lyse the non-nucleated red cells. After that, cells were centrifuged for 5 min at 430×g (in WB 
samples this step was repeated) and the cell pellet was resuspended in 250 µl of PBS. Data 
acquisition was performed in a FACSCanto™II flow cytometer (BD) and data was analysed using the 
software Infinicyt™ (v1.6, Cytonos SL, Salamanca, Spain). 
 
 
 
 
 
 
 
 
 
 
IV. Results & Discussion 
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IV.1.Enrichment test  
Plasma is perhaps the most studied sample for PBCs discovery37. However, due to the wide 
dynamic range in abundance of plasma proteins, its proteome is very difficult to characterize 
without a previous depletion step of the most abundant proteins38. PBMCs represent a significant 
part of the immune system, providing access to potential physiological relevant proteins40,41, thus 
representing an alternative to plasma samples as valuable source of PBC of the most diverse 
illnesses42–45.  
The first part of this master thesis project intended to verify if there is an enrichment of 
immune system proteins in isolated PBMCs comparing to plasma samples using BD Vacutainer® 
CPT™ for this purpose. Thereby, three different samples were analysed by LC-MS/MS: isolated 
PBMCs, plasma depleted from PBMCs (plasma samples) and plasma still with PBMCs (P+C samples). 
Blood was collected from four healthy individuals (Supplementary Table VII.1.) and the samples 
were processed as described in section III.1.1. For library creation of each sample, the four 
biological samples were pooled together and protein identification was performed by LC-MS/MS 
(sections III.3. and III.6.). 
IV.1.1. Protein  identif ication  
As expected, the number of proteins identified in each sample was very different (Figure 
IV.1.). In PBMCs samples it was possible to identify 671 proteins while in P+C and plasma samples 
only 115 and 143 proteins were identified, respectively. At least 74% of the proteins were identified 
with at least two peptides with a confidence of 95% (496, 100, and 106 in PBMCs, P+C and plasma 
samples, respectively). It is clear that the isolation step of PBMCs resulted in a decrease of highly 
abundant proteins present in plasma and consequently in the identification of a higher number of 
proteins. The low number of identified proteins in plasma and P+C samples (143 and 115, 
respectively) is due to the lack of a depletion step of the most abundant proteins, making it nearly 
impossible to identify proteins present in low concentrations.  
The comparison between the three different samples using a Venn diagram (Figure IV.2.) 
revealed that from the 761 proteins identified only 53 were shared by all samples. Six hundred 
proteins were found to be unique of PBMCs, 34 of plasma and 12 of P+C samples. The higher 
number of unique proteins in PBMCs is undoubtedly a result of the increased number of proteins 
identified in this sample by LC-MS/MS.  
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Figure IV.2. Venn diagram illustrating the number of shared and unique confidently identified proteins in each sample. 
The total number of proteins identified was 761 with only 53 being common to all samples. 
Proteins coming from plasma and platelets (e.g. albumin and platelet glycoprotein 4) were 
identified in PBMCs samples, probably due to their adherence to lymphocytes surface during the 
isolation or their collection along with the buffy coat79,106. 
IV.1.2. GO analysis  
For the biological interpretation of the identified proteins, a GO analysis was performed 
using the PANTHER tool to visualise proteins according to their cellular component, biological 
process, and molecular function (section III.8.).  
 
Figure IV.1. Number of proteins identified in PBMCs, P+C and plasma samples by LC-MS/MS. Bar chart of the identified 
proteins in each sample with at least two peptides (white) and with one peptide (black). 
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Regarding the cellular component of the identified proteins (Figure IV.3.) in PBMCs it is 
possible to see that P+C and plasma the more expressive cellular component is extracellular region 
(48% and 52%, respectively). The low representation of membrane proteins (7.2%, 4.5%, and 2.9% 
in PBMCs, P+C, and plasma samples, respectively) is most likely because their isolation requires 
adequate protocols to their hydrophobicity, basic pH, and low abundance67. 
 
Figure IV.3. Pie charts illustrating the cellular component of the proteins identified in the three different samples: (A) 
PBMCs, (B) plasma with PBMCs and (C) plasma depleted from PBMCs. 
When looking to the biological processes where the identified proteins are involved in 
(Figure IV.4.), it is clear that all samples comprise proteins that take part in very general processes 
such as cellular process, apoptotic process, and biological regulation, with metabolic processes 
being the most represented in the three samples. Proteins involved in immune system processes 
represent 4.4%, 8.7%, and 10.3% in PBMCs, P+C and plasma, respectively. However, in absolute 
numbers there are more immune system-related proteins in PBMCs (59) than in P+C and plasma 
samples (25 and 35, respectively) (Figure IV.5. and Supplementary Tables VII.2, 3, and 4). That is, 
PBMCs provide access to more immune-relevant proteins than plasma do.  
The molecular functions of the identified proteins can be seen in figure IV.6. The first thing 
that stands out is that PBMCs proteins are involved in more molecular functions than P+C and 
plasma ones. This may be a consequence of the higher number of identified proteins in PBMCs 
samples but on the other hand, it shows that isolated PBMCs provide access to a more diverse set 
of proteins, comparing to plasma and P+C samples without a previous depletion step. However, in 
all samples catalytic activity is the most represented molecular function.  
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Figure IV.4. Pie charts illustrating the biological process of the proteins identified in the three different samples: (A) 
PBMCs, (B) plasma with PBMCs and (C) plasma depleted from PBMCs. 
 
Figure IV.5. Number of identified proteins with an “immune system” GO term assigned in PBMCs, P+C and plasma 
samples.  
 
Figure IV.6. Pie charts illustrating the molecular functions of the proteins identified in the three different samples: (A) 
PBMCs, (B) plasma with PBMCs and (C) plasma depleted from PBMCs. 
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Regarding the three GO classifications (cellular component, biological process and 
molecular function), it is possible to observe that the pie charts of P+C and plasma samples are 
almost indistinguishable, which was already expected considering that at least 68% of the identified 
proteins in these two samples is shared between them (Figure IV.2.). This possibly occurs because 
P+C samples still contain the high amounts of the most abundant proteins present in plasma 
therefore it is less likely to identify PBMCs-related proteins, probably because high abundant 
plasmatic proteins masked them. 
IV.1.3. SWATH analys is  
To verify the quantitative distribution of immune-related proteins among the three samples 
a SWATH analysis was performed. Briefly, this analysis generates a complete recording of the 
fragment ion spectra of all analytes in a sample within a determined m/z window, and then acquired 
data from XICs of each peptide is used to determine the relative quantity of a given protein.  
Since the aim of this quantitative analysis was to understand if proteins involved in the 
immune system are present in higher amounts in PBMCs samples, a GO analysis of biological 
processes was performed and only proteins with a GO term of “immune system” assigned were 
considered in the following results (42 out of the 363 quantified proteins). 
By the analysis of SWATH files in PeakView® it is possible to see that XICs intensity of a given 
albumin peptide (Figure IV.7. A) is higher in P+C and plasma samples than in PBMCs samples. On 
the other hand, XICs intensities of a given peptide of C-C motif chemokine 5 and MHC class I antigen 
B 55 (proteins involved in immune system) (Figures IV.7. B and C, respectively) are increased in 
PBMCs samples. After normalisation of protein levels to total intensity (Figure IV.8.) the relative 
intensity of these two proteins in PBMCs samples is higher than in the two other samples. In 
contrast, albumin (the most abundant plasma protein) intensity is decreased in PBMCs and it almost 
quadruples in plasma and P+C samples. Meaning that PBMCs isolation resulted in a decrease of 
albumin and in an increase of MHC class I antigen and C-C motif chemokine 5. However, comparing 
to MHC class I antigen and C-C motif chemokine 5, the relative intensity of albumin in PBMCs 
samples is 36 and 500 times higher, respectively.     
When looking to all proteins with an “immune system” GO term assigned (Supplementary 
Table VII.5.), it is possible to verify that the majority of the immune system-related quantified 
proteins are present in higher amounts in PBMCs samples than in the P+C and plasma samples 
(Figure IV.9.). Meaning that in PBMCs samples there is an enrichment of immune-related proteins. 
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Figure IV.7. Peptide profile of albumin, C-C motif chemokine 5, and MHC class I antigen B55 among the three different 
samples. Peak groups (XICs of a chosen peptide) of (A) albumin, (B) C-C motif chemokine 5 and (C) MHC class I antigen B 
55 peptides previously identified in IDA experiments of each sample. For each peak group it is presented the MS/MS 
fragmentation spectrum of the identified peptides of (D) albumin, (E) C-C motif chemokine 5 and (F) MHC class I antigen 
B 55. The transitions used are indicated with coloured balls according with its respective extracted ion trace colour. 
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Figure IV.8. Relative intensity of albumin, MHC class I antigen B 55 and C-C motif chemokine 5 in PBMCs, P+C and 
plasma samples. The summed intensity of each protein was normalised to the total intensity. The vertical axis is shown 
in logarithmic scale. 
 
Figure IV.9. Heat map analysis of quantified proteins involved in immune system processes. Heat map generated from 
SWATH data comparing the immune system-related proteins among the three different samples. 
 IV.2. 1D LC-MS/MS vs. 2D LC-MS/MS 
In proteomic analysis of complex peptide mixtures, such as the ones that result from tryptic 
digestion of mammalian samples, it is difficult to obtain a good proteome coverage by 1D LC-
MS/MS66. Therefore,  it becomes necessary to adopt multidimensional separation approaches to 
increase peptide separation, its identification, and consequently protein identification66. Several 
approaches can be used to increase 2D LC-MS/MS orthogonality and thus improve the number of 
identified proteins however, RPC at high pH coupled with RPC at low pH has proved to perform 
better than other 2D-LC combinations (e.g. SCX with pH gradient followed by RPC at low pH)67. 
Thus, after the enrichment test assay, the next step was to try to increase the number of 
identified proteins by different LC-MS/MS approaches: 1D LC-MS/MS, 1D LC-MS/MS with exclusion 
list (EL) (i.e. excluding previous identified peptides) and 2D LC-MS/MS (sections III.3. and III.4.). The 
approach that results in more identifications will be use in subsequent qualitative analysis of PBMCs 
proteins as well as in SWATH library creation. 
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IV.2.1. Protein  identif ication  
One dimensional LC-MS/MS analysis resulted in the identification of 6021 peptides with a 
confidence of 95% and 1067 proteins (Figure IV.10.). Out of the 1067 proteins, 787 (73.8%) were 
identified with at least two peptides. Comparing to the number of PBMCs’ proteins identified in the 
enrichment test (671) (section IV.1.2), this analysis yielded more identifications. As the acquisition 
parameters were the same it was not expected such increase in the number of identifications 
however, in this test, PBMCs proteins were precipitated with methanol before solubilisation with 
Laemmli Sample Buffer, which clearly resulted in improvement of protein solubilisation and 
identification.  
In EL analysis peptides identified in previous 1D LC-MS/MS analysis were excluded from 
data acquisition, resulting in the identification of 2144 and 665 peptides and proteins, respectively. 
After searching 1D LC-MS/MS and EL analyses together, a total of 6609 peptides with a confidence 
of 95% were identified corresponding to 1160 proteins (Figure IV.10). Although EL analysis 
increased the number of identified proteins in 8.7%, the percentage of those identified with at least 
two peptides remains the same.  
 
Figure IV.10. Number of peptides and proteins identified by 1D LC-MS/MS (1D), 1D LC-MS/MS with EL (1D w/ EL) and 
2D LC-MS/MS (2D) approaches. Bar chart of the identified proteins by the three different approaches with at least two 
peptides (white) and with one peptide (black). The line chart shows the number of the identified peptides.  
In 2D LC-MS/MS analysis, peptides were resolved by RPC at high pH in the first LC dimension 
throughout which 28 fractions were collected and joined into eight final fractions (F1 to F8) as 
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shown in figure IV.11. Fractions 1 and 28 were kept separated since as it is possibly to see in the 
chromatogram, the number of peptides being eluted in time ranges 0-9 min and 35-45 min, 
respectively, is low. The peptides from final fraction pools were then separated by RPC at low pH 
and identified by MS/MS. For each fraction, m/z of all identified peptides was plotted against 
retention time so it can be confirmed the orthogonality of this 2D-LC approach. In F2 to F8, five or 
four fractions collected with a 6-minute difference were joined, and it can be seen that there are 
peptides being identified along the entire second LC dimension run, meaning that co-eluted 
peptides in first LC dimension are resolved in second LC dimension. With the exception of F1, F4 
and F8 where 15, 1763 and 963 peptides were identified, respectively, in all fractions more than 
3000 peptides were identified.  
This approach resulted in the identification of 13281 peptides with a confidence of 95% 
corresponding to 1929 identified proteins, of which 1534 were identified with at least two peptides 
(79.5%) (Figure IV.10). Therefore, in 2D-LC, there was a 66.3% increase of the identified proteins 
and a 79.6% increase of the proteins identified with at least two peptides with 95% of confidence, 
comparing to 1D-LC approach (1D LC-MS/MS combined with EL analysis). Nevertheless, there are 
peptides (1014) and proteins (18) only identified in 1D-LC samples (Figure IV.12.). 
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Figure IV
.11. Schem
atic representation of the 2D
 LC-M
S/M
S analysis. Throughout the first LC dim
ension, 28 fractions w
ere collected (colour bars over the chrom
atogram
). 
The fractions represented in grey (1 and 28) w
ere kept separated, w
hereas fractions of the sam
e colour shade (2 to 27) w
ere joined for subsequent LC-M
S/M
S analysis. For 
each fraction, m
/z of all identified peptides w
as plotted against retention tim
e. 
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Figure IV.12. Venn diagrams illustrating the number of shared and unique (A) peptides and (B) proteins identified 
by MS/MS preceded by 1D or 2D-LC fractionation. 
In addition, looking to the 1072 common proteins identified by the two approaches, those 
identified by 2D LC-MS/MS show an increased coverage (with 95% of confidence) of their 
sequence (Figure IV.13), as a result of the increase in the number of identified peptides.  Thus, 
this approach outperform 1D LC-MS/MS not only in the number of identified proteins, but also 
in proteins coverage, what makes these results more interesting. 
 
Figure IV.13. Box plots illustrating the percentage of protein coverage with 95% of confidence of the 1072 common 
proteins identified by 1D and 2D LC-MS/MS analyses. 
 
IV.2.2. SWATH analys is  
To quantify the proteins previously identified by the different approaches a SWATH analysis 
was performed (section III.6.). In this quantitative analysis, only one SWATH acquisition was 
performed (section III.3), but three different libraries were used: 1D LC-MS/MS, 1D LC-MS/MS with 
EL and 2D LC-MS/MS. 
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 Out of the 1067 confidently identified proteins by 1D LC-MS/MS, 857 were quantified 
(80.3%), corresponding to 3087 peptides (Figure IV.14). Combining the 1D LC-MS/MS with EL library 
(1D-LC approach) it was possible to quantify 918 out of 1160 identified proteins (79.1%), using 3213 
peptides. In both cases, the percentage of quantified proteins with at least two peptides was 65%.  
In the quantification using the 2D LC-MS/MS library 3356 peptides were used. From the 
1924 identified proteins 1077 were quantified (55.0%), of which 654 were quantified with at least 
two peptides (60.7%) (Figure IV.14.). As expected, the number of quantified proteins was higher 
using 2D LC-MS/MS library once the number of identified proteins increased 66.3%. However, the 
increase of quantified proteins was not that high (16.9%) possibly because the SWATH acquisition 
was performed after a 1D-LC peptide separation instead of 2D-LC. Contrary to protein identification 
where the number of identified peptides was 101% higher in 2D-LC approach, that was not 
observed in protein quantification.  
Using a Venn diagram to illustrate the unique and shared peptides used in the 
quantification of 1D-LC with 2D-LC approaches (Figure IV.15. A) it is possible to see that from the 
4573 peptides used in quantification only 2013 are shared by both libraries. The number of unique 
peptides used in each of the approaches is similar (1208 in 1D-LC and 1350 in 2D-LC), and the same 
happens in proteins; 286 are exclusive of 2D-LC library whereas 127 are only quantified using 1D-
LC library. Out of 1204 quantified proteins, 791 are common to both approaches (Figure IV.15. B).   
 
Figure IV.14. Number of peptides and proteins quantified by SWATH-MS analysis using three different libraries: 1D LC-
MS/MS (1D), 1D LC-MS/MS with EL (1D w/ EL), and 2D LC-MS/MS (2D). Bar chart of the quantified proteins using the 
three different libraries with at least two peptides (white) and with one peptide (black). The line chart shows the number 
of quantified peptides. 
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Figure IV.15. Venn diagrams illustrating the number of shared or unique (A) peptides and (B) proteins quantified by 
SWATH-MS using 1D or 2D IDA libraries. (A) 4573 peptides were quantified, with 2006 being common to both libraries. 
(B) There are 791 common proteins out of 1204 quantified proteins.   
Although the 2D LC-MS/MS analysis is more time consuming (almost two working days) 
comparing to 1D LC-MS/MS (one hour), it is worth to mention that once the SWATH library is 
created, it is possible to quantify 17% more proteins in one hour ( SWATH acquisition). 
IV.2.3. GO analysis  
For the biological interpretation of the identified and quantified proteins by both 
approaches, a GO analysis was performed using the PANTHER tool to visualise proteins according 
to their cellular component, biological process, and molecular function (section III.8.).  
In figure IV.16. it is possible to see that both the identified and quantified proteins by 1D-
LC and 2D-LC approaches show similar cellular components, and the majority of the proteins 
belongs to cell part and organelle (70%), an expected result once no organelle protein extraction 
procedure was used.  
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Figure IV.16. Pie charts illustrating the cellular component of the proteins identified by (A) 1D LC-MS/MS and (B) 2D 
LC-MS/MS, and quantified by SWATH-MS using (C) 1D and (D) 2D libraries. 
Regarding the biological processes in which the identified and quantified proteins be part 
of (Figure IV.17), it is clear that all profiles are quite similar between them, representing proteins 
involved in very general processes such as cellular component organization, reproduction and 
localisation. However, more than 50% of the proteins belong to cellular and metabolic processes. 
The profiles of the molecular functions of the identified and quantified proteins (Figure 
IV.18) are also quite similar between them. Such as the biological processes, the represented 
molecular functions are very general. Among them, catalytic activity and binding are the most 
represented ones.  
Although the two different approaches result in an extremely distinct number of identified 
proteins, cellular components, biological processes and molecular functions are represented in 
equal proportions, and the same applies to the quantified proteins. Moreover, the profiles of the 
quantified proteins are identical to that of the identified proteins, which means that the quantified 
proteins reflect the GO of the identified proteins. 
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Figure IV.17. Pie charts illustrating the biological process of the proteins identified by (A) 1D LC-MS/MS and (B) 2D 
LC-MS/MS, and quantified by SWATH-MS using (C) 1D and (D) 2D libraries. 
 
 
  
 
 
Figure IV.18. Pie charts illustrating the molecular function of the proteins identified by (A) 1D LC-MS/MS and (B) 2D 
LC-MS/MS, and quantified by SWATH-MS using (C) 1D and (D) 2D libraries. 
IV.3. Qualitative analysis  
Altogether, this work resulted in the identification of 2071 different proteins 
(Supplementary Table VII.6.). Previous studies reached a maximum of 1500 identified proteins41,79–
81, except one that achieved 4129 identified proteins40 however, in this last study 49 different LC-
MS/MS analyses were performed.  
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The GO analysis can be seen in figure IV.19. As found previously, the majority of the proteins 
belongs to cell part and organelle (69.8%). From those with an “organelle” GO term assigned 60% 
belong to cytoskeleton (data not shown) and some of these proteins (e.g. talin-1, myosin-9, and 
filamin-A) were the ones identified with the highest number of peptides (more than 100 peptides). 
Although their function is mainly structural, they have been associated to some pathologies such 
as cancer107,108, multiple sclerosis109, and HIV110.  
Regarding biological processes, 51.4% of the proteins are involved in cellular and metabolic 
processes, and it is worth to mention that there are studies that point to an energy metabolism 
dysregulation in SCZ111,112.  Although only 4.10% of the identified proteins were assigned with an 
“immune system process” GO term, the analysis of the identified proteins in KEGG database 
revealed that they are involved in numerous metabolic pathways (Supplementary Figure VII.1. A), 
namely in “T cell receptor signalling pathway”, “B cell receptor signalling pathway”, “NK cell 
mediated cytotoxicity”, “leukocyte transendothelial migration”, “antigen processing and 
presentation”, “complement and coagulation cascades”, and “chemokine signalling pathway” 
(Supplementary Figures VII.1. B, C, D, E, F, G, and H, respectively). That is, this dataset provide a 
good coverage of some of the PBMCs metabolic pathways, which means that the approached used 
provide access to proteins that play important roles in the immune system.  
  
 
 
 
 
 
 
 
 
 
 
Figure IV.19. Pie charts illustrating the (A) cellular component, (B) biological processes, and (C) molecular functions 
of all identified proteins.  
Cellular component
synapse
cell junction
membrane
macromolecular complex
extracellular matrix
cell part
organelle
extracellular region
Biological process
cellular component organization
or biogenesis
cellular process
localization
apoptotic process
reproduction
biological regulation
response to stimulus
developmental process
multicellular organismal process
locomotion
biological adhesion
metabolic process
growth
immune system process
Molecular function
transporter activity
translation regulator activity
protein binding transcription factor
activity
enzyme regulator activity
catalytic activity
receptor activity
nucleic acid binding transcription
factor activity
antioxidant activity
structural molecule activity
binding
A B C 
RESULTS & DISCUSSION | 53 
 
Similarly to the analysis of the biological processes, the represented molecular functions 
are quite general. Among them, catalytic activity and binding are the most represented ones (38.5% 
and 30.5%. respectively).  
CD proteins are widely used in the immunophenotyping of PBMCs97, but they are also used 
to access activation or proliferation of lymphocytes113. Only ten proteins with a CD name assigned 
were identified, what was already expected since these proteins belong to surface membrane114 
and no protocol of membrane-enrichment was used. Nicotinamide phosphoribosyltransferase, 
plasminogen activator inhibitor 2, programmed cell death protein 5, and interleukine-1β can also 
be used to determine PBMCs activation41 and are included in this dataset too. Various heat shock 
proteins were identified and it is known that in addition to their role as chaperones, they are also 
involved in autoimmune diseases115. Moreover, there are also some proteins that were previously 
associated with other human illnesses such as Parkinson’s (e.g. DJ-1, α-synuclein, and parkin)116 and 
Alzheimer’s (e.g. amyloid β A4)117 diseases, and SCZ (e.g. fructose-bisphosphate aldolase C, β-actin, 
tropomyosin α-1 chain, and dihydropyrimidinase-related protein 2)118.  
IV.4. SWATH library creation  
For the creation of SWATH library, PBMCs samples from six healthy volunteers were pooled 
together and proteins were identified by 2D LC-MS/MS (section III.5.). This resulted in the 
identification of 6906 peptides, corresponding to 1102 identified proteins of which 768 (69.7%) 
were identified with at least two peptides. 
In order to verify the reproducibility of the method, the pool of the six biological samples 
was made and it was analysed three times by SWATH as describe in sections III.3. and III.7. Four 
hundred and seventeen out of the 1102 identified proteins were quantified. Of these 417 quantified 
proteins, 358 were quantified with high reproducibility between technical replicates (CV<20%) 
(Figure IV.20. A and B). Moreover, this method also showed good accuracy with a strong linear 
correlation (mean r2 of 0.9922) among the three different replicates (Figure IV.20. C). 
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Figure IV.20. Reproducibility analysis of SWATH acquisition method. (A) Total number of quantified proteins among the 
three technical replicates (white) and those with a CV value below 20% (black). It is presented the percentage of proteins 
quantified with high reproducibility (CV<20%). (B) Box plot illustrating the range of method reproducibility. (C) Evaluation 
of the linearity/reproducibility of the method, assessed by plotting the intensity values of the replicates against the 
intensity value of the first replicate. #1, #2, and #3 = technical replicates.  
For SWATH acquisition, the six biological samples were analysed individually (sections III.3 
and III.7.). The number of quantified peptides and proteins was similar among the six samples 
(Figure IV.21.) and it was possible to quantify 922 different proteins. The comparison between the 
different samples using a Venn diagram (Figure IV.22.) showed that 445 were shared by all samples 
(Supplementary Table VII.7.), and the number of unique quantified proteins in each sample range 
between 9 and 27. 
 
Figure IV.21. Number of peptides and proteins quantified by SWATH-MS. Bar chart of the quantified proteins with at 
least two peptides (white) and with one peptide (black). The line chart shows the number of quantified peptides. #1, 
#2, #3, #4, #5, and #6 = biological samples of the six different donors. 
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Figure IV.22. Venn diagrams illustrating the number of shared or unique proteins quantified by SWATH-MS. The 
samples #1, #2, #3, #4, #5, and #6 are represented in black, light grey, dark grey, light blue, blue, and dark blue, 
respectively.  
Considering the quantified proteins common to all samples (445), there are only 85 proteins 
(19.1%) with a CV value below 20% (Figure IV.23). Although far lower than the CV value obtained 
among the three technical replicates (85.9%), it is an expected result since among different 
biological samples (e.g. human PBMCs) there is a considerably high variability. However, when 
considering only female or male samples, the number of quantified proteins with a CV value below 
20% is 208 and 191 (Figure IV.23), respectively.  
For this reason, a PCA analysis was performed in order to verify if there was any distinction 
between samples. Figure IV.24. A shows the score values represented in the two first principal 
components (PC1 and PC2) using Pareto scaling, where 75.7% of sample variance is explained. It is 
possible to observe the formation of two main groups along the first principal component (PC1), 
corresponding to female (green) and male (red) samples. The loadings plot (Figure IV.24. B) shows 
proteins that have the largest contribution along the PC1, and that explain the separation of the 
two groups. Histone H4 seems to be the main contributor for the separation of males group, 
whereas females group seems to be distinguished due to talin-1, integrin α-II b, and γ-actin. This 
confirms that PBMCs proteome of females and males is quite different, calling for the need of 
considering gender when comparing healthy controls and a disease group. That is, the proportion 
of females:males should be the same in the two groups (i.e. healthy controls and disease), since the 
observed differences might be due to the gender instead of the disease itself. However, this does 
not always happens119,120; at least one study was found121 where the two disease groups have more 
females than males, and the healthy control groups does not even includes females.  
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Figure IV.23. Reproducibility analysis of the six biological samples. (A) Number of quantified proteins shared between 
all samples (white) and those with a CV value below 20% (black) considering all samples, only female samples, and 
male samples. It is presented the percentage of proteins quantified with high reproducibility (CV<20%). (B) Box plot 
illustrating the reproducibility range considering all samples, only female samples, and male samples. 
 
 
 
 
 
Figure IV.24. PCA analysis of quantified proteins common to the six biological samples with Pareto scaling. (A) Score 
plot shows two different groups along the PC1, which separation is best explained by the proteins most represented 
along the PC1 on the loading plot (B).   
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IV.5. Flow cytometric analysis  
Both WB and PBMCs samples from six healthy volunteers (Supplementary Table VII.1.) were 
analysed by flow cytometry. This analysis aimed to confirm the enrichment in PBMCs after their 
isolation using the commercially available BD Vacutainer® CPT™, and on the other hand to establish 
a repertoire of PBMCs subpopulations of healthy individuals so it can be later compared to that of 
patients with SCZ. Before flow cytometric analysis, cells from PBMCs samples were counted on a 
COULTER® Ac·T diff2™ (Beckman Coulter) (Supplementary Table VII.8.).  
In figure IV.25. it is shown the phenotypic strategy used in the identification of PBMCs 
subpopulations (the  example shown refers to the WB sample  of the donor  #1) and the results are 
present in the table IV.1. As expected, the isolation step resulted in an enrichment of all PBMCs 
subpopulations, corresponding to an increase of more than 100% (Figure IV.26.). 
   
   
Figure IV.25. Bivariate dot plot histograms illustrating the phenotypic strategy for the identification of the different 
PBMCs subpopulations in #1 WB sample. (A) T cells subsets. A gate was set on CD3+ and CD4 vs. CD8 expression is 
shown. CD4+, CD8+, CD4+CD8+, and γδ T cells are shown in green, yellow, orange, and blue, respectively. (B) B cells. A 
gate was set on CD3- and CD20 vs. HLA-DR expression is shown. (C) NK cells. A gate on CD3- and CD20- was set and 
CD56 vs. CD14 expression is shown. (D) Monocytes. A gate was set on CD3- and CD14 vs. CD33 expression is shown. 
Classical monocytes are shown in yellow, and non-classical monocytes are shown in orange. (E) Dendritic cells. A gate 
was set on CD3-, CD14-, and CD20- and HLA-DR vs. CD123 expression is shown. (F) Basophils. A gate was set on CD3- 
and HLA-DR vs. CD123 expression is shown. 
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Figure IV.26. Increase of the main PBMCs subpopulations in isolated PBMCs. 
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Table IV.1. Percentage of PBMCs subpopulations in isolated PBMCs and WB samples determined by flow cytometric analysis. 
PBMCs 
subpopulations 
#1 #2 #3 #4 #5 #6 
PBMCs WB PBMCs WB PBMCs WB PBMCs WB PBMCs WB PBMCs WB 
T cells 50.20 23.90 61.80 21.30 66.20 27.70 44.00 15.30 65.60 20.90 67.30 23.60 
CD4+ 51.32 51.10 60.90 58.00 66.00 62.00 62.00 59.00 69.00 69.20 64.10 65.00 
CD8+ 41.80 41.70 31.90 37.00 24.80 25.26 30.30 31.60 25.20 24.70 30.60 28.00 
CD4+CD8+ 2.10 3.40 1.20 2.00 4.40 6.67 3.80 5.90 1.50 1.60 2.70 4.40 
γδ 3.06 2.94 3.28 2.60 3.85 3.21 1.73 2.23 3.74 3.00 0.80 1.00 
B cells 5.61 2.56 9.43 4.11 8.55 2.85 2.60 1.10 4.57 2.20 8.60 3.30 
NK cells 25.00 9.00 11.60 2.60 6.32 2.40 22.67 6.50 15.80 3.90 4.70 1.60 
CD56bright 1.64 2.20 2.20 1.80 1.87 2.30 1.60 2.20 3.80 3.50 12.30 12.50 
Monocytes 18.15 7.60 13.90 5.20 13.90 4.70 23.93 6.90 10.10 3.30 14.90 5.30 
NCM 0.79 0.27 0.20 0.12 0.28 0.11 1.52 0.82 0.63 0.22 0.36 0.22 
pDC 0.76 0.23 0.30 0.15 0.53 0.21 0.32 0.14 0.40 0.17 0.47 0.15 
mDC 0.39 0.14 0.31 0.08 0.70 0.29 0.43 0.19 0.21 0.12 0.50 0.20 
Basophils 0.30 0.39 0.29 0.42 0.54 0.76 0.40 0.68 0.19 0.40 0.20 0.40 
All results are present in percentage of cells in relation to the total number of cells in each sample, except the percentage of T cells 
(CD4+, CD8+, CD4+CD8+, and γδ), and NK cells (CD56bright) subsets that is presented in relation to total percentage of T and NK cells, 
respectively. #1, #2, #3, #4, #5, #6 = biological samples of the six different donors.   
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Future Perspectives 
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The main goal of this study was to provide a comprehensive proteome characterisation of 
PBMCs and the creation of a SWATH library. It was also evaluated whether isolated PBMCs could 
provide access to more immune-relevant proteins than plasma samples do, using the commercially 
available BD Vacutainer® CPT™ for this purpose. These tubes allow blood collection and PBMCs 
isolation in a single centrifugation step and therefore are suitable for clinical use. The main PBMCs 
subpopulations were also analysed by flow cytometry in order to establish a catalogue of some of 
the PBMCs subpopulations of healthy individuals so it can be later compared to that of patients 
with diverse pathologies, namely SCZ. 
The enrichment test revealed that there are more identified proteins with an “immune 
system process” GO term assigned in isolated PBMCs than in plasma samples. It was also found that 
the majority of the quantified “immune” proteins are increased in PBMCs samples.  
1D LC-MS/MS was compared to 2D LC-MS/MS in order to choose the approach that perform 
better in the identification and quantification of PBMCs proteins. 2D LC-MS/MS resulted in an 
increase of 66.3% in the number of identified proteins and 79.6% in those identified with at least 
two peptides, comparing to 1D LC-MS/MS approach. It was also observed an increased in protein 
coverage. Regarding SWATH analysis, using 2D LC-MS/MS library it was possible to quantify 16.9% 
more proteins. 
Altogether, this work allowed the identification of 2071 different proteins, and the 
qualitative analysis of those proteins revealed that PBMCs proteins are involved in different 
diseases. Furthermore, it was possible to quantify 992 different proteins in six different samples. 
Of those, 445 proteins were common to all samples. Although the percentage of quantified proteins 
with a CV value below 20% was low (19.1%) in the six different samples, technical replicates showed 
that 85.9% of the quantified proteins have a CV value below 20%. Meaning that SWATH acquisition 
is a reproducible quantitation method and the higher CV values among biological samples is due to 
interindividual variation of PBMCs proteome. Flow cytometric data confirm the enrichment of the 
main PBMCs subpopulations in isolated PBMCs comparing to whole blood samples. 
In summary, the results present in this study culminate in a clear conclusion: the 
comprehensive PBMCs proteome here provide includes proteins related to different diseases, 
supporting the suggestion that PBMCs are a valuable source of potential biomarker candidates, and 
can provide an alternative to plasma in future scientific studies. Thus, these findings will be useful 
to further studies that aim to compare PBMCs proteomes of healthy and diseased individuals.   
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VII.1. PBMCs cryopreservation and culture  
In order to assess if PBMCs cryopreservation and its culture influences the amount of 
protein obtained, cells were cryopreserved during one month and then seeded for two days. PBMCs 
were isolated and processed as described in III.1.2. but instead of precipitating proteins with 
methanol, the cell pellet was resuspended in 2 mL of Dulbecco's modified Eagle’s medium (DMEM) 
with Glutamax™ and low glucose supplemented with 10% FBS, Gibco (hereafter DMEM medium). 
Viable cells were counted in a haemocytometer and then cryopreserved in culture medium with 
10% DMSO. After one month of cryopreservation in liquid nitrogen, PBMCs were thawed in a 37˚C 
water bath and diluted in pre-warmed culture medium. Viable cells were determined using a 
haemocytometer and PBMCs were seeded at 3.7×104 cells/cm2 in culture medium in 6-well plates 
(Corning) at 37˚C, 5% CO2/95% air in a humidified incubator (Sheldon Manufacturing, Inc.). After 
48 hours of plating, cells were scraped and washed twice with PBS. Proteins were precipitated with 
methanol and the cell pellet was resuspended in Laemmli Sample Buffer. Protein concentration was 
determined using the 2-D Quant Kit (section III.1.1.). 
Before cryopreservation the number of viable cells was 2.18×106 cells and after one month 
of cryopreservation this number decreased to 1.11×106 cells. As PBMCs can be cryopreserved for 
periods longer than one year without loss of viability61 this difference in the number of viable cells 
was not expected. It is recommended to use RPMI-1640 medium in its cryopreservation122 instead 
of DMEM which could have led to cell death, although it was found one previous study used DMEM 
medium in PBMCs culture with no report of cell death123.  
The average of protein obtained without PBMCs cryopreservation and culture was 435 µg 
per sample, whereas after this procedure the amount of protein per sample was 174 µg. Although 
in the literature there is no mention of protein content decrease after PBMCs cryopreservation and 
culture, it was found that the total amount of protein was 2.5 times lower. 
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VII.2. Tables and figures  
Supplementary Table VII.1. Demographic and clinical characteristics of healthy donors. 
Samples Individuals 
Gender 
(F/M) 
Age BMI (kg/m2)  
Smokers 
(Y/N) 
ET 
#1 M 36 20.83 N 
#2 F 24 24.80 Y 
#3 F 24 24.28 N 
#4 M 22 17.76 Y 
SC 
#1 M 26 19.62 N 
#2 M 22 17.76 Y 
#3 F 23 20.55 N 
#4 M 36 20.83 N 
#5 F 26 23.03 N 
#6 F 23 24.77 N 
BMI = body mass index; ET = samples used in the enrichment test assay; SC = samples used in the SWATH library 
creation and in the flow cytometric analysis. 
 
Supplementary Table VII.2. Identified proteins with an “immune system” 
GO term assigned by LC-MS/MS in PBMCs samples. For each protein it is 
shown its entry name in UniProt database. 
Entry name Protein name 
A1BG_HUMAN Alpha-1B-glycoprotein 
A2MG_HUMAN Alpha-2-macroglobulin 
APOH_HUMAN Beta-2-glycoprotein 1 
B2MG_HUMAN Beta-2-microglobulin 
CCL5_HUMAN C-C motif chemokine 5 
CD36_HUMAN Platelet glycoprotein 4 
CD47_HUMAN Leukocyte surface antigen CD47 
CERU_HUMAN Ceruloplasmin 
CFAB_HUMAN Complement factor B 
CO4A_HUMAN Complement C4-A 
CSK_HUMAN Tyrosine-protein kinase CSK 
CSRP1_HUMAN Cysteine and glycine-rich protein 1 
CXCL7_HUMAN Platelet basic protein 
DOPD_HUMAN D-dopachrome decarboxylase 
DUS3_HUMAN Dual specificity protein phosphatase 3 
EF1G_HUMAN Elongation factor 1-gamma 
ENPL_HUMAN Endoplasmin 
F13A_HUMAN Coagulation factor XIII A chain 
FA5_HUMAN Coagulation factor V 
FETUA_HUMAN Alpha-2-HS-glycoprotein 
FHL1_HUMAN Four and a half LIM domains protein 1 
GPVI_HUMAN Platelet glycoprotein VI 
GPX1_HUMAN Glutathione peroxidase 1 
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GSTO1_HUMAN Glutathione S-transferase omega-1 
HPT_HUMAN Haptoglobin 
HS90A_HUMAN Heat shock protein HSP 90-alpha 
HS90B_HUMAN Heat shock protein HSP 90-beta 
HSP71_HUMAN Heat shock 70 kDa protein 1A/1B 
HSP7C_HUMAN Heat shock cognate 71 kDa protein 
HSPB1_HUMAN Heat shock protein beta-1 
ILF2_HUMAN Interleukin enhancer-binding factor 2 
ILK_HUMAN Integrin-linked protein kinase 
KSYK_HUMAN Tyrosine-protein kinase SYK 
LOX12_HUMAN Arachidonate 12-lipoxygenase, 12S-type 
LYAM3_HUMAN P-selectin 
MK01_HUMAN Mitogen-activated protein kinase 1 
OTUB1_HUMAN Ubiquitin thioesterase OTUB1 
PECA1_HUMAN Platelet endothelial cell adhesion molecule 
PERM_HUMAN Myeloperoxidase 
PLF4_HUMAN Platelet factor 4 
PP1A_HUMAN 
Serine/threonine-protein phosphatase PP1-
alpha catalytic subunit 
PRDX1_HUMAN Peroxiredoxin-1 
PRDX2_HUMAN Peroxiredoxin-2 
PRDX4_HUMAN Peroxiredoxin-4 
RINI_HUMAN Ribonuclease inhibitor 
S10A4_HUMAN Protein S100-A4 
S10A6_HUMAN Protein S100-A6 
S10A9_HUMAN Protein S100-A9 
S10AB_HUMAN Protein S100-A11 
SLAF5_HUMAN SLAM family member 5 
SRC_HUMAN Proto-oncogene tyrosine-protein kinase Src 
STAT3_HUMAN 
Signal transducer and activator of 
transcription 3 
TCTP_HUMAN Translationally-controlled tumor protein 
THAS_HUMAN Thromboxane-A synthase 
THRB_HUMAN Prothrombin 
TRML1_HUMAN Trem-like transcript 1 protein 
XRCC6_HUMAN X-ray repair cross-complementing protein 6 
YES_HUMAN Tyrosine-protein kinase Yes 
ZA2G_HUMAN Zinc-alpha-2-glycoprotein 
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Supplementary Table VII.3. Identified proteins with an “immune system” GO 
term assigned by LC-MS/MS in P+C samples. For each protein it is shown its entry 
name in UniProt database. 
Entry name Protein name 
A1BG_HUMAN Alpha-1B-glycoprotein 
A2MG_HUMAN Alpha-2-macroglobulin 
AMBP_HUMAN Protein AMBP 
APOH_HUMAN Beta-2-glycoprotein 1 
C1R_HUMAN Complement C1r subcomponent 
C1S_HUMAN Complement C1s subcomponent 
C4BPA_HUMAN C4b-binding protein alpha chain 
CERU_HUMAN Ceruloplasmin 
CFAB_HUMAN Complement factor B 
CFAH_HUMAN Complement factor H 
CFAI_HUMAN Complement factor I 
CO2_HUMAN Complement C2 
CO4A_HUMAN Complement C4-A 
CO4B_HUMAN Complement C4-B 
CO5_HUMAN Complement C5 
CO7_HUMAN Complement component C7 
CO8A_HUMAN Complement component C8 alpha chain 
FA12_HUMAN Coagulation factor XII 
FETUA_HUMAN Alpha-2-HS-glycoprotein 
HPT_HUMAN Haptoglobin 
HPTR_HUMAN Haptoglobin-related protein 
LUM_HUMAN Lumican 
PZP_HUMAN Pregnancy zone protein 
THRB_HUMAN Prothrombin 
ZA2G_HUMAN Zinc-alpha-2-glycoprotein 
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Supplementary Table VII.4. Identified proteins with an “immune system” GO term 
assigned by LC-MS/MS in plasma samples. For each protein it is shown its entry 
name in UniProt database. 
Entry name Protein name 
A1BG_HUMAN Alpha-1B-glycoprotein 
A2MG_HUMAN Alpha-2-macroglobulin 
AMBP_HUMAN Protein AMBP 
APOH_HUMAN Beta-2-glycoprotein 1 
C1R_HUMAN Complement C1r subcomponent 
C1S_HUMAN Complement C1s subcomponent 
C4BPA_HUMAN C4b-binding protein alpha chain 
CERU_HUMAN Ceruloplasmin 
CFAB_HUMAN Complement factor B 
CFAH_HUMAN Complement factor H 
CFAI_HUMAN Complement factor I 
CO2_HUMAN Complement C2 
CO4A_HUMAN Complement C4-A 
CO4B_HUMAN Complement C4-B 
CO5_HUMAN Complement C5 
CO6_HUMAN Complement component C6 
CO7_HUMAN Complement component C7 
CO8A_HUMAN Complement component C8 alpha chain 
CO8G_HUMAN Complement component C8 gamma chain 
F13A_HUMAN Coagulation factor XIII A chain 
F13B_HUMAN Coagulation factor XIII B chain 
FETUA_HUMAN Alpha-2-HS-glycoprotein 
GPX3_HUMAN Glutathione peroxidase 3 
HPT_HUMAN Haptoglobin 
HPTR_HUMAN Haptoglobin-related protein 
KV110_HUMAN Ig kappa chain V-I region HK102 (Fragment) 
LBP_HUMAN Lipopolysaccharide-binding protein 
LUM_HUMAN Lumican 
PZP_HUMAN Pregnancy zone protein 
THRB_HUMAN Prothrombin 
ZA2G_HUMAN Zinc-alpha-2-glycoprotein 
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Supplementary Table VII.5. Quantified proteins with an “immune system” GO term assigned by SWATH-MS. For each 
protein it is shown its entry name in UniProt database and its relative intensity in each of the samples. 
Entry name Protein name PBMCs P+C Plasma 
A1BG_HUMAN Alpha-1B-glycoprotein 1.36E-04 5.63E-04 6.27E-04 
A2MG_HUMAN Alpha-2-macroglobulin 2.04E-03 1.33E-02 1.45E-02 
AMBP_HUMAN Protein AMBP 4.70E-05 2.87E-04 3.91E-04 
APOH_HUMAN Beta-2-glycoprotein 1 8.45E-05 5.45E-04 3.36E-04 
B2MG_HUMAN Beta-2-microglobulin 1.80E-04 2.13E-05 1.65E-05 
CCL5_HUMAN C-C motif chemokine 5 3.36E-04 3.28E-06 2.16E-06 
CD36_HUMAN Platelet glycoprotein 4 7.44E-05 1.02E-06 7.95E-07 
CERU_HUMAN Ceruloplasmin 1.48E-04 1.42E-03 1.33E-03 
CFAB_HUMAN Complement factor B 5.81E-05 4.24E-04 9.80E-04 
CFAH_HUMAN Complement factor H 2.27E-05 1.42E-04 9.93E-05 
CO4A_HUMAN Complement C4-A 7.40E-06 1.51E-04 1.19E-04 
CSK_HUMAN Tyrosine-protein kinase CSK 9.41E-05 9.98E-07 1.26E-06 
CXCL7_HUMAN Platelet basic protein 8.80E-03 3.12E-05 5.23E-05 
DUS3_HUMAN Dual specificity protein phosphatase 3 5.41E-05 2.16E-06 2.63E-07 
ENPL_HUMAN Endoplasmin 1.83E-03 8.51E-05 1.07E-04 
F13A_HUMAN Coagulation factor XIII A chain 3.35E-03 6.73E-05 9.39E-05 
FA5_HUMAN Coagulation factor V 6.52E-05 3.24E-06 1.03E-06 
FHL1_HUMAN Four and a half LIM domains protein 1 1.81E-04 6.92E-06 9.14E-07 
GPX1_HUMAN Glutathione peroxidase 1 4.11E-05 6.64E-06 1.44E-05 
GSTO1_HUMAN Glutathione S-transferase omega-1 2.46E-03 4.43E-05 1.07E-05 
HPT_HUMAN Haptoglobin 4.24E-04 2.75E-03 2.08E-03 
HS90A_HUMAN Heat shock protein HSP 90-alpha 1.14E-03 2.20E-05 1.03E-05 
HS90B_HUMAN Heat shock protein HSP 90-beta 1.13E-04 3.26E-06 1.27E-06 
HSP71_HUMAN Heat shock 70 kDa protein 1A 2.53E-04 6.97E-06 9.22E-06 
HSP7C_HUMAN Heat shock cognate 71 kDa protein 2.95E-03 1.97E-04 1.51E-04 
HSPB1_HUMAN Heat shock protein beta-1 1.55E-03 6.69E-05 6.12E-05 
ILK_HUMAN Integrin-linked protein kinase 4.88E-03 1.00E-04 1.20E-04 
LYAM3_HUMAN P-selectin 4.32E-04 2.27E-05 1.88E-05 
MK01_HUMAN Mitogen-activated protein kinase 1 1.38E-04 2.54E-05 1.31E-05 
PECA1_HUMAN Platelet endothelial cell adhesion molecule 2.44E-04 1.38E-05 3.70E-06 
PERM_HUMAN Myeloperoxidase 1.38E-04 1.67E-06 1.80E-06 
PLF4_HUMAN Platelet factor 4 3.92E-03 8.92E-05 9.95E-06 
PP1A_HUMAN 
Serine/threonine-protein phosphatase PP1-alpha 
catalytic subunit 
9.65E-05 8.50E-06 4.69E-07 
PRDX1_HUMAN Peroxiredoxin-1 1.10E-03 1.01E-05 5.62E-06 
PRDX2_HUMAN Peroxiredoxin-2 2.33E-04 1.33E-05 1.05E-05 
RINI_HUMAN Ribonuclease inhibitor 2.09E-04 2.90E-06 1.53E-06 
S10A4_HUMAN Protein S100-A4 7.10E-04 6.77E-05 1.56E-05 
S10A9_HUMAN Protein S100-A9 4.64E-04 1.21E-04 2.38E-05 
THAS_HUMAN Thromboxane-A synthase 3.28E-04 2.87E-06 6.32E-06 
THRB_HUMAN Prothrombin 5.97E-05 2.67E-04 1.66E-04 
TRML1_HUMAN Trem-like transcript 1 protein 3.49E-04 2.80E-05 1.49E-05 
ZA2G_HUMAN Zinc-alpha-2-glycoprotein 4.34E-05 6.93E-05 8.17E-05 
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Supplementary Table VII.6. All identified proteins during this study. For each protein it is shown its entry name in 
UniProt database. 
Entry name Protein name Entry name Protein name 
1433B_HUMAN 14-3-3 protein beta/alpha MCCB_HUMAN 
Methylcrotonoyl-CoA carboxylase 
beta chain, mitochondrial 
1433E_HUMAN 14-3-3 protein epsilon MCTS1_HUMAN 
Malignant T-cell-amplified 
sequence 1 
1433F_HUMAN 14-3-3 protein eta MCU_HUMAN 
Calcium uniporter protein, 
mitochondrial 
1433G_HUMAN 14-3-3 protein gamma MDHC_HUMAN 
Malate dehydrogenase, 
cytoplasmic 
1433T_HUMAN 14-3-3 protein theta MDHM_HUMAN 
Malate dehydrogenase, 
mitochondrial 
1433Z_HUMAN 14-3-3 protein zeta/delta MECP2_HUMAN Methyl-CpG-binding protein 2 
1A01_HUMAN 
HLA class I histocompatibility antigen, 
A-1 alpha chain 
MEMO1_HUMAN Protein MEMO1 
1A02_HUMAN 
HLA class I histocompatibility antigen, 
A-2 alpha chain 
MESD_HUMAN LDLR chaperone MESD 
1A03_HUMAN 
HLA class I histocompatibility antigen, 
A-3 alpha chain 
METK2_HUMAN 
S-adenosylmethionine synthase 
isoform type-2 
1B08_HUMAN 
HLA class I histocompatibility antigen, 
B-8 alpha chain 
MFN2_HUMAN Mitofusin-2 
1B27_HUMAN 
HLA class I histocompatibility antigen, 
B-27 alpha chain 
MGLL_HUMAN Monoglyceride lipase 
1B35_HUMAN 
HLA class I histocompatibility antigen, 
B-35 alpha chain 
MGMT_HUMAN 
Methylated-DNA--protein-cysteine 
methyltransferase 
1B40_HUMAN 
HLA class I histocompatibility antigen, 
B-40 alpha chain 
MGN2_HUMAN Protein mago nashi homolog 2 
1B44_HUMAN 
HLA class I histocompatibility antigen, 
B-44 alpha chain 
MGST3_HUMAN 
Microsomal glutathione S-
transferase 3 
1B45_HUMAN 
HLA class I histocompatibility antigen, 
B-45 alpha chain 
MIC19_HUMAN MIC complex subunit MIC19 
1B47_HUMAN 
HLA class I histocompatibility antigen, 
B-47 alpha chain 
MIC60_HUMAN MIC complex subunit MIC60 
1B81_HUMAN 
HLA class I histocompatibility antigen, 
B-81 alpha chain 
MICA1_HUMAN 
Protein-methionine sulfoxide 
oxidase MICAL1 
1C03_HUMAN 
HLA class I histocompatibility antigen, 
Cw-3 alpha chain 
MICU1_HUMAN 
Calcium uptake protein 1, 
mitochondrial 
1C07_HUMAN 
HLA class I histocompatibility antigen, 
Cw-7 alpha chain 
MIF_HUMAN 
Macrophage migration inhibitory 
factor 
2A5A_HUMAN 
Serine/threonine-protein 
phosphatase 2A 56 kDa regulatory 
subunit alpha isoform 
MK01_HUMAN Mitogen-activated protein kinase 1 
2AAA_HUMAN 
Serine/threonine-protein 
phosphatase 2A 65 kDa regulatory 
subunit A alpha isoform 
MK03_HUMAN Mitogen-activated protein kinase 3 
2ABA_HUMAN 
Serine/threonine-protein 
phosphatase 2A 55 kDa regulatory 
subunit B alpha isoform 
MK14_HUMAN 
Mitogen-activated protein kinase 
14 
2B1D_HUMAN 
HLA class II histocompatibility antigen, 
DRB1-13 beta chain 
ML12A_HUMAN Myosin regulatory light chain 12A 
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2B1F_HUMAN 
HLA class II histocompatibility antigen, 
DRB1-15 beta chain 
MLEC_HUMAN Malectin 
3BP1_HUMAN SH3 domain-binding protein 1 MMRN1_HUMAN Multimerin-1 
41_HUMAN Protein 4.1 MNDA_HUMAN 
Myeloid cell nuclear differentiation 
antigen 
4F2_HUMAN 4F2 cell-surface antigen heavy chain MOB1A_HUMAN MOB kinase activator 1A 
5NT3A_HUMAN Cytosolic 5'-nucleotidase 3A MOES_HUMAN Moesin 
6PGD_HUMAN 
6-phosphogluconate dehydrogenase, 
decarboxylating 
MOGS_HUMAN 
Mannosyl-oligosaccharide 
glucosidase 
6PGL_HUMAN 6-phosphogluconolactonase MOT4_HUMAN Monocarboxylate transporter 4 
A16A1_HUMAN 
Aldehyde dehydrogenase family 16 
member A1 
MP2K1_HUMAN 
Dual specificity mitogen-activated 
protein kinase kinase 1 
A1AT_HUMAN Alpha-1-antitrypsin MP2K2_HUMAN 
Dual specificity mitogen-activated 
protein kinase kinase 2 
A1BG_HUMAN Alpha-1B-glycoprotein MP2K3_HUMAN 
Dual specificity mitogen-activated 
protein kinase kinase 3 
A2MG_HUMAN Alpha-2-macroglobulin MPCP_HUMAN 
Phosphate carrier protein, 
mitochondrial 
A4_HUMAN Amyloid beta A4 protein MPI_HUMAN Mannose-6-phosphate isomerase 
AACT_HUMAN Alpha-1-antichymotrypsin MPRD_HUMAN 
Cation-dependent mannose-6-
phosphate receptor 
AAKG1_HUMAN 
5'-AMP-activated protein kinase 
subunit gamma-1 
MPU1_HUMAN 
Mannose-P-dolichol utilization 
defect 1 protein 
AAPK1_HUMAN 
5'-AMP-activated protein kinase 
catalytic subunit alpha-1 
MRCKB_HUMAN 
Serine/threonine-protein kinase 
MRCK beta 
AATC_HUMAN 
Aspartate aminotransferase, 
cytoplasmic 
MRE11_HUMAN 
Double-strand break repair protein 
MRE11A 
AATM_HUMAN 
Aspartate aminotransferase, 
mitochondrial 
MRVI1_HUMAN Protein MRVI1 
ABCAA_HUMAN 
ATP-binding cassette sub-family A 
member 10 
MSRA_HUMAN 
Mitochondrial peptide methionine 
sulfoxide reductase 
ABCE1_HUMAN 
ATP-binding cassette sub-family E 
member 1 
MTA2_HUMAN 
Metastasis-associated protein 
MTA2 
ABCF1_HUMAN 
ATP-binding cassette sub-family F 
member 1 
MTAP_HUMAN 
S-methyl-5'-thioadenosine 
phosphorylase 
ABCF3_HUMAN 
ATP-binding cassette sub-family F 
member 3 
MTCH1_HUMAN Mitochondrial carrier homolog 1 
ABHDA_HUMAN 
Mycophenolic acid acyl-glucuronide 
esterase, mitochondrial 
MTCH2_HUMAN Mitochondrial carrier homolog 2 
ABHEB_HUMAN 
Alpha/beta hydrolase domain-
containing protein 14B 
MTHFS_HUMAN 
5-formyltetrahydrofolate cyclo-
ligase 
ABHGA_HUMAN 
Abhydrolase domain-containing 
protein 16A 
MTM1_HUMAN Myotubularin 
ABI1_HUMAN Abl interactor 1 MTMRC_HUMAN Myotubularin-related protein 12 
ABLM1_HUMAN Actin-binding LIM protein 1 MTNA_HUMAN 
Methylthioribose-1-phosphate 
isomerase 
ABLM3_HUMAN Actin-binding LIM protein 3 MTPN_HUMAN Myotrophin 
ABRAL_HUMAN Costars family protein ABRACL MUC19_HUMAN Mucin-19 
ACADM_HUMAN 
Medium-chain specific acyl-CoA 
dehydrogenase, mitochondrial 
MUCB_HUMAN Ig mu heavy chain disease protein 
ACADV_HUMAN 
Very long-chain specific acyl-CoA 
dehydrogenase, mitochondrial 
MVP_HUMAN Major vault protein 
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ACAP1_HUMAN 
Arf-GAP with coiled-coil, ANK repeat 
and PH domain-containing protein 1 
MX1_HUMAN 
Interferon-induced GTP-binding 
protein Mx1 
ACBP_HUMAN Acyl-CoA-binding protein MY18A_HUMAN Unconventional myosin-XVIIIa 
ACDSB_HUMAN 
Short/branched chain specific acyl-
CoA dehydrogenase, mitochondrial 
MYADM_HUMAN 
Myeloid-associated differentiation 
marker 
ACLY_HUMAN ATP-citrate synthase MYCT1_HUMAN Myc target protein 1 
ACOC_HUMAN Cytoplasmic aconitate hydratase MYG1_HUMAN 
UPF0160 protein MYG1, 
mitochondrial 
ACON_HUMAN Aconitate hydratase, mitochondrial MYH9_HUMAN Myosin-9 
ACOT9_HUMAN 
Acyl-coenzyme A thioesterase 9, 
mitochondrial 
MYL6_HUMAN Myosin light polypeptide 6 
ACOX1_HUMAN 
Peroxisomal acyl-coenzyme A oxidase 
1 
MYL9_HUMAN 
Myosin regulatory light polypeptide 
9 
ACPH_HUMAN Acylamino-acid-releasing enzyme MYLK_HUMAN 
Myosin light chain kinase, smooth 
muscle 
ACS2L_HUMAN 
Acetyl-coenzyme A synthetase 2-like, 
mitochondrial 
MYO1F_HUMAN Unconventional myosin-If 
ACSL1_HUMAN Long-chain-fatty-acid--CoA ligase 1 MYO1G_HUMAN Unconventional myosin-Ig 
ACSL4_HUMAN Long-chain-fatty-acid--CoA ligase 4 MYO9B_HUMAN Unconventional myosin-IXb 
ACTB_HUMAN Actin, cytoplasmic 1 MYPT1_HUMAN 
Protein phosphatase 1 regulatory 
subunit 12A 
ACTBL_HUMAN Beta-actin-like protein 2 NAAA_HUMAN 
N-acylethanolamine-hydrolyzing 
acid amidase 
ACTBM_HUMAN Putative beta-actin-like protein 3 NACAD_HUMAN 
NAC-alpha domain-containing 
protein 1 
ACTC_HUMAN Actin, alpha cardiac muscle 1 NACAM_HUMAN 
Nascent polypeptide-associated 
complex subunit alpha, muscle-
specific form 
ACTG_HUMAN Actin, cytoplasmic 2 NAGK_HUMAN N-acetyl-D-glucosamine kinase 
ACTN1_HUMAN Alpha-actinin-1 NAMPT_HUMAN 
Nicotinamide 
phosphoribosyltransferase 
ACTN2_HUMAN Alpha-actinin-2 NAT10_HUMAN N-acetyltransferase 10 
ACTN4_HUMAN Alpha-actinin-4 NB5R1_HUMAN NADH-cytochrome b5 reductase 1 
ACTY_HUMAN Beta-centractin NB5R3_HUMAN NADH-cytochrome b5 reductase 3 
ACTZ_HUMAN Alpha-centractin NBEL2_HUMAN Neurobeachin-like protein 2 
ADA_HUMAN Adenosine deaminase NCBP1_HUMAN 
Nuclear cap-binding protein subunit 
1 
ADA10_HUMAN 
Disintegrin and metalloproteinase 
domain-containing protein 10 
NCF1_HUMAN Neutrophil cytosol factor 1 
ADAS_HUMAN 
Alkyldihydroxyacetonephosphate 
synthase, peroxisomal 
NCF2_HUMAN Neutrophil cytosol factor 2 
ADCY6_HUMAN Adenylate cyclase type 6 NCK2_HUMAN Cytoplasmic protein NCK2 
ADDA_HUMAN Alpha-adducin NCKP1_HUMAN Nck-associated protein 1 
ADDB_HUMAN Beta-adducin NCKPL_HUMAN Nck-associated protein 1-like 
ADDG_HUMAN Gamma-adducin NCPR_HUMAN 
NADPH--cytochrome P450 
reductase 
ADHX_HUMAN Alcohol dehydrogenase class-3 NDK3_HUMAN Nucleoside diphosphate kinase 3 
ADK_HUMAN Adenosine kinase NDKA_HUMAN Nucleoside diphosphate kinase A 
ADPRH_HUMAN 
[Protein ADP-ribosylarginine] 
hydrolase 
NDKB_HUMAN Nucleoside diphosphate kinase B 
ADT2_HUMAN ADP/ATP translocase 2 NDRG1_HUMAN Protein NDRG1 
ADT3_HUMAN ADP/ATP translocase 3 NDUA4_HUMAN 
Cytochrome c oxidase subunit 
NDUFA4 
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AFAM_HUMAN Afamin NDUA5_HUMAN 
NADH dehydrogenase [ubiquinone] 
1 alpha subcomplex subunit 5 
AGFG1_HUMAN 
Arf-GAP domain and FG repeat-
containing protein 1 
NDUA8_HUMAN 
NADH dehydrogenase [ubiquinone] 
1 alpha subcomplex subunit 8 
AHNK_HUMAN 
Neuroblast differentiation-associated 
protein AHNAK 
NDUA9_HUMAN 
NADH dehydrogenase [ubiquinone] 
1 alpha subcomplex subunit 9, 
mitochondrial 
AHSA1_HUMAN 
Activator of 90 kDa heat shock protein 
ATPase homolog 1 
NDUAA_HUMAN 
NADH dehydrogenase [ubiquinone] 
1 alpha subcomplex subunit 10, 
mitochondrial 
AIFM1_HUMAN 
Apoptosis-inducing factor 1, 
mitochondrial 
NDUAB_HUMAN 
NADH dehydrogenase [ubiquinone] 
1 alpha subcomplex subunit 11 
AIMP1_HUMAN 
Aminoacyl tRNA synthase complex-
interacting multifunctional protein 1 
NDUAD_HUMAN 
NADH dehydrogenase [ubiquinone] 
1 alpha subcomplex subunit 13 
AK1A1_HUMAN Alcohol dehydrogenase [NADP(+)] NDUB4_HUMAN 
NADH dehydrogenase [ubiquinone] 
1 beta subcomplex subunit 4 
AKT1_HUMAN 
RAC-alpha serine/threonine-protein 
kinase 
NDUBA_HUMAN 
NADH dehydrogenase [ubiquinone] 
1 beta subcomplex subunit 10 
AL3A2_HUMAN Fatty aldehyde dehydrogenase NDUBB_HUMAN 
NADH dehydrogenase [ubiquinone] 
1 beta subcomplex subunit 11, 
mitochondrial 
AL5AP_HUMAN 
Arachidonate 5-lipoxygenase-
activating protein 
NDUS1_HUMAN 
NADH-ubiquinone oxidoreductase 
75 kDa subunit, mitochondrial 
AL9A1_HUMAN 
4-trimethylaminobutyraldehyde 
dehydrogenase 
NDUS2_HUMAN 
NADH dehydrogenase [ubiquinone] 
iron-sulfur protein 2, mitochondrial 
ALBU_HUMAN Serum albumin NDUS3_HUMAN 
NADH dehydrogenase [ubiquinone] 
iron-sulfur protein 3, mitochondrial 
ALDH2_HUMAN 
Aldehyde dehydrogenase, 
mitochondrial 
NDUS5_HUMAN 
NADH dehydrogenase [ubiquinone] 
iron-sulfur protein 5 
ALDOA_HUMAN Fructose-bisphosphate aldolase A NDUS8_HUMAN 
NADH dehydrogenase [ubiquinone] 
iron-sulfur protein 8, mitochondrial 
ALDOC_HUMAN Fructose-bisphosphate aldolase C NDUV1_HUMAN 
NADH dehydrogenase [ubiquinone] 
flavoprotein 1, mitochondrial 
ALDR_HUMAN Aldose reductase NDUV2_HUMAN 
NADH dehydrogenase [ubiquinone] 
flavoprotein 2, mitochondrial 
AMBP_HUMAN Protein AMBP NEB2_HUMAN Neurabin-2 
AMPB_HUMAN Aminopeptidase B NECP2_HUMAN 
Adaptin ear-binding coat-
associated protein 2 
AMPD2_HUMAN AMP deaminase 2 NEDD8_HUMAN NEDD8 
AMPL_HUMAN Cytosol aminopeptidase NEK7_HUMAN 
Serine/threonine-protein kinase 
Nek7 
AMPN_HUMAN Aminopeptidase N NEMO_HUMAN NF-kappa-B essential modulator 
AN32A_HUMAN 
Acidic leucine-rich nuclear 
phosphoprotein 32 family member A 
NEUG_HUMAN Neurogranin 
AN32B_HUMAN 
Acidic leucine-rich nuclear 
phosphoprotein 32 family member B 
NEXN_HUMAN Nexilin 
AN32E_HUMAN 
Acidic leucine-rich nuclear 
phosphoprotein 32 family member E 
NFKB1_HUMAN 
Nuclear factor NF-kappa-B p105 
subunit 
ANFY1_HUMAN Rabankyrin-5 NHLC2_HUMAN NHL repeat-containing protein 2 
ANGT_HUMAN Angiotensinogen NHRF1_HUMAN 
Na(+)/H(+) exchange regulatory 
cofactor NHE-RF1 
ANK1_HUMAN Ankyrin-1 NIBAN_HUMAN Protein Niban 
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ANM1_HUMAN 
Protein arginine N-methyltransferase 
1 
NICA_HUMAN Nicastrin 
ANO6_HUMAN Anoctamin-6 NID1_HUMAN Nidogen-1 
ANR44_HUMAN 
Serine/threonine-protein 
phosphatase 6 regulatory ankyrin 
repeat subunit B 
NIPS1_HUMAN Protein NipSnap homolog 1 
ANT3_HUMAN Antithrombin-III NIPS2_HUMAN Protein NipSnap homolog 2 
ANX11_HUMAN Annexin A11 NNRE_HUMAN NAD(P)H-hydrate epimerase 
ANXA1_HUMAN Annexin A1 NNTM_HUMAN 
NAD(P) transhydrogenase, 
mitochondrial 
ANXA2_HUMAN Annexin A2 NOL4_HUMAN Nucleolar protein 4 
ANXA3_HUMAN Annexin A3 NONO_HUMAN 
Non-POU domain-containing 
octamer-binding protein 
ANXA4_HUMAN Annexin A4 NOP56_HUMAN Nucleolar protein 56 
ANXA5_HUMAN Annexin A5 NOP58_HUMAN Nucleolar protein 58 
ANXA6_HUMAN Annexin A6 NP1L1_HUMAN 
Nucleosome assembly protein 1-
like 1 
ANXA7_HUMAN Annexin A7 NP1L4_HUMAN 
Nucleosome assembly protein 1-
like 4 
AOFB_HUMAN Amine oxidase [flavin-containing] B NPL4_HUMAN 
Nuclear protein localization protein 
4 homolog 
AP1B1_HUMAN AP-1 complex subunit beta-1 NPM_HUMAN Nucleophosmin 
AP1G1_HUMAN AP-1 complex subunit gamma-1 NPS3A_HUMAN Protein NipSnap homolog 3A 
AP1M1_HUMAN AP-1 complex subunit mu-1 NRBP_HUMAN Nuclear receptor-binding protein 
AP1S1_HUMAN AP-1 complex subunit sigma-1A NSDHL_HUMAN 
Sterol-4-alpha-carboxylate 3-
dehydrogenase, decarboxylating 
AP1S2_HUMAN AP-1 complex subunit sigma-2 NSF_HUMAN Vesicle-fusing ATPase 
AP2A1_HUMAN AP-2 complex subunit alpha-1 NSF1C_HUMAN NSFL1 cofactor p47 
AP2B1_HUMAN AP-2 complex subunit beta NT5C_HUMAN 
5'(3')-deoxyribonucleotidase, 
cytosolic type 
AP2M1_HUMAN AP-2 complex subunit mu NTF2_HUMAN Nuclear transport factor 2 
AP2S1_HUMAN AP-2 complex subunit sigma NU205_HUMAN 
Nuclear pore complex protein 
Nup205 
AP3B1_HUMAN AP-3 complex subunit beta-1 NUBP2_HUMAN 
Cytosolic Fe-S cluster assembly 
factor NUBP2 
AP3D1_HUMAN AP-3 complex subunit delta-1 NUCB1_HUMAN Nucleobindin-1 
APEX1_HUMAN 
DNA-(apurinic or apyrimidinic site) 
lyase 
NUCB2_HUMAN Nucleobindin-2 
API5_HUMAN Apoptosis inhibitor 5 NUCKS_HUMAN 
Nuclear ubiquitous casein and 
cyclin-dependent kinase substrate 1 
APMAP_HUMAN 
Adipocyte plasma membrane-
associated protein 
NUCL_HUMAN Nucleolin 
APOA1_HUMAN Apolipoprotein A-I NUD16_HUMAN U8 snoRNA-decapping enzyme 
APOA2_HUMAN Apolipoprotein A-II NUDC_HUMAN Nuclear migration protein nudC 
APOA4_HUMAN Apolipoprotein A-IV NUDT5_HUMAN ADP-sugar pyrophosphatase 
APOB_HUMAN Apolipoprotein B-100 NUMA1_HUMAN Nuclear mitotic apparatus protein 1 
APOBR_HUMAN Apolipoprotein B receptor NUP93_HUMAN 
Nuclear pore complex protein 
Nup93 
APOC1_HUMAN Apolipoprotein C-I OAS2_HUMAN 2'-5'-oligoadenylate synthase 2 
APOC3_HUMAN Apolipoprotein C-III ODO1_HUMAN 
2-oxoglutarate dehydrogenase, 
mitochondrial 
APOD_HUMAN Apolipoprotein D ODO2_HUMAN 
Dihydrolipoyllysine-residue 
succinyltransferase component of 
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2-oxoglutarate dehydrogenase 
complex, mitochondrial 
APOE_HUMAN Apolipoprotein E ODP2_HUMAN 
Dihydrolipoyllysine-residue 
acetyltransferase component of 
pyruvate dehydrogenase complex, 
mitochondrial 
APOH_HUMAN Beta-2-glycoprotein 1 ODPA_HUMAN 
Pyruvate dehydrogenase E1 
component subunit alpha, somatic 
form, mitochondrial 
APT_HUMAN Adenine phosphoribosyltransferase ODPB_HUMAN 
Pyruvate dehydrogenase E1 
component subunit beta, 
mitochondrial 
ARAP1_HUMAN 
Arf-GAP with Rho-GAP domain, ANK 
repeat and PH domain-containing 
protein 1 
OGFR_HUMAN Opioid growth factor receptor 
ARBK1_HUMAN Beta-adrenergic receptor kinase 1 OLA1_HUMAN Obg-like ATPase 1 
ARBK2_HUMAN Beta-adrenergic receptor kinase 2 OPA1_HUMAN 
Dynamin-like 120 kDa protein, 
mitochondrial 
ARC1B_HUMAN 
Actin-related protein 2/3 complex 
subunit 1B 
OPTN_HUMAN Optineurin 
ARF1_HUMAN ADP-ribosylation factor 1 OST48_HUMAN 
Dolichyl-diphosphooligosaccharide-
-protein glycosyltransferase 48 kDa 
subunit 
ARF4_HUMAN ADP-ribosylation factor 4 OSTF1_HUMAN Osteoclast-stimulating factor 1 
ARF6_HUMAN ADP-ribosylation factor 6 OTU1_HUMAN Ubiquitin thioesterase OTU1 
ARFG2_HUMAN 
ADP-ribosylation factor GTPase-
activating protein 2 
OTUB1_HUMAN Ubiquitin thioesterase OTUB1 
ARH_HUMAN 
Low density lipoprotein receptor 
adapter protein 1 
OXR1_HUMAN Oxidation resistance protein 1 
ARHG1_HUMAN 
Rho guanine nucleotide exchange 
factor 1 
OXSR1_HUMAN Serine/threonine-protein kinase R1 
ARHG2_HUMAN 
Rho guanine nucleotide exchange 
factor 2 
P2RX1_HUMAN P2X purinoceptor 1 
ARHG7_HUMAN 
Rho guanine nucleotide exchange 
factor 7 
P3H1_HUMAN Prolyl 3-hydroxylase 1 
ARHL2_HUMAN Poly(ADP-ribose) glycohydrolase ARH3 PA1B2_HUMAN 
Platelet-activating factor 
acetylhydrolase IB subunit beta 
ARK72_HUMAN 
Aflatoxin B1 aldehyde reductase 
member 2 
PA24A_HUMAN Cytosolic phospholipase A2 
ARK74_HUMAN 
Aflatoxin B1 aldehyde reductase 
member 4 
PA2G4_HUMAN 
Proliferation-associated protein 
2G4 
ARL1_HUMAN ADP-ribosylation factor-like protein 1 PABP1_HUMAN Polyadenylate-binding protein 1 
ARL8A_HUMAN ADP-ribosylation factor-like protein 8A PABP2_HUMAN Polyadenylate-binding protein 2 
ARL8B_HUMAN ADP-ribosylation factor-like protein 8B PABP3_HUMAN Polyadenylate-binding protein 3 
ARMX3_HUMAN 
Armadillo repeat-containing X-linked 
protein 3 
PACN2_HUMAN 
Protein kinase C and casein kinase 
substrate in neurons protein 2 
ARP2_HUMAN Actin-related protein 2 PACS1_HUMAN 
Phosphofurin acidic cluster sorting 
protein 1 
ARP3_HUMAN Actin-related protein 3 PAI1_HUMAN Plasminogen activator inhibitor 1 
ARP5L_HUMAN 
Actin-related protein 2/3 complex 
subunit 5-like protein 
PAI2_HUMAN Plasminogen activator inhibitor 2 
ARPC2_HUMAN 
Actin-related protein 2/3 complex 
subunit 2 
PAIRB_HUMAN 
Plasminogen activator inhibitor 1 
RNA-binding protein 
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ARPC3_HUMAN 
Actin-related protein 2/3 complex 
subunit 3 
PAK2_HUMAN 
Serine/threonine-protein kinase 
PAK 2 
ARPC4_HUMAN 
Actin-related protein 2/3 complex 
subunit 4 
PARK7_HUMAN Protein DJ-1 
ARPC5_HUMAN 
Actin-related protein 2/3 complex 
subunit 5 
PARP1_HUMAN Poly [ADP-ribose] polymerase 1 
ARRB1_HUMAN Beta-arrestin-1 PARP9_HUMAN Poly [ADP-ribose] polymerase 9 
ARRB2_HUMAN Beta-arrestin-2 PARVB_HUMAN Beta-parvin 
ARSA_HUMAN Arylsulfatase A PCAT1_HUMAN 
Lysophosphatidylcholine 
acyltransferase 1 
ASAH1_HUMAN Acid ceramidase PCBP1_HUMAN Poly(rC)-binding protein 1 
ASAP1_HUMAN 
Arf-GAP with SH3 domain, ANK repeat 
and PH domain-containing protein 1 
PCBP2_HUMAN Poly(rC)-binding protein 2 
ASAP2_HUMAN 
Arf-GAP with SH3 domain, ANK repeat 
and PH domain-containing protein 2 
PCKGM_HUMAN 
Phosphoenolpyruvate 
carboxykinase [GTP], mitochondrial 
ASC_HUMAN 
Apoptosis-associated speck-like 
protein containing a CARD 
PCNA_HUMAN Proliferating cell nuclear antigen 
ASML_HUMAN 
N-acetylserotonin O-
methyltransferase-like protein 
PCP_HUMAN Lysosomal Pro-X carboxypeptidase 
ASNA_HUMAN ATPase ASNA1 PCSK6_HUMAN 
Proprotein convertase 
subtilisin/kexin type 6 
AT1A1_HUMAN 
Sodium/potassium-transporting 
ATPase subunit alpha-1 
PCY2_HUMAN 
Ethanolamine-phosphate 
cytidylyltransferase 
AT1B3_HUMAN 
Sodium/potassium-transporting 
ATPase subunit beta-3 
PCYOX_HUMAN Prenylcysteine oxidase 1 
AT2A2_HUMAN 
Sarcoplasmic/endoplasmic reticulum 
calcium ATPase 2 
PCYXL_HUMAN Prenylcysteine oxidase-like 
AT2A3_HUMAN 
Sarcoplasmic/endoplasmic reticulum 
calcium ATPase 3 
PDC10_HUMAN Programmed cell death protein 10 
AT5F1_HUMAN 
ATP synthase F(0) complex subunit B1, 
mitochondrial 
PDC6I_HUMAN 
Programmed cell death 6-
interacting protein 
AT8A1_HUMAN Phospholipid-transporting ATPase IA PDCD4_HUMAN Programmed cell death protein 4 
ATE1_HUMAN Arginyl-tRNA--protein transferase 1 PDCD5_HUMAN Programmed cell death protein 5 
ATG3_HUMAN 
Ubiquitin-like-conjugating enzyme 
ATG3 
PDCD6_HUMAN Programmed cell death protein 6 
ATG7_HUMAN 
Ubiquitin-like modifier-activating 
enzyme ATG7 
PDE12_HUMAN 2',5'-phosphodiesterase 12 
ATLA3_HUMAN Atlastin-3 PDE3A_HUMAN 
cGMP-inhibited 3',5'-cyclic 
phosphodiesterase A 
ATP5H_HUMAN ATP synthase subunit d, mitochondrial PDE5A_HUMAN 
cGMP-specific 3',5'-cyclic 
phosphodiesterase 
ATP5I_HUMAN ATP synthase subunit e, mitochondrial PDIA1_HUMAN Protein disulfide-isomerase 
ATP5L_HUMAN ATP synthase subunit g, mitochondrial PDIA3_HUMAN Protein disulfide-isomerase A3 
ATP6_HUMAN ATP synthase subunit a PDIA4_HUMAN Protein disulfide-isomerase A4 
ATPA_HUMAN 
ATP synthase subunit alpha, 
mitochondrial 
PDIA5_HUMAN Protein disulfide-isomerase A5 
ATPB_HUMAN 
ATP synthase subunit beta, 
mitochondrial 
PDIA6_HUMAN Protein disulfide-isomerase A6 
ATPD_HUMAN 
ATP synthase subunit delta, 
mitochondrial 
PDK1_HUMAN 
[Pyruvate dehydrogenase (acetyl-
transferring)] kinase isozyme 1, 
mitochondrial 
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ATPG_HUMAN 
ATP synthase subunit gamma, 
mitochondrial 
PDK3_HUMAN 
[Pyruvate dehydrogenase (acetyl-
transferring)] kinase isozyme 3, 
mitochondrial 
ATPK_HUMAN ATP synthase subunit f, mitochondrial PDLI1_HUMAN PDZ and LIM domain protein 1 
ATPO_HUMAN ATP synthase subunit O, mitochondrial PDLI5_HUMAN PDZ and LIM domain protein 5 
ATX10_HUMAN Ataxin-10 PDLI7_HUMAN PDZ and LIM domain protein 7 
B2MG_HUMAN Beta-2-microglobulin PDPK2_HUMAN 
Putative 3-phosphoinositide-
dependent protein kinase 2 
B3AT_HUMAN Band 3 anion transport protein PDS5B_HUMAN 
Sister chromatid cohesion protein 
PDS5 homolog B 
BABA1_HUMAN 
BRISC and BRCA1-A complex member 
1 
PDXK_HUMAN Pyridoxal kinase 
BACH_HUMAN 
Cytosolic acyl coenzyme A thioester 
hydrolase 
PEA15_HUMAN Astrocytic phosphoprotein PEA-15 
BAF_HUMAN Barrier-to-autointegration factor PEAR1_HUMAN 
Platelet endothelial aggregation 
receptor 1 
BAG5_HUMAN 
BAG family molecular chaperone 
regulator 5 
PEBP1_HUMAN 
Phosphatidylethanolamine-binding 
protein 1 
BAG6_HUMAN Large proline-rich protein BAG6 PECA1_HUMAN 
Platelet endothelial cell adhesion 
molecule 
BAP31_HUMAN B-cell receptor-associated protein 31 PEDF_HUMAN Pigment epithelium-derived factor 
BASI_HUMAN Basigin PEF1_HUMAN Peflin 
BAX_HUMAN Apoptosis regulator BAX PEPD_HUMAN Xaa-Pro dipeptidase 
BGH3_HUMAN 
Transforming growth factor-beta-
induced protein ig-h3 
PERF_HUMAN Perforin-1 
BGLR_HUMAN Beta-glucuronidase PERM_HUMAN Myeloperoxidase 
BID_HUMAN BH3-interacting domain death agonist PFD2_HUMAN Prefoldin subunit 2 
BIEA_HUMAN Biliverdin reductase A PFD4_HUMAN Prefoldin subunit 4 
BIN2_HUMAN Bridging integrator 2 PFKAL_HUMAN 
ATP-dependent 6-
phosphofructokinase, liver type 
BLMH_HUMAN Bleomycin hydrolase PFKAP_HUMAN 
ATP-dependent 6-
phosphofructokinase, platelet type 
BLVRB_HUMAN Flavin reductase (NADPH) PGAM1_HUMAN Phosphoglycerate mutase 1 
BRE_HUMAN BRCA1-A complex subunit BRE PGES2_HUMAN Prostaglandin E synthase 2 
BRK1_HUMAN Protein BRICK1 PGH1_HUMAN Prostaglandin G/H synthase 1 
BROX_HUMAN 
BRO1 domain-containing protein 
BROX 
PGK1_HUMAN Phosphoglycerate kinase 1 
BRSK2_HUMAN 
Serine/threonine-protein kinase 
BRSK2 
PGM1_HUMAN Phosphoglucomutase-1 
BTF3_HUMAN Transcription factor BTF3 PGM2_HUMAN Phosphoglucomutase-2 
BTK_HUMAN Tyrosine-protein kinase BTK PGM2L_HUMAN Glucose 1,6-bisphosphate synthase 
BZW1_HUMAN 
Basic leucine zipper and W2 domain-
containing protein 1 
PGRC1_HUMAN 
Membrane-associated 
progesterone receptor component 
1 
C1QBP_HUMAN 
Complement component 1 Q 
subcomponent-binding protein, 
mitochondrial 
PGRC2_HUMAN 
Membrane-associated 
progesterone receptor component 
2 
C1TC_HUMAN 
C-1-tetrahydrofolate synthase, 
cytoplasmic 
PHB_HUMAN Prohibitin 
C4BPA_HUMAN C4b-binding protein alpha chain PHB2_HUMAN Prohibitin-2 
CA123_HUMAN UPF0587 protein C1orf123 PI42A_HUMAN 
Phosphatidylinositol 5-phosphate 
4-kinase type-2 alpha 
CA198_HUMAN Uncharacterized protein C1orf198 PI4KA_HUMAN Phosphatidylinositol 4-kinase alpha 
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CAB39_HUMAN Calcium-binding protein 39 PICAL_HUMAN 
Phosphatidylinositol-binding 
clathrin assembly protein 
CACO1_HUMAN 
Calcium-binding and coiled-coil 
domain-containing protein 1 
PIMT_HUMAN 
Protein-L-isoaspartate(D-aspartate) 
O-methyltransferase 
CAH1_HUMAN Carbonic anhydrase 1 PIN1_HUMAN 
Peptidyl-prolyl cis-trans isomerase 
NIMA-interacting 1 
CAH13_HUMAN Carbonic anhydrase 13 PIPNA_HUMAN 
Phosphatidylinositol transfer 
protein alpha isoform 
CAH2_HUMAN Carbonic anhydrase 2 PITH1_HUMAN PITH domain-containing protein 1 
CALD1_HUMAN Caldesmon PKHF2_HUMAN 
Pleckstrin homology domain-
containing family F member 2 
CALM_HUMAN Calmodulin PKHO2_HUMAN 
Pleckstrin homology domain-
containing family O member 2 
CALR_HUMAN Calreticulin PKN1_HUMAN Serine/threonine-protein kinase N1 
CALU_HUMAN Calumenin PLAP_HUMAN 
Phospholipase A-2-activating 
protein 
CALX_HUMAN Calnexin PLBL1_HUMAN Phospholipase B-like 1 
CAN1_HUMAN Calpain-1 catalytic subunit PLCB2_HUMAN 
1-phosphatidylinositol 4,5-
bisphosphate phosphodiesterase 
beta-2 
CAN2_HUMAN Calpain-2 catalytic subunit PLCB3_HUMAN 
1-phosphatidylinositol 4,5-
bisphosphate phosphodiesterase 
beta-3 
CANB1_HUMAN Calcineurin subunit B type 1 PLCG2_HUMAN 
1-phosphatidylinositol 4,5-
bisphosphate phosphodiesterase 
gamma-2 
CAND1_HUMAN 
Cullin-associated NEDD8-dissociated 
protein 1 
PLD3_HUMAN Phospholipase D3 
CAP1_HUMAN Adenylyl cyclase-associated protein 1 PLEC_HUMAN Plectin 
CAP7_HUMAN Azurocidin PLEK_HUMAN Pleckstrin 
CAPG_HUMAN Macrophage-capping protein PLF4_HUMAN Platelet factor 4 
CAPZB_HUMAN F-actin-capping protein subunit beta PLIN3_HUMAN Perilipin-3 
CASP1_HUMAN Caspase-1 PLMN_HUMAN Plasminogen 
CASP3_HUMAN Caspase-3 PLP2_HUMAN Proteolipid protein 2 
CASP6_HUMAN Caspase-6 PLSL_HUMAN Plastin-2 
CASS4_HUMAN 
Cas scaffolding protein family member 
4 
PLST_HUMAN Plastin-3 
CATA_HUMAN Catalase PLXB2_HUMAN Plexin-B2 
CATB_HUMAN Cathepsin B PML_HUMAN Protein PML 
CATC_HUMAN Dipeptidyl peptidase 1 PMVK_HUMAN Phosphomevalonate kinase 
CATD_HUMAN Cathepsin D PNCB_HUMAN 
Nicotinate 
phosphoribosyltransferase 
CATG_HUMAN Cathepsin G PNPH_HUMAN Purine nucleoside phosphorylase 
CATS_HUMAN Cathepsin S POSTN_HUMAN Periostin 
CATZ_HUMAN Cathepsin Z POTEE_HUMAN 
POTE ankyrin domain family 
member E 
CAZA1_HUMAN 
F-actin-capping protein subunit alpha-
1 
POTEI_HUMAN 
POTE ankyrin domain family 
member I 
CAZA2_HUMAN 
F-actin-capping protein subunit alpha-
2 
PP14A_HUMAN 
Protein phosphatase 1 regulatory 
subunit 14A 
CBPN_HUMAN Carboxypeptidase N catalytic chain PP1A_HUMAN 
Serine/threonine-protein 
phosphatase PP1-alpha catalytic 
subunit 
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CBR1_HUMAN Carbonyl reductase [NADPH] 1 PP1G_HUMAN 
Serine/threonine-protein 
phosphatase PP1-gamma catalytic 
subunit 
CBX1_HUMAN Chromobox protein homolog 1 PP1R7_HUMAN 
Protein phosphatase 1 regulatory 
subunit 7 
CBX3_HUMAN Chromobox protein homolog 3 PP2AA_HUMAN 
Serine/threonine-protein 
phosphatase 2A catalytic subunit 
alpha isoform 
CC50A_HUMAN Cell cycle control protein 50A PP2BA_HUMAN 
Serine/threonine-protein 
phosphatase 2B catalytic subunit 
alpha isoform 
CC90B_HUMAN 
Coiled-coil domain-containing protein 
90B, mitochondrial 
PP2BB_HUMAN 
Serine/threonine-protein 
phosphatase 2B catalytic subunit 
beta isoform 
CCAR2_HUMAN 
Cell cycle and apoptosis regulator 
protein 2 
PP6R1_HUMAN 
Serine/threonine-protein 
phosphatase 6 regulatory subunit 1 
CCD22_HUMAN 
Coiled-coil domain-containing protein 
22 
PP6R3_HUMAN 
Serine/threonine-protein 
phosphatase 6 regulatory subunit 3 
CCD47_HUMAN 
Coiled-coil domain-containing protein 
47 
PPAC_HUMAN 
Low molecular weight 
phosphotyrosine protein 
phosphatase 
CCDC6_HUMAN 
Coiled-coil domain-containing protein 
6 
PPCE_HUMAN Prolyl endopeptidase 
CCL5_HUMAN C-C motif chemokine 5 PPGB_HUMAN Lysosomal protective protein 
CCS_HUMAN 
Copper chaperone for superoxide 
dismutase 
PPIA_HUMAN 
Peptidyl-prolyl cis-trans isomerase 
A 
CD109_HUMAN CD109 antigen PPIB_HUMAN 
Peptidyl-prolyl cis-trans isomerase 
B 
CD14_HUMAN 
Monocyte differentiation antigen 
CD14 
PPID_HUMAN 
Peptidyl-prolyl cis-trans isomerase 
D 
CD226_HUMAN CD226 antigen PPIF_HUMAN 
Peptidyl-prolyl cis-trans isomerase 
F, mitochondrial 
CD2AP_HUMAN CD2-associated protein PPIL3_HUMAN 
Peptidyl-prolyl cis-trans isomerase-
like 3 
CD36_HUMAN Platelet glycoprotein 4 PPIP2_HUMAN 
Proline-serine-threonine 
phosphatase-interacting protein 2 
CD3Z_HUMAN 
T-cell surface glycoprotein CD3 zeta 
chain 
PPM1A_HUMAN Protein phosphatase 1A 
CD44_HUMAN CD44 antigen PPM1B_HUMAN Protein phosphatase 1B 
CD47_HUMAN Leukocyte surface antigen CD47 PPM1F_HUMAN Protein phosphatase 1F 
CD63_HUMAN CD63 antigen PPP5_HUMAN 
Serine/threonine-protein 
phosphatase 5 
CD68_HUMAN Macrosialin PPP6_HUMAN 
Serine/threonine-protein 
phosphatase 6 catalytic subunit 
CD9_HUMAN CD9 antigen PPR18_HUMAN Phostensin 
CDC37_HUMAN Hsp90 co-chaperone Cdc37 PPR21_HUMAN 
Protein phosphatase 1 regulatory 
subunit 21 
CDC42_HUMAN 
Cell division control protein 42 
homolog 
PRAF3_HUMAN PRA1 family protein 3 
CDV3_HUMAN Protein CDV3 homolog PRDC1_HUMAN 
Phosphoribosyltransferase domain-
containing protein 1 
CE051_HUMAN UPF0600 protein C5orf51 PRDX1_HUMAN Peroxiredoxin-1 
SUPPLEMENTARY DATA | 93 
 
CECR5_HUMAN 
Cat eye syndrome critical region 
protein 5 
PRDX2_HUMAN Peroxiredoxin-2 
CELF2_HUMAN CUGBP Elav-like family member 2 PRDX3_HUMAN 
Thioredoxin-dependent peroxide 
reductase, mitochondrial 
CERS2_HUMAN Ceramide synthase 2 PRDX4_HUMAN Peroxiredoxin-4 
CERU_HUMAN Ceruloplasmin PRDX5_HUMAN Peroxiredoxin-5, mitochondrial 
CFAB_HUMAN Complement factor B PRDX6_HUMAN Peroxiredoxin-6 
CH10_HUMAN 
10 kDa heat shock protein, 
mitochondrial 
PREB_HUMAN 
Prolactin regulatory element-
binding protein 
CH60_HUMAN 
60 kDa heat shock protein, 
mitochondrial 
PRKDC_HUMAN 
DNA-dependent protein kinase 
catalytic subunit 
CHID1_HUMAN Chitinase domain-containing protein 1 PROF1_HUMAN Profilin-1 
CHMP6_HUMAN Charged multivesicular body protein 6 PROF3_HUMAN Profilin-3 
CI142_HUMAN Uncharacterized protein C9orf142 PROS_HUMAN Vitamin K-dependent protein S 
CIRBP_HUMAN Cold-inducible RNA-binding protein PROSC_HUMAN 
Proline synthase co-transcribed 
bacterial homolog protein 
CISD2_HUMAN 
CDGSH iron-sulfur domain-containing 
protein 2 
PRP19_HUMAN Pre-mRNA-processing factor 19 
CISY_HUMAN Citrate synthase, mitochondrial PRP31_HUMAN 
U4/U6 small nuclear 
ribonucleoprotein Prp31 
CJ131_HUMAN Uncharacterized protein C10orf131 PRP4B_HUMAN 
Serine/threonine-protein kinase 
PRP4 homolog 
CK5P3_HUMAN 
CDK5 regulatory subunit-associated 
protein 3 
PRP6_HUMAN Pre-mRNA-processing factor 6 
CKAP4_HUMAN Cytoskeleton-associated protein 4 PRP8_HUMAN 
Pre-mRNA-processing-splicing 
factor 8 
CKAP5_HUMAN Cytoskeleton-associated protein 5 PRPS1_HUMAN 
Ribose-phosphate 
pyrophosphokinase 1 
CKLF5_HUMAN 
CKLF-like MARVEL transmembrane 
domain-containing protein 5 
PRPS2_HUMAN 
Ribose-phosphate 
pyrophosphokinase 2 
CKLF6_HUMAN 
CKLF-like MARVEL transmembrane 
domain-containing protein 6 
PRRC1_HUMAN Protein PRRC1 
CLAP1_HUMAN CLIP-associating protein 1 PRS10_HUMAN 
26S protease regulatory subunit 
10B 
CLC1B_HUMAN 
C-type lectin domain family 1 member 
B 
PRS4_HUMAN 26S protease regulatory subunit 4 
CLCA_HUMAN Clathrin light chain A PRS6A_HUMAN 26S protease regulatory subunit 6A 
CLD5_HUMAN Claudin-5 PRS6B_HUMAN 26S protease regulatory subunit 6B 
CLH1_HUMAN Clathrin heavy chain 1 PRS7_HUMAN 26S protease regulatory subunit 7 
CLIC1_HUMAN 
Chloride intracellular channel protein 
1 
PRS8_HUMAN 26S protease regulatory subunit 8 
CLIC4_HUMAN 
Chloride intracellular channel protein 
4 
PRSR2_HUMAN Proline and serine-rich protein 2 
CLUS_HUMAN Clusterin PRTN3_HUMAN Myeloblastin 
CMC1_HUMAN 
Calcium-binding mitochondrial carrier 
protein Aralar1 
PRUNE_HUMAN Protein prune homolog 
CMC2_HUMAN 
Calcium-binding mitochondrial carrier 
protein Aralar2 
PSA_HUMAN 
Puromycin-sensitive 
aminopeptidase 
CMIP_HUMAN C-Maf-inducing protein PSA1_HUMAN Proteasome subunit alpha type-1 
CN166_HUMAN UPF0568 protein C14orf166 PSA2_HUMAN Proteasome subunit alpha type-2 
CN37_HUMAN 
2',3'-cyclic-nucleotide 3'-
phosphodiesterase 
PSA3_HUMAN Proteasome subunit alpha type-3 
CNDP2_HUMAN Cytosolic non-specific dipeptidase PSA4_HUMAN Proteasome subunit alpha type-4 
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CNN2_HUMAN Calponin-2 PSA5_HUMAN Proteasome subunit alpha type-5 
CNPY2_HUMAN Protein canopy homolog 2 PSA6_HUMAN Proteasome subunit alpha type-6 
CNST_HUMAN Consortin PSA7_HUMAN Proteasome subunit alpha type-7 
CO1A1_HUMAN Collagen alpha-1(I) chain PSB1_HUMAN Proteasome subunit beta type-1 
CO1A2_HUMAN Collagen alpha-2(I) chain PSB10_HUMAN Proteasome subunit beta type-10 
CO3_HUMAN Complement C3 PSB2_HUMAN Proteasome subunit beta type-2 
CO3A1_HUMAN Collagen alpha-1(III) chain PSB3_HUMAN Proteasome subunit beta type-3 
CO4A_HUMAN Complement C4-A PSB4_HUMAN Proteasome subunit beta type-4 
CO4B_HUMAN Complement C4-B PSB7_HUMAN Proteasome subunit beta type-7 
CO5_HUMAN Complement C5 PSB8_HUMAN Proteasome subunit beta type-8 
CO6A1_HUMAN Collagen alpha-1(VI) chain PSB9_HUMAN Proteasome subunit beta type-9 
CO6A3_HUMAN Collagen alpha-3(VI) chain PSD10_HUMAN 
26S proteasome non-ATPase 
regulatory subunit 10 
CO9_HUMAN Complement component C9 PSD11_HUMAN 
26S proteasome non-ATPase 
regulatory subunit 11 
COF1_HUMAN Cofilin-1 PSD12_HUMAN 
26S proteasome non-ATPase 
regulatory subunit 12 
COMP_HUMAN Cartilage oligomeric matrix protein PSD13_HUMAN 
26S proteasome non-ATPase 
regulatory subunit 13 
COMT_HUMAN Catechol O-methyltransferase PSDE_HUMAN 
26S proteasome non-ATPase 
regulatory subunit 14 
COPA_HUMAN Coatomer subunit alpha PSIP1_HUMAN PC4 and SFRS1-interacting protein 
COPB_HUMAN Coatomer subunit beta PSMD1_HUMAN 
26S proteasome non-ATPase 
regulatory subunit 1 
COPB2_HUMAN Coatomer subunit beta' PSMD2_HUMAN 
26S proteasome non-ATPase 
regulatory subunit 2 
COPD_HUMAN Coatomer subunit delta PSMD3_HUMAN 
26S proteasome non-ATPase 
regulatory subunit 3 
COPE_HUMAN Coatomer subunit epsilon PSMD5_HUMAN 
26S proteasome non-ATPase 
regulatory subunit 5 
COPG1_HUMAN Coatomer subunit gamma-1 PSMD6_HUMAN 
26S proteasome non-ATPase 
regulatory subunit 6 
COPG2_HUMAN Coatomer subunit gamma-2 PSMD7_HUMAN 
26S proteasome non-ATPase 
regulatory subunit 7 
COPZ1_HUMAN Coatomer subunit zeta-1 PSMD8_HUMAN 
26S proteasome non-ATPase 
regulatory subunit 8 
COR1A_HUMAN Coronin-1A PSMD9_HUMAN 
26S proteasome non-ATPase 
regulatory subunit 9 
COR1B_HUMAN Coronin-1B PSME1_HUMAN 
Proteasome activator complex 
subunit 1 
COR1C_HUMAN Coronin-1C PSME2_HUMAN 
Proteasome activator complex 
subunit 2 
CORO7_HUMAN Coronin-7 PSMF1_HUMAN Proteasome inhibitor PI31 subunit 
COTL1_HUMAN Coactosin-like protein PSPC1_HUMAN Paraspeckle component 1 
COX2_HUMAN Cytochrome c oxidase subunit 2 PTBP1_HUMAN 
Polypyrimidine tract-binding 
protein 1 
COX41_HUMAN 
Cytochrome c oxidase subunit 4 
isoform 1, mitochondrial 
PTCA_HUMAN 
Protein tyrosine phosphatase 
receptor type C-associated protein 
COX5A_HUMAN 
Cytochrome c oxidase subunit 5A, 
mitochondrial 
PTMA_HUMAN Prothymosin alpha 
COX5B_HUMAN 
Cytochrome c oxidase subunit 5B, 
mitochondrial 
PTN1_HUMAN 
Tyrosine-protein phosphatase non-
receptor type 1 
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COX6C_HUMAN Cytochrome c oxidase subunit 6C PTN11_HUMAN 
Tyrosine-protein phosphatase non-
receptor type 11 
CP062_HUMAN UPF0505 protein C16orf62 PTN12_HUMAN 
Tyrosine-protein phosphatase non-
receptor type 12 
CPIN1_HUMAN Anamorsin PTN6_HUMAN 
Tyrosine-protein phosphatase non-
receptor type 6 
CPNE1_HUMAN Copine-1 PTPA_HUMAN 
Serine/threonine-protein 
phosphatase 2A activator 
CPNE3_HUMAN Copine-3 PTPRC_HUMAN 
Receptor-type tyrosine-protein 
phosphatase C 
CPNS1_HUMAN Calpain small subunit 1 PTPRJ_HUMAN 
Receptor-type tyrosine-protein 
phosphatase eta 
CPPED_HUMAN 
Serine/threonine-protein 
phosphatase CPPED1 
PTPRO_HUMAN 
Receptor-type tyrosine-protein 
phosphatase O 
CPSF5_HUMAN 
Cleavage and polyadenylation 
specificity factor subunit 5 
PUR2_HUMAN 
Trifunctional purine biosynthetic 
protein adenosine-3 
CPSF6_HUMAN 
Cleavage and polyadenylation 
specificity factor subunit 6 
PUR4_HUMAN 
Phosphoribosylformylglycinamidine 
synthase 
CPT1A_HUMAN 
Carnitine O-palmitoyltransferase 1, 
liver isoform 
PUR6_HUMAN Multifunctional protein ADE2 
CREG1_HUMAN Protein CREG1 PUR8_HUMAN Adenylosuccinate lyase 
CRKL_HUMAN Crk-like protein PUR9_HUMAN 
Bifunctional purine biosynthesis 
protein PURH 
CRLF3_HUMAN Cytokine receptor-like factor 3 PURA_HUMAN 
Transcriptional activator protein 
Pur-alpha 
CS010_HUMAN UPF0556 protein C19orf10 PURA2_HUMAN 
Adenylosuccinate synthetase 
isozyme 2 
CS066_HUMAN UPF0515 protein C19orf66 PYGB_HUMAN 
Glycogen phosphorylase, brain 
form 
CSCL1_HUMAN CSC1-like protein 1 PYGL_HUMAN Glycogen phosphorylase, liver form 
CSK_HUMAN Tyrosine-protein kinase CSK PYR1_HUMAN CAD protein 
CSK23_HUMAN Casein kinase II subunit alpha 3 QCR1_HUMAN 
Cytochrome b-c1 complex subunit 
1, mitochondrial 
CSN1_HUMAN COP9 signalosome complex subunit 1 QCR2_HUMAN 
Cytochrome b-c1 complex subunit 
2, mitochondrial 
CSN2_HUMAN COP9 signalosome complex subunit 2 QCR7_HUMAN Cytochrome b-c1 complex subunit 7 
CSN4_HUMAN COP9 signalosome complex subunit 4 QOR_HUMAN Quinone oxidoreductase 
CSN6_HUMAN COP9 signalosome complex subunit 6 RAB10_HUMAN Ras-related protein Rab-10 
CSN8_HUMAN COP9 signalosome complex subunit 8 RAB13_HUMAN Ras-related protein Rab-13 
CSRP1_HUMAN Cysteine and glycine-rich protein 1 RAB14_HUMAN Ras-related protein Rab-14 
CTBP1_HUMAN C-terminal-binding protein 1 RAB18_HUMAN Ras-related protein Rab-18 
CTL1_HUMAN Choline transporter-like protein 1 RAB1A_HUMAN Ras-related protein Rab-1A 
CTND1_HUMAN Catenin delta-1 RAB1B_HUMAN Ras-related protein Rab-1B 
CUL3_HUMAN Cullin-3 RAB21_HUMAN Ras-related protein Rab-21 
CUL4B_HUMAN Cullin-4B RAB2A_HUMAN Ras-related protein Rab-2A 
CUTA_HUMAN Protein CutA RAB2B_HUMAN Ras-related protein Rab-2B 
CX6B1_HUMAN Cytochrome c oxidase subunit 6B1 RAB32_HUMAN Ras-related protein Rab-32 
CX7A2_HUMAN 
Cytochrome c oxidase subunit 7A2, 
mitochondrial 
RAB37_HUMAN Ras-related protein Rab-37 
CXCL7_HUMAN Platelet basic protein RAB3C_HUMAN Ras-related protein Rab-3C 
CY1_HUMAN 
Cytochrome c1, heme protein, 
mitochondrial 
RAB3D_HUMAN Ras-related protein Rab-3D 
CY24A_HUMAN Cytochrome b-245 light chain RAB4A_HUMAN Ras-related protein Rab-4A 
96 | SUPPLEMENTARY DATA 
 
CY24B_HUMAN Cytochrome b-245 heavy chain RAB4B_HUMAN Ras-related protein Rab-4B 
CYB5B_HUMAN Cytochrome b5 type B RAB5A_HUMAN Ras-related protein Rab-5A 
CYBP_HUMAN Calcyclin-binding protein RAB5B_HUMAN Ras-related protein Rab-5B 
CYC_HUMAN Cytochrome c RAB5C_HUMAN Ras-related protein Rab-5C 
CYFP1_HUMAN 
Cytoplasmic FMR1-interacting protein 
1 
RAB6A_HUMAN Ras-related protein Rab-6A 
CYFP2_HUMAN 
Cytoplasmic FMR1-interacting protein 
2 
RAB6B_HUMAN Ras-related protein Rab-6B 
CYTB_HUMAN Cystatin-B RAB6C_HUMAN Ras-related protein Rab-6C 
CYTSB_HUMAN Cytospin-B RAB7A_HUMAN Ras-related protein Rab-7a 
DAAM1_HUMAN 
Disheveled-associated activator of 
morphogenesis 1 
RAB8A_HUMAN Ras-related protein Rab-8A 
DAB2_HUMAN Disabled homolog 2 RAB8B_HUMAN Ras-related protein Rab-8B 
DAD1_HUMAN 
Dolichyl-diphosphooligosaccharide--
protein glycosyltransferase subunit 
DAD1 
RABL6_HUMAN Rab-like protein 6 
DAPP1_HUMAN 
Dual adapter for phosphotyrosine and 
3-phosphotyrosine and 3-
phosphoinositide 
RAC1_HUMAN 
Ras-related C3 botulinum toxin 
substrate 1 
DAZP1_HUMAN DAZ-associated protein 1 RAC2_HUMAN 
Ras-related C3 botulinum toxin 
substrate 2 
DBLOH_HUMAN Diablo homolog, mitochondrial RAC3_HUMAN 
Ras-related C3 botulinum toxin 
substrate 3 
DBNL_HUMAN Drebrin-like protein RADI_HUMAN Radixin 
DC1I2_HUMAN 
Cytoplasmic dynein 1 intermediate 
chain 2 
RAE1L_HUMAN mRNA export factor 
DCAF7_HUMAN DDB1- and CUL4-associated factor 7 RALA_HUMAN Ras-related protein Ral-A 
DCD_HUMAN Dermcidin RALB_HUMAN Ras-related protein Ral-B 
DCK_HUMAN Deoxycytidine kinase RALY_HUMAN RNA-binding protein Raly 
DCPS_HUMAN m7GpppX diphosphatase RAN_HUMAN GTP-binding nuclear protein Ran 
DCTN1_HUMAN Dynactin subunit 1 RANG_HUMAN 
Ran-specific GTPase-activating 
protein 
DCTN2_HUMAN Dynactin subunit 2 RAP1A_HUMAN Ras-related protein Rap-1A 
DCTN3_HUMAN Dynactin subunit 3 RAP1B_HUMAN Ras-related protein Rap-1b 
DCTN4_HUMAN Dynactin subunit 4 RAP2B_HUMAN Ras-related protein Rap-2b 
DCUP_HUMAN Uroporphyrinogen decarboxylase RASA3_HUMAN Ras GTPase-activating protein 3 
DCXR_HUMAN L-xylulose reductase RASH_HUMAN GTPase HRas 
DDAH2_HUMAN 
N(G),N(G)-dimethylarginine 
dimethylaminohydrolase 2 
RASK_HUMAN GTPase KRas 
DDB1_HUMAN DNA damage-binding protein 1 RASL3_HUMAN RAS protein activator like-3 
DDRGK_HUMAN DDRGK domain-containing protein 1 RB11B_HUMAN Ras-related protein Rab-11B 
DDX1_HUMAN ATP-dependent RNA helicase DDX1 RB27B_HUMAN Ras-related protein Rab-27B 
DDX17_HUMAN 
Probable ATP-dependent RNA helicase 
DDX17 
RBBP4_HUMAN Histone-binding protein RBBP4 
DDX21_HUMAN Nucleolar RNA helicase 2 RBBP7_HUMAN Histone-binding protein RBBP7 
DDX3X_HUMAN ATP-dependent RNA helicase DDX3X RBM14_HUMAN RNA-binding protein 14 
DDX3Y_HUMAN ATP-dependent RNA helicase DDX3Y RBM25_HUMAN RNA-binding protein 25 
DDX5_HUMAN 
Probable ATP-dependent RNA helicase 
DDX5 
RBM3_HUMAN RNA-binding protein 3 
DDX6_HUMAN 
Probable ATP-dependent RNA helicase 
DDX6 
RBM39_HUMAN RNA-binding protein 39 
DECR_HUMAN 
2,4-dienoyl-CoA reductase, 
mitochondrial 
RBMX_HUMAN 
RNA-binding motif protein, X 
chromosome 
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DEK_HUMAN Protein DEK RBP56_HUMAN 
TATA-binding protein-associated 
factor 2N 
DEMA_HUMAN Dematin RCC2_HUMAN Protein RCC2 
DENR_HUMAN Density-regulated protein RCN2_HUMAN Reticulocalbin-2 
DEOC_HUMAN Deoxyribose-phosphate aldolase RD23B_HUMAN 
UV excision repair protein RAD23 
homolog B 
DERL1_HUMAN Derlin-1 RDH11_HUMAN Retinol dehydrogenase 11 
DESP_HUMAN Desmoplakin RECQ1_HUMAN ATP-dependent DNA helicase Q1 
DEST_HUMAN Destrin REEP5_HUMAN 
Receptor expression-enhancing 
protein 5 
DGKA_HUMAN Diacylglycerol kinase alpha RENBP_HUMAN N-acylglucosamine 2-epimerase 
DHAK_HUMAN 
Bifunctional ATP-dependent 
dihydroxyacetone kinase/FAD-AMP 
lyase (cyclizing) 
RENT1_HUMAN Regulator of nonsense transcripts 1 
DHB11_HUMAN Estradiol 17-beta-dehydrogenase 11 RET4_HUMAN Retinol-binding protein 4 
DHB12_HUMAN Estradiol 17-beta-dehydrogenase 12 RFA1_HUMAN 
Replication protein A 70 kDa DNA-
binding subunit 
DHB4_HUMAN 
Peroxisomal multifunctional enzyme 
type 2 
RFA3_HUMAN 
Replication protein A 14 kDa 
subunit 
DHE3_HUMAN 
Glutamate dehydrogenase 1, 
mitochondrial 
RFIP3_HUMAN Rab11 family-interacting protein 3 
DHPR_HUMAN Dihydropteridine reductase RGCC_HUMAN Regulator of cell cycle RGCC 
DHRS4_HUMAN 
Dehydrogenase/reductase SDR family 
member 4 
RGS10_HUMAN Regulator of G-protein signaling 10 
DHRS7_HUMAN 
Dehydrogenase/reductase SDR family 
member 7 
RGS18_HUMAN Regulator of G-protein signaling 18 
DHSO_HUMAN Sorbitol dehydrogenase RGS6_HUMAN Regulator of G-protein signaling 6 
DHX15_HUMAN 
Putative pre-mRNA-splicing factor 
ATP-dependent RNA helicase DHX15 
RHG01_HUMAN Rho GTPase-activating protein 1 
DHX9_HUMAN ATP-dependent RNA helicase A RHG04_HUMAN Rho GTPase-activating protein 4 
DIAP1_HUMAN Protein diaphanous homolog 1 RHG06_HUMAN Rho GTPase-activating protein 6 
DJB11_HUMAN DnaJ homolog subfamily B member 11 RHG17_HUMAN Rho GTPase-activating protein 17 
DJC13_HUMAN DnaJ homolog subfamily C member 13 RHG18_HUMAN Rho GTPase-activating protein 18 
DKC1_HUMAN 
H/ACA ribonucleoprotein complex 
subunit 4 
RHG25_HUMAN Rho GTPase-activating protein 25 
DLDH_HUMAN 
Dihydrolipoyl dehydrogenase, 
mitochondrial 
RHOA_HUMAN Transforming protein RhoA 
DNJA1_HUMAN DnaJ homolog subfamily A member 1 RHOC_HUMAN 
Rho-related GTP-binding protein 
RhoC 
DNJA2_HUMAN DnaJ homolog subfamily A member 2 RHOG_HUMAN 
Rho-related GTP-binding protein 
RhoG 
DNJB1_HUMAN DnaJ homolog subfamily B member 1 RIC8A_HUMAN Synembryn-A 
DNJB2_HUMAN DnaJ homolog subfamily B member 2 RINI_HUMAN Ribonuclease inhibitor 
DNJC3_HUMAN DnaJ homolog subfamily C member 3 RIPK1_HUMAN 
Receptor-interacting 
serine/threonine-protein kinase 1 
DNJC7_HUMAN DnaJ homolog subfamily C member 7 RISC_HUMAN 
Retinoid-inducible serine 
carboxypeptidase 
DNJC9_HUMAN DnaJ homolog subfamily C member 9 RL10_HUMAN 60S ribosomal protein L10 
DNLI3_HUMAN DNA ligase 3 RL10A_HUMAN 60S ribosomal protein L10a 
DNM1L_HUMAN Dynamin-1-like protein RL11_HUMAN 60S ribosomal protein L11 
DNPH1_HUMAN 
2'-deoxynucleoside 5'-phosphate N-
hydrolase 1 
RL12_HUMAN 60S ribosomal protein L12 
DOC10_HUMAN Dedicator of cytokinesis protein 10 RL13_HUMAN 60S ribosomal protein L13 
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DOCK2_HUMAN Dedicator of cytokinesis protein 2 RL13A_HUMAN 60S ribosomal protein L13a 
DOCK8_HUMAN Dedicator of cytokinesis protein 8 RL14_HUMAN 60S ribosomal protein L14 
DOK1_HUMAN Docking protein 1 RL15_HUMAN 60S ribosomal protein L15 
DOK2_HUMAN Docking protein 2 RL17_HUMAN 60S ribosomal protein L17 
DOK3_HUMAN Docking protein 3 RL18_HUMAN 60S ribosomal protein L18 
DOPD_HUMAN D-dopachrome decarboxylase RL18A_HUMAN 60S ribosomal protein L18a 
DP13A_HUMAN DCC-interacting protein 13-alpha RL19_HUMAN 60S ribosomal protein L19 
DP13B_HUMAN DCC-interacting protein 13-beta RL21_HUMAN 60S ribosomal protein L21 
DPM1_HUMAN 
Dolichol-phosphate 
mannosyltransferase subunit 1 
RL22_HUMAN 60S ribosomal protein L22 
DPP2_HUMAN Dipeptidyl peptidase 2 RL23_HUMAN 60S ribosomal protein L23 
DPP3_HUMAN Dipeptidyl peptidase 3 RL23A_HUMAN 60S ribosomal protein L23a 
DPYL2_HUMAN Dihydropyrimidinase-related protein 2 RL24_HUMAN 60S ribosomal protein L24 
DRA_HUMAN 
HLA class II histocompatibility antigen, 
DR alpha chain 
RL26L_HUMAN 60S ribosomal protein L26-like 1 
DREB_HUMAN Drebrin RL27_HUMAN 60S ribosomal protein L27 
DRG1_HUMAN 
Developmentally-regulated GTP-
binding protein 1 
RL27A_HUMAN 60S ribosomal protein L27a 
DTD1_HUMAN D-tyrosyl-tRNA(Tyr) deacylase 1 RL28_HUMAN 60S ribosomal protein L28 
DUS3_HUMAN Dual specificity protein phosphatase 3 RL29_HUMAN 60S ribosomal protein L29 
DX39A_HUMAN ATP-dependent RNA helicase DDX39A RL3_HUMAN 60S ribosomal protein L3 
DX39B_HUMAN Spliceosome RNA helicase DDX39B RL30_HUMAN 60S ribosomal protein L30 
DYHC1_HUMAN Cytoplasmic dynein 1 heavy chain 1 RL31_HUMAN 60S ribosomal protein L31 
DYL2_HUMAN Dynein light chain 2, cytoplasmic RL32_HUMAN 60S ribosomal protein L32 
DYN1_HUMAN Dynamin-1 RL34_HUMAN 60S ribosomal protein L34 
DYN2_HUMAN Dynamin-2 RL35_HUMAN 60S ribosomal protein L35 
DYN3_HUMAN Dynamin-3 RL35A_HUMAN 60S ribosomal protein L35a 
ECE1_HUMAN Endothelin-converting enzyme 1 RL36_HUMAN 60S ribosomal protein L36 
ECH1_HUMAN 
Delta(3,5)-Delta(2,4)-dienoyl-CoA 
isomerase, mitochondrial 
RL38_HUMAN 60S ribosomal protein L38 
ECHA_HUMAN 
Trifunctional enzyme subunit alpha, 
mitochondrial 
RL4_HUMAN 60S ribosomal protein L4 
ECHB_HUMAN 
Trifunctional enzyme subunit beta, 
mitochondrial 
RL40_HUMAN 
Ubiquitin-60S ribosomal protein 
L40 
ECHD1_HUMAN Ethylmalonyl-CoA decarboxylase RL5_HUMAN 60S ribosomal protein L5 
ECHM_HUMAN Enoyl-CoA hydratase, mitochondrial RL6_HUMAN 60S ribosomal protein L6 
ECI2_HUMAN 
Enoyl-CoA delta isomerase 2, 
mitochondrial 
RL7_HUMAN 60S ribosomal protein L7 
ECP_HUMAN Eosinophil cationic protein RL7A_HUMAN 60S ribosomal protein L7a 
EDEM1_HUMAN 
ER degradation-enhancing alpha-
mannosidase-like protein 1 
RL8_HUMAN 60S ribosomal protein L8 
EEA1_HUMAN Early endosome antigen 1 RL9_HUMAN 60S ribosomal protein L9 
EF1A3_HUMAN 
Putative elongation factor 1-alpha-like 
3 
RLA0_HUMAN 60S acidic ribosomal protein P0 
EF1B_HUMAN Elongation factor 1-beta RLA1_HUMAN 60S acidic ribosomal protein P1 
EF1D_HUMAN Elongation factor 1-delta RLA2_HUMAN 60S acidic ribosomal protein P2 
EF1G_HUMAN Elongation factor 1-gamma RMXL1_HUMAN 
RNA binding motif protein, X-linked-
like-1 
EF2_HUMAN Elongation factor 2 RN213_HUMAN E3 ubiquitin-protein ligase RNF213 
EFHD2_HUMAN EF-hand domain-containing protein D2 RN5A_HUMAN 2-5A-dependent ribonuclease 
EFNB1_HUMAN Ephrin-B1 RNF11_HUMAN RING finger protein 11 
EFTU_HUMAN Elongation factor Tu, mitochondrial RNPS1_HUMAN 
RNA-binding protein with serine-
rich domain 1 
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EHD1_HUMAN EH domain-containing protein 1 RNT2_HUMAN Ribonuclease T2 
EHD3_HUMAN EH domain-containing protein 3 RO52_HUMAN E3 ubiquitin-protein ligase TRIM21 
EHD4_HUMAN EH domain-containing protein 4 RO60_HUMAN 60 kDa SS-A/Ro ribonucleoprotein 
EIF1_HUMAN 
Eukaryotic translation initiation factor 
1 
ROA0_HUMAN 
Heterogeneous nuclear 
ribonucleoprotein A0 
EIF3A_HUMAN 
Eukaryotic translation initiation factor 
3 subunit A 
ROA1_HUMAN 
Heterogeneous nuclear 
ribonucleoprotein A1 
EIF3B_HUMAN 
Eukaryotic translation initiation factor 
3 subunit B 
ROA2_HUMAN 
Heterogeneous nuclear 
ribonucleoproteins A2/B1 
EIF3C_HUMAN 
Eukaryotic translation initiation factor 
3 subunit C 
ROA3_HUMAN 
Heterogeneous nuclear 
ribonucleoprotein A3 
EIF3D_HUMAN 
Eukaryotic translation initiation factor 
3 subunit D 
ROAA_HUMAN 
Heterogeneous nuclear 
ribonucleoprotein A/B 
EIF3E_HUMAN 
Eukaryotic translation initiation factor 
3 subunit E 
ROCK1_HUMAN Rho-associated protein kinase 1 
EIF3F_HUMAN 
Eukaryotic translation initiation factor 
3 subunit F 
ROCK2_HUMAN Rho-associated protein kinase 2 
EIF3G_HUMAN 
Eukaryotic translation initiation factor 
3 subunit G 
RPB2_HUMAN 
DNA-directed RNA polymerase II 
subunit RPB2 
EIF3H_HUMAN 
Eukaryotic translation initiation factor 
3 subunit H 
RPB9_HUMAN 
DNA-directed RNA polymerase II 
subunit RPB9 
EIF3I_HUMAN 
Eukaryotic translation initiation factor 
3 subunit I 
RPN1_HUMAN 
Dolichyl-diphosphooligosaccharide-
-protein glycosyltransferase subunit 
1 
EIF3J_HUMAN 
Eukaryotic translation initiation factor 
3 subunit J 
RPN2_HUMAN 
Dolichyl-diphosphooligosaccharide-
-protein glycosyltransferase subunit 
2 
EIF3K_HUMAN 
Eukaryotic translation initiation factor 
3 subunit K 
RPR1B_HUMAN 
Regulation of nuclear pre-mRNA 
domain-containing protein 1B 
EIF3L_HUMAN 
Eukaryotic translation initiation factor 
3 subunit L 
RRAS_HUMAN Ras-related protein R-Ras 
ELAV1_HUMAN ELAV-like protein 1 RRBP1_HUMAN Ribosome-binding protein 1 
ELMO1_HUMAN Engulfment and cell motility protein 1 RRF2M_HUMAN 
Ribosome-releasing factor 2, 
mitochondrial 
ELNE_HUMAN Neutrophil elastase RS10_HUMAN 40S ribosomal protein S10 
ELOB_HUMAN 
Transcription elongation factor B 
polypeptide 2 
RS11_HUMAN 40S ribosomal protein S11 
EM55_HUMAN 55 kDa erythrocyte membrane protein RS12_HUMAN 40S ribosomal protein S12 
EMAL2_HUMAN 
Echinoderm microtubule-associated 
protein-like 2 
RS13_HUMAN 40S ribosomal protein S13 
EMAL3_HUMAN 
Echinoderm microtubule-associated 
protein-like 3 
RS14_HUMAN 40S ribosomal protein S14 
EMD_HUMAN Emerin RS15A_HUMAN 40S ribosomal protein S15a 
EMIL1_HUMAN EMILIN-1 RS16_HUMAN 40S ribosomal protein S16 
EMSA1_HUMAN 
ELM2 and SANT domain-containing 
protein 1 
RS17L_HUMAN 40S ribosomal protein S17-like 
ENDD1_HUMAN 
Endonuclease domain-containing 1 
protein 
RS18_HUMAN 40S ribosomal protein S18 
ENOA_HUMAN Alpha-enolase RS19_HUMAN 40S ribosomal protein S19 
ENOG_HUMAN Gamma-enolase RS2_HUMAN 40S ribosomal protein S2 
ENOPH_HUMAN Enolase-phosphatase E1 RS20_HUMAN 40S ribosomal protein S20 
ENPL_HUMAN Endoplasmin RS23_HUMAN 40S ribosomal protein S23 
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ENPP7_HUMAN 
Ectonucleotide 
pyrophosphatase/phosphodiesterase 
family member 7 
RS24_HUMAN 40S ribosomal protein S24 
EP15R_HUMAN 
Epidermal growth factor receptor 
substrate 15-like 1 
RS25_HUMAN 40S ribosomal protein S25 
EPDR1_HUMAN 
Mammalian ependymin-related 
protein 1 
RS26_HUMAN 40S ribosomal protein S26 
EPN1_HUMAN Epsin-1 RS27A_HUMAN 
Ubiquitin-40S ribosomal protein 
S27a 
EPN4_HUMAN Clathrin interactor 1 RS27L_HUMAN 40S ribosomal protein S27-like 
EPS15_HUMAN 
Epidermal growth factor receptor 
substrate 15 
RS28_HUMAN 40S ribosomal protein S28 
ERAP1_HUMAN 
Endoplasmic reticulum 
aminopeptidase 1 
RS3_HUMAN 40S ribosomal protein S3 
ERAP2_HUMAN 
Endoplasmic reticulum 
aminopeptidase 2 
RS30_HUMAN 40S ribosomal protein S30 
ERF1_HUMAN 
Eukaryotic peptide chain release 
factor subunit 1 
RS3A_HUMAN 40S ribosomal protein S3a 
ERF3A_HUMAN 
Eukaryotic peptide chain release 
factor GTP-binding subunit ERF3A 
RS4X_HUMAN 40S ribosomal protein S4, X isoform 
ERG7_HUMAN Lanosterol synthase RS4Y2_HUMAN 
40S ribosomal protein S4, Y isoform 
2 
ERGI1_HUMAN 
Endoplasmic reticulum-Golgi 
intermediate compartment protein 1 
RS5_HUMAN 40S ribosomal protein S5 
ERLN1_HUMAN Erlin-1 RS6_HUMAN 40S ribosomal protein S6 
ERO1A_HUMAN ERO1-like protein alpha RS7_HUMAN 40S ribosomal protein S7 
ERP29_HUMAN 
Endoplasmic reticulum resident 
protein 29 
RS8_HUMAN 40S ribosomal protein S8 
ERP44_HUMAN 
Endoplasmic reticulum resident 
protein 44 
RS9_HUMAN 40S ribosomal protein S9 
ES1_HUMAN ES1 protein homolog, mitochondrial RSMN_HUMAN 
Small nuclear ribonucleoprotein-
associated protein N 
ESAM_HUMAN 
Endothelial cell-selective adhesion 
molecule 
RSSA_HUMAN 40S ribosomal protein SA 
EST1_HUMAN Liver carboxylesterase 1 RSU1_HUMAN Ras suppressor protein 1 
ESTD_HUMAN S-formylglutathione hydrolase RTCA_HUMAN RNA 3'-terminal phosphate cyclase 
ESYT1_HUMAN Extended synaptotagmin-1 RTCB_HUMAN tRNA-splicing ligase RtcB homolog 
ESYT2_HUMAN Extended synaptotagmin-2 RTN1_HUMAN Reticulon-1 
ETFA_HUMAN 
Electron transfer flavoprotein subunit 
alpha, mitochondrial 
RTN2_HUMAN Reticulon-2 
ETFB_HUMAN 
Electron transfer flavoprotein subunit 
beta 
RTN3_HUMAN Reticulon-3 
ETHE1_HUMAN 
Persulfide dioxygenase ETHE1, 
mitochondrial 
RTN4_HUMAN Reticulon-4 
EVL_HUMAN Ena/VASP-like protein RU17_HUMAN 
U1 small nuclear ribonucleoprotein 
70 kDa 
EWS_HUMAN RNA-binding protein EWS RU2A_HUMAN 
U2 small nuclear ribonucleoprotein 
A' 
EXOC2_HUMAN Exocyst complex component 2 RU2B_HUMAN 
U2 small nuclear ribonucleoprotein 
B'' 
EZRI_HUMAN Ezrin RUFY1_HUMAN 
RUN and FYVE domain-containing 
protein 1 
F10A1_HUMAN Hsc70-interacting protein RUVB1_HUMAN RuvB-like 1 
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F1142_HUMAN Protein FAM114A2 RUVB2_HUMAN RuvB-like 2 
F120A_HUMAN 
Constitutive coactivator of PPAR-
gamma-like protein 1 
RUXE_HUMAN Small nuclear ribonucleoprotein E 
F13A_HUMAN Coagulation factor XIII A chain RUXF_HUMAN Small nuclear ribonucleoprotein F 
F162A_HUMAN Protein FAM162A S10A4_HUMAN Protein S100-A4 
F16P1_HUMAN Fructose-1,6-bisphosphatase 1 S10A6_HUMAN Protein S100-A6 
F1712_HUMAN Protein FAM171A2 S10A7_HUMAN Protein S100-A7 
F177A_HUMAN Protein FAM177A1 S10A8_HUMAN Protein S100-A8 
FA10_HUMAN Coagulation factor X S10A9_HUMAN Protein S100-A9 
FA49B_HUMAN Protein FAM49B S10AA_HUMAN Protein S100-A10 
FA5_HUMAN Coagulation factor V S10AB_HUMAN Protein S100-A11 
FA63A_HUMAN Protein FAM63A S38A2_HUMAN 
Sodium-coupled neutral amino acid 
transporter 2 
FA98B_HUMAN Protein FAM98B SAC1_HUMAN 
Phosphatidylinositide phosphatase 
SAC1 
FAAA_HUMAN Fumarylacetoacetase SAE1_HUMAN SUMO-activating enzyme subunit 1 
FABP5_HUMAN Fatty acid-binding protein, epidermal SAFB2_HUMAN Scaffold attachment factor B2 
FACE1_HUMAN CAAX prenyl protease 1 homolog SAHH_HUMAN Adenosylhomocysteinase 
FAF1_HUMAN FAS-associated factor 1 SAHH3_HUMAN Putative adenosylhomocysteinase 3 
FAF2_HUMAN FAS-associated factor 2 SAMH1_HUMAN 
Deoxynucleoside triphosphate 
triphosphohydrolase SAMHD1 
FAK1_HUMAN Focal adhesion kinase 1 SAP18_HUMAN 
Histone deacetylase complex 
subunit SAP18 
FAK2_HUMAN Protein-tyrosine kinase 2-beta SAR1A_HUMAN GTP-binding protein SAR1a 
FAS_HUMAN Fatty acid synthase SARNP_HUMAN 
SAP domain-containing 
ribonucleoprotein 
FBLN1_HUMAN Fibulin-1 SART3_HUMAN 
Squamous cell carcinoma antigen 
recognized by T-cells 3 
FBRL_HUMAN rRNA 2'-O-methyltransferase fibrillarin SASH3_HUMAN 
SAM and SH3 domain-containing 
protein 3 
FBX7_HUMAN F-box only protein 7 SC11A_HUMAN 
Signal peptidase complex catalytic 
subunit SEC11A 
FCERG_HUMAN 
High affinity immunoglobulin epsilon 
receptor subunit gamma 
SC22B_HUMAN Vesicle-trafficking protein SEC22b 
FCG2C_HUMAN 
Low affinity immunoglobulin gamma 
Fc region receptor II-c 
SC23A_HUMAN Protein transport protein Sec23A 
FCG3A_HUMAN 
Low affinity immunoglobulin gamma 
Fc region receptor III-A 
SC23B_HUMAN Protein transport protein Sec23B 
FCL_HUMAN GDP-L-fucose synthase SC24C_HUMAN Protein transport protein Sec24C 
FCN1_HUMAN Ficolin-1 SC31A_HUMAN Protein transport protein Sec31A 
FEN1_HUMAN Flap endonuclease 1 SC61B_HUMAN 
Protein transport protein Sec61 
subunit beta 
FETA_HUMAN Alpha-fetoprotein SCAFB_HUMAN Protein SCAF11 
FETUA_HUMAN Alpha-2-HS-glycoprotein SCAM2_HUMAN 
Secretory carrier-associated 
membrane protein 2 
FHL1_HUMAN Four and a half LIM domains protein 1 SCAM3_HUMAN 
Secretory carrier-associated 
membrane protein 3 
FHOD1_HUMAN FH1/FH2 domain-containing protein 1 SCFD1_HUMAN 
Sec1 family domain-containing 
protein 1 
FHR1_HUMAN 
Complement factor H-related protein 
1 
SCMC1_HUMAN 
Calcium-binding mitochondrial 
carrier protein SCaMC-1 
FIBA_HUMAN Fibrinogen alpha chain SCOT1_HUMAN 
Succinyl-CoA:3-ketoacid coenzyme 
A transferase 1, mitochondrial 
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FIBB_HUMAN Fibrinogen beta chain SCPDL_HUMAN 
Saccharopine dehydrogenase-like 
oxidoreductase 
FIBG_HUMAN Fibrinogen gamma chain SCRN1_HUMAN Secernin-1 
FINC_HUMAN Fibronectin SCYL2_HUMAN SCY1-like protein 2 
FKB15_HUMAN FK506-binding protein 15 SDHA_HUMAN 
Succinate dehydrogenase 
[ubiquinone] flavoprotein subunit, 
mitochondrial 
FKB1A_HUMAN 
Peptidyl-prolyl cis-trans isomerase 
FKBP1A 
SDHB_HUMAN 
Succinate dehydrogenase 
[ubiquinone] iron-sulfur subunit, 
mitochondrial 
FKBP2_HUMAN 
Peptidyl-prolyl cis-trans isomerase 
FKBP2 
SDOS_HUMAN Protein syndesmos 
FKBP3_HUMAN 
Peptidyl-prolyl cis-trans isomerase 
FKBP3 
SDPR_HUMAN 
Serum deprivation-response 
protein 
FKBP4_HUMAN 
Peptidyl-prolyl cis-trans isomerase 
FKBP4 
SEC13_HUMAN Protein SEC13 homolog 
FKBP5_HUMAN 
Peptidyl-prolyl cis-trans isomerase 
FKBP5 
SELH_HUMAN Selenoprotein H 
FLII_HUMAN Protein flightless-1 homolog SEP11_HUMAN Septin-11 
FLNA_HUMAN Filamin-A SEP15_HUMAN 15 kDa selenoprotein 
FLNB_HUMAN Filamin-B SEPT1_HUMAN Septin-1 
FLOT1_HUMAN Flotillin-1 SEPT2_HUMAN Septin-2 
FLOT2_HUMAN Flotillin-2 SEPT4_HUMAN Septin-4 
FMNL_HUMAN Formin-like protein 1 SEPT5_HUMAN Septin-5 
FN3K_HUMAN Fructosamine-3-kinase SEPT6_HUMAN Septin-6 
FNBP1_HUMAN Formin-binding protein 1 SEPT7_HUMAN Septin-7 
FPPS_HUMAN Farnesyl pyrophosphate synthase SEPT9_HUMAN Septin-9 
FRIH_HUMAN Ferritin heavy chain SERA_HUMAN 
D-3-phosphoglycerate 
dehydrogenase 
FRIL_HUMAN Ferritin light chain SERPH_HUMAN Serpin H1 
FRM4B_HUMAN FERM domain-containing protein 4B SET_HUMAN Protein SET 
FUBP1_HUMAN 
Far upstream element-binding protein 
1 
SETD8_HUMAN N-lysine methyltransferase SETD8 
FUBP2_HUMAN 
Far upstream element-binding protein 
2 
SF01_HUMAN Splicing factor 1 
FUBP3_HUMAN 
Far upstream element-binding protein 
3 
SF3A1_HUMAN Splicing factor 3A subunit 1 
FUMH_HUMAN Fumarate hydratase, mitochondrial SF3A3_HUMAN Splicing factor 3A subunit 3 
FUS_HUMAN RNA-binding protein FUS SF3B1_HUMAN Splicing factor 3B subunit 1 
FYB_HUMAN FYN-binding protein SF3B2_HUMAN Splicing factor 3B subunit 2 
FYN_HUMAN Tyrosine-protein kinase Fyn SF3B3_HUMAN Splicing factor 3B subunit 3 
G3BP1_HUMAN 
Ras GTPase-activating protein-binding 
protein 1 
SF3B4_HUMAN Splicing factor 3B subunit 4 
G3P_HUMAN 
Glyceraldehyde-3-phosphate 
dehydrogenase 
SFPQ_HUMAN 
Splicing factor, proline- and 
glutamine-rich 
G6B_HUMAN Protein G6b SFXN1_HUMAN Sideroflexin-1 
G6PD_HUMAN 
Glucose-6-phosphate 1-
dehydrogenase 
SFXN3_HUMAN Sideroflexin-3 
G6PI_HUMAN Glucose-6-phosphate isomerase SH21A_HUMAN SH2 domain-containing protein 1A 
GALK1_HUMAN Galactokinase SH3G1_HUMAN Endophilin-A2 
GALM_HUMAN Aldose 1-epimerase SH3K1_HUMAN 
SH3 domain-containing kinase-
binding protein 1 
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GANAB_HUMAN Neutral alpha-glucosidase AB SH3L1_HUMAN 
SH3 domain-binding glutamic acid-
rich-like protein 
GAPR1_HUMAN 
Golgi-associated plant pathogenesis-
related protein 1 
SH3L2_HUMAN 
SH3 domain-binding glutamic acid-
rich-like protein 2 
GAR1_HUMAN 
H/ACA ribonucleoprotein complex 
subunit 1 
SH3L3_HUMAN 
SH3 domain-binding glutamic acid-
rich-like protein 3 
GBB1_HUMAN 
Guanine nucleotide-binding protein 
G(I)/G(S)/G(T) subunit beta-1 
SHBG_HUMAN Sex hormone-binding globulin 
GBB2_HUMAN 
Guanine nucleotide-binding protein 
G(I)/G(S)/G(T) subunit beta-2 
SHIP1_HUMAN 
Phosphatidylinositol 3,4,5-
trisphosphate 5-phosphatase 1 
GBLP_HUMAN 
Guanine nucleotide-binding protein 
subunit beta-2-like 1 
SHLB1_HUMAN Endophilin-B1 
GBP1_HUMAN 
Interferon-induced guanylate-binding 
protein 1 
SHLB2_HUMAN Endophilin-B2 
GCDH_HUMAN 
Glutaryl-CoA dehydrogenase, 
mitochondrial 
SIAS_HUMAN Sialic acid synthase 
GCYA3_HUMAN 
Guanylate cyclase soluble subunit 
alpha-3 
SIR2_HUMAN 
NAD-dependent protein 
deacetylase sirtuin-2 
GCYB1_HUMAN 
Guanylate cyclase soluble subunit 
beta-1 
SKAP1_HUMAN 
Src kinase-associated 
phosphoprotein 1 
GDE_HUMAN Glycogen debranching enzyme SKAP2_HUMAN 
Src kinase-associated 
phosphoprotein 2 
GDIA_HUMAN Rab GDP dissociation inhibitor alpha SKP1_HUMAN S-phase kinase-associated protein 1 
GDIB_HUMAN Rab GDP dissociation inhibitor beta SLAF5_HUMAN SLAM family member 5 
GDIR1_HUMAN Rho GDP-dissociation inhibitor 1 SLAI2_HUMAN SLAIN motif-containing protein 2 
GDIR2_HUMAN Rho GDP-dissociation inhibitor 2 SLFN5_HUMAN Schlafen family member 5 
GDN_HUMAN Glia-derived nexin SLK_HUMAN 
STE20-like serine/threonine-protein 
kinase 
GDS1_HUMAN 
Rap1 GTPase-GDP dissociation 
stimulator 1 
SLMAP_HUMAN 
Sarcolemmal membrane-associated 
protein 
GELS_HUMAN Gelsolin SLN14_HUMAN Schlafen family member 14 
GET4_HUMAN Golgi to ER traffic protein 4 homolog SMAKA_HUMAN 
Small membrane A-kinase anchor 
protein 
GFPT1_HUMAN 
Glutamine--fructose-6-phosphate 
aminotransferase [isomerizing] 1 
SMAP2_HUMAN 
Stromal membrane-associated 
protein 2 
GIMA1_HUMAN GTPase IMAP family member 1 SMC1A_HUMAN 
Structural maintenance of 
chromosomes protein 1A 
GIMA4_HUMAN GTPase IMAP family member 4 SMC3_HUMAN 
Structural maintenance of 
chromosomes protein 3 
GIMA5_HUMAN GTPase IMAP family member 5 SMD1_HUMAN 
Small nuclear ribonucleoprotein Sm 
D1 
GIMA7_HUMAN GTPase IMAP family member 7 SMD2_HUMAN 
Small nuclear ribonucleoprotein Sm 
D2 
GIMA8_HUMAN GTPase IMAP family member 8 SMD3_HUMAN 
Small nuclear ribonucleoprotein Sm 
D3 
GIPC1_HUMAN PDZ domain-containing protein GIPC1 SMIM1_HUMAN Small integral membrane protein 1 
GIPC3_HUMAN PDZ domain-containing protein GIPC3 SMRD2_HUMAN 
SWI/SNF-related matrix-associated 
actin-dependent regulator of 
chromatin subfamily D member 2 
GIT1_HUMAN ARF GTPase-activating protein GIT1 SNAA_HUMAN 
Alpha-soluble NSF attachment 
protein 
GLCM_HUMAN Glucosylceramidase SNAG_HUMAN 
Gamma-soluble NSF attachment 
protein 
104 | SUPPLEMENTARY DATA 
 
GLGB_HUMAN 1,4-alpha-glucan-branching enzyme SND1_HUMAN 
Staphylococcal nuclease domain-
containing protein 1 
GLO2_HUMAN 
Hydroxyacylglutathione hydrolase, 
mitochondrial 
SNP23_HUMAN 
Synaptosomal-associated protein 
23 
GLOD4_HUMAN 
Glyoxalase domain-containing protein 
4 
SNP29_HUMAN 
Synaptosomal-associated protein 
29 
GLPK_HUMAN Glycerol kinase SNTB1_HUMAN Beta-1-syntrophin 
GLRX3_HUMAN Glutaredoxin-3 SNX12_HUMAN Sorting nexin-12 
GLSK_HUMAN 
Glutaminase kidney isoform, 
mitochondrial 
SNX2_HUMAN Sorting nexin-2 
GLU2B_HUMAN Glucosidase 2 subunit beta SNX3_HUMAN Sorting nexin-3 
GLYC_HUMAN 
Serine hydroxymethyltransferase, 
cytosolic 
SNX5_HUMAN Sorting nexin-5 
GLYM_HUMAN 
Serine hydroxymethyltransferase, 
mitochondrial 
SNX6_HUMAN Sorting nexin-6 
GLYR1_HUMAN Putative oxidoreductase GLYR1 SNX9_HUMAN Sorting nexin-9 
GMFG_HUMAN Glia maturation factor gamma SODC_HUMAN Superoxide dismutase [Cu-Zn] 
GMPPA_HUMAN 
Mannose-1-phosphate 
guanyltransferase alpha 
SODM_HUMAN 
Superoxide dismutase [Mn], 
mitochondrial 
GMPPB_HUMAN 
Mannose-1-phosphate 
guanyltransferase beta 
SORCN_HUMAN Sorcin 
GMPR1_HUMAN GMP reductase 1 SP16H_HUMAN FACT complex subunit SPT16 
GNA13_HUMAN 
Guanine nucleotide-binding protein 
subunit alpha-13 
SPB10_HUMAN Serpin B10 
GNAI2_HUMAN 
Guanine nucleotide-binding protein 
G(i) subunit alpha-2 
SPB4_HUMAN Serpin B4 
GNAI3_HUMAN 
Guanine nucleotide-binding protein 
G(k) subunit alpha 
SPB6_HUMAN Serpin B6 
GNAQ_HUMAN 
Guanine nucleotide-binding protein 
G(q) subunit alpha 
SPB8_HUMAN Serpin B8 
GNAS1_HUMAN 
Guanine nucleotide-binding protein 
G(s) subunit alpha isoforms XLas 
SPB9_HUMAN Serpin B9 
GNAZ_HUMAN 
Guanine nucleotide-binding protein 
G(z) subunit alpha 
SPCS1_HUMAN Signal peptidase complex subunit 1 
GNLY_HUMAN Granulysin SPCS2_HUMAN Signal peptidase complex subunit 2 
GOT1B_HUMAN Vesicle transport protein GOT1B SPCS3_HUMAN Signal peptidase complex subunit 3 
GP1BA_HUMAN Platelet glycoprotein Ib alpha chain SPG20_HUMAN Spartin 
GP1BB_HUMAN Platelet glycoprotein Ib beta chain SPHM_HUMAN 
N-sulphoglucosamine 
sulphohydrolase 
GPD1L_HUMAN 
Glycerol-3-phosphate dehydrogenase 
1-like protein 
SPN90_HUMAN 
NCK-interacting protein with SH3 
domain 
GPDM_HUMAN 
Glycerol-3-phosphate dehydrogenase, 
mitochondrial 
SPRC_HUMAN SPARC 
GPIX_HUMAN Platelet glycoprotein IX SPT5H_HUMAN 
Transcription elongation factor 
SPT5 
GPV_HUMAN Platelet glycoprotein V SPTB1_HUMAN Spectrin beta chain, erythrocytic 
GPVI_HUMAN Platelet glycoprotein VI SPTB2_HUMAN 
Spectrin beta chain, non-
erythrocytic 1 
GPX1_HUMAN Glutathione peroxidase 1 SPTC1_HUMAN Serine palmitoyltransferase 1 
GPX4_HUMAN 
Phospholipid hydroperoxide 
glutathione peroxidase, mitochondrial 
SPTN1_HUMAN 
Spectrin alpha chain, non-
erythrocytic 1 
GRAA_HUMAN Granzyme A SQRD_HUMAN 
Sulfide:quinone oxidoreductase, 
mitochondrial 
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GRAH_HUMAN Granzyme H SRC_HUMAN 
Proto-oncogene tyrosine-protein 
kinase Src 
GRAM_HUMAN Granzyme M SRC8_HUMAN Src substrate cortactin 
GRAN_HUMAN Grancalcin SRGN_HUMAN Serglycin 
GRAP1_HUMAN GRIP1-associated protein 1 SRP09_HUMAN 
Signal recognition particle 9 kDa 
protein 
GRAP2_HUMAN GRB2-related adapter protein 2 SRP14_HUMAN 
Signal recognition particle 14 kDa 
protein 
GRB2_HUMAN 
Growth factor receptor-bound protein 
2 
SRP54_HUMAN 
Signal recognition particle 54 kDa 
protein 
GRHPR_HUMAN 
Glyoxylate 
reductase/hydroxypyruvate reductase 
SRPRB_HUMAN 
Signal recognition particle receptor 
subunit beta 
GRK6_HUMAN G protein-coupled receptor kinase 6 SRRT_HUMAN 
Serrate RNA effector molecule 
homolog 
GRP2_HUMAN RAS guanyl-releasing protein 2 SRS10_HUMAN 
Serine/arginine-rich splicing factor 
10 
GRP75_HUMAN Stress-70 protein, mitochondrial SRSF1_HUMAN 
Serine/arginine-rich splicing factor 
1 
GRP78_HUMAN 78 kDa glucose-regulated protein SRSF2_HUMAN 
Serine/arginine-rich splicing factor 
2 
GSDMD_HUMAN Gasdermin-D SRSF3_HUMAN 
Serine/arginine-rich splicing factor 
3 
GSHB_HUMAN Glutathione synthetase SRSF4_HUMAN 
Serine/arginine-rich splicing factor 
4 
GSHR_HUMAN Glutathione reductase, mitochondrial SRSF6_HUMAN 
Serine/arginine-rich splicing factor 
6 
GSTK1_HUMAN Glutathione S-transferase kappa 1 SRSF7_HUMAN 
Serine/arginine-rich splicing factor 
7 
GSTM2_HUMAN Glutathione S-transferase Mu 2 SRSF8_HUMAN 
Serine/arginine-rich splicing factor 
8 
GSTM3_HUMAN Glutathione S-transferase Mu 3 SSBP_HUMAN 
Single-stranded DNA-binding 
protein, mitochondrial 
GSTM5_HUMAN Glutathione S-transferase Mu 5 SSRA_HUMAN 
Translocon-associated protein 
subunit alpha 
GSTO1_HUMAN Glutathione S-transferase omega-1 SSRD_HUMAN 
Translocon-associated protein 
subunit delta 
GSTP1_HUMAN Glutathione S-transferase P SSRG_HUMAN 
Translocon-associated protein 
subunit gamma 
GT251_HUMAN Procollagen galactosyltransferase 1 SSRP1_HUMAN FACT complex subunit SSRP1 
GTPB2_HUMAN GTP-binding protein 2 ST134_HUMAN Putative protein FAM10A4 
GTPC1_HUMAN 
Putative GTP cyclohydrolase 1 type 2 
NIF3L1 
ST1A1_HUMAN Sulfotransferase 1A1 
GTR14_HUMAN 
Solute carrier family 2, facilitated 
glucose transporter member 14 
ST1A4_HUMAN Sulfotransferase 1A4 
GTR3_HUMAN 
Solute carrier family 2, facilitated 
glucose transporter member 3 
STA5A_HUMAN 
Signal transducer and activator of 
transcription 5A 
GUAA_HUMAN 
GMP synthase [glutamine-
hydrolyzing] 
STA5B_HUMAN 
Signal transducer and activator of 
transcription 5B 
GYS1_HUMAN Glycogen [starch] synthase, muscle STAM1_HUMAN 
Signal transducing adapter 
molecule 1 
H10_HUMAN Histone H1.0 STAT1_HUMAN 
Signal transducer and activator of 
transcription 1-alpha/beta 
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H12_HUMAN Histone H1.2 STAT3_HUMAN 
Signal transducer and activator of 
transcription 3 
H13_HUMAN Histone H1.3 STAT6_HUMAN 
Signal transducer and activator of 
transcription 6 
H14_HUMAN Histone H1.4 STIM1_HUMAN Stromal interaction molecule 1 
H15_HUMAN Histone H1.5 STIM2_HUMAN Stromal interaction molecule 2 
H1X_HUMAN Histone H1x STING_HUMAN 
Stimulator of interferon genes 
protein 
H2A1C_HUMAN Histone H2A type 1-C STIP1_HUMAN Stress-induced-phosphoprotein 1 
H2A1J_HUMAN Histone H2A type 1-J STK10_HUMAN Serine/threonine-protein kinase 10 
H2A2A_HUMAN Histone H2A type 2-A STK24_HUMAN Serine/threonine-protein kinase 24 
H2A2B_HUMAN Histone H2A type 2-B STK26_HUMAN Serine/threonine-protein kinase 26 
H2AV_HUMAN Histone H2A.V STK38_HUMAN Serine/threonine-protein kinase 38 
H2AY_HUMAN Core histone macro-H2A.1 STK4_HUMAN Serine/threonine-protein kinase 4 
H2B1C_HUMAN Histone H2B type 1-C/E/F/G/I STML2_HUMAN 
Stomatin-like protein 2, 
mitochondrial 
H2B1L_HUMAN Histone H2B type 1-L STMN1_HUMAN Stathmin 
H2B1M_HUMAN Histone H2B type 1-M STOM_HUMAN 
Erythrocyte band 7 integral 
membrane protein 
H2B2D_HUMAN Putative histone H2B type 2-D STON2_HUMAN Stonin-2 
H2B3B_HUMAN Histone H2B type 3-B STRAP_HUMAN 
Serine-threonine kinase receptor-
associated protein 
H31_HUMAN Histone H3.1 STRN_HUMAN Striatin 
H32_HUMAN Histone H3.2 STRN4_HUMAN Striatin-4 
H33_HUMAN Histone H3.3 STT3A_HUMAN 
Dolichyl-diphosphooligosaccharide-
-protein glycosyltransferase subunit 
STT3A 
H4_HUMAN Histone H4 STT3B_HUMAN 
Dolichyl-diphosphooligosaccharide-
-protein glycosyltransferase subunit 
STT3B 
HAP28_HUMAN 
28 kDa heat- and acid-stable 
phosphoprotein 
STUM_HUMAN Protein stum homolog 
HBA_HUMAN Hemoglobin subunit alpha STX11_HUMAN Syntaxin-11 
HBB_HUMAN Hemoglobin subunit beta STX12_HUMAN Syntaxin-12 
HBD_HUMAN Hemoglobin subunit delta STX4_HUMAN Syntaxin-4 
HBG1_HUMAN Hemoglobin subunit gamma-1 STX7_HUMAN Syntaxin-7 
HCD2_HUMAN 
3-hydroxyacyl-CoA dehydrogenase 
type-2 
STXB2_HUMAN Syntaxin-binding protein 2 
HCDH_HUMAN 
Hydroxyacyl-coenzyme A 
dehydrogenase, mitochondrial 
STXB3_HUMAN Syntaxin-binding protein 3 
HCFC1_HUMAN Host cell factor 1 SUCA_HUMAN 
Succinyl-CoA ligase [ADP/GDP-
forming] subunit alpha, 
mitochondrial 
HCK_HUMAN Tyrosine-protein kinase HCK SUCB1_HUMAN 
Succinyl-CoA ligase [ADP-forming] 
subunit beta, mitochondrial 
HCLS1_HUMAN 
Hematopoietic lineage cell-specific 
protein 
SUCB2_HUMAN 
Succinyl-CoA ligase [GDP-forming] 
subunit beta, mitochondrial 
HDGF_HUMAN Hepatoma-derived growth factor SUGT1_HUMAN 
Suppressor of G2 allele of SKP1 
homolog 
HDHD2_HUMAN 
Haloacid dehalogenase-like hydrolase 
domain-containing protein 2 
SUMO2_HUMAN Small ubiquitin-related modifier 2 
HEBP1_HUMAN Heme-binding protein 1 SUMO4_HUMAN Small ubiquitin-related modifier 4 
HEM2_HUMAN Delta-aminolevulinic acid dehydratase SUN2_HUMAN SUN domain-containing protein 2 
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HEM6_HUMAN 
Oxygen-dependent 
coproporphyrinogen-III oxidase, 
mitochondrial 
SURF4_HUMAN Surfeit locus protein 4 
HEMO_HUMAN Hemopexin SYAC_HUMAN Alanine--tRNA ligase, cytoplasmic 
HEP2_HUMAN Heparin cofactor 2 SYCC_HUMAN Cysteine--tRNA ligase, cytoplasmic 
HEXA_HUMAN Beta-hexosaminidase subunit alpha SYDC_HUMAN Aspartate--tRNA ligase, cytoplasmic 
HEXB_HUMAN Beta-hexosaminidase subunit beta SYEP_HUMAN 
Bifunctional glutamate/proline--
tRNA ligase 
HG2A_HUMAN 
HLA class II histocompatibility antigen 
gamma chain 
SYFA_HUMAN 
Phenylalanine--tRNA ligase alpha 
subunit 
HGFA_HUMAN Hepatocyte growth factor activator SYFB_HUMAN 
Phenylalanine--tRNA ligase beta 
subunit 
HGS_HUMAN 
Hepatocyte growth factor-regulated 
tyrosine kinase substrate 
SYG_HUMAN Glycine--tRNA ligase 
HIBCH_HUMAN 
3-hydroxyisobutyryl-CoA hydrolase, 
mitochondrial 
SYHC_HUMAN Histidine--tRNA ligase, cytoplasmic 
HIKES_HUMAN Protein Hikeshi SYIC_HUMAN Isoleucine--tRNA ligase, cytoplasmic 
HINT1_HUMAN 
Histidine triad nucleotide-binding 
protein 1 
SYIM_HUMAN 
Isoleucine--tRNA ligase, 
mitochondrial 
HINT2_HUMAN 
Histidine triad nucleotide-binding 
protein 2, mitochondrial 
SYJ2B_HUMAN Synaptojanin-2-binding protein 
HM13_HUMAN Minor histocompatibility antigen H13 SYK_HUMAN Lysine--tRNA ligase 
HMGB1_HUMAN High mobility group protein B1 SYLC_HUMAN Leucine--tRNA ligase, cytoplasmic 
HMGB2_HUMAN High mobility group protein B2 SYMC_HUMAN 
Methionine--tRNA ligase, 
cytoplasmic 
HMGN2_HUMAN 
Non-histone chromosomal protein 
HMG-17 
SYNC_HUMAN 
Asparagine--tRNA ligase, 
cytoplasmic 
HMHA1_HUMAN Minor histocompatibility protein HA-1 SYNE3_HUMAN Nesprin-3 
HMOX2_HUMAN Heme oxygenase 2 SYPL1_HUMAN Synaptophysin-like protein 1 
HNRDL_HUMAN 
Heterogeneous nuclear 
ribonucleoprotein D-like 
SYQ_HUMAN Glutamine--tRNA ligase 
HNRH1_HUMAN 
Heterogeneous nuclear 
ribonucleoprotein H 
SYRC_HUMAN Arginine--tRNA ligase, cytoplasmic 
HNRH2_HUMAN 
Heterogeneous nuclear 
ribonucleoprotein H2 
SYSC_HUMAN Serine--tRNA ligase, cytoplasmic 
HNRH3_HUMAN 
Heterogeneous nuclear 
ribonucleoprotein H3 
SYTC_HUMAN 
Threonine--tRNA ligase, 
cytoplasmic 
HNRL1_HUMAN 
Heterogeneous nuclear 
ribonucleoprotein U-like protein 1 
SYTL4_HUMAN Synaptotagmin-like protein 4 
HNRL2_HUMAN 
Heterogeneous nuclear 
ribonucleoprotein U-like protein 2 
SYUA_HUMAN Alpha-synuclein 
HNRPC_HUMAN 
Heterogeneous nuclear 
ribonucleoproteins C1/C2 
SYVC_HUMAN Valine--tRNA ligase 
HNRPD_HUMAN 
Heterogeneous nuclear 
ribonucleoprotein D0 
SYWC_HUMAN 
Tryptophan--tRNA ligase, 
cytoplasmic 
HNRPF_HUMAN 
Heterogeneous nuclear 
ribonucleoprotein F 
SYYC_HUMAN Tyrosine--tRNA ligase, cytoplasmic 
HNRPK_HUMAN 
Heterogeneous nuclear 
ribonucleoprotein K 
T179B_HUMAN Transmembrane protein 179B 
HNRPL_HUMAN 
Heterogeneous nuclear 
ribonucleoprotein L 
T3JAM_HUMAN 
TRAF3-interacting JNK-activating 
modulator 
HNRPM_HUMAN 
Heterogeneous nuclear 
ribonucleoprotein M 
TACC1_HUMAN 
Transforming acidic coiled-coil-
containing protein 1 
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HNRPQ_HUMAN 
Heterogeneous nuclear 
ribonucleoprotein Q 
TADBP_HUMAN TAR DNA-binding protein 43 
HNRPR_HUMAN 
Heterogeneous nuclear 
ribonucleoprotein R 
TAGL2_HUMAN Transgelin-2 
HNRPU_HUMAN 
Heterogeneous nuclear 
ribonucleoprotein U 
TALDO_HUMAN Transaldolase 
HOOK3_HUMAN Protein Hook homolog 3 TAOK1_HUMAN 
Serine/threonine-protein kinase 
TAO1 
HP1B3_HUMAN 
Heterochromatin protein 1-binding 
protein 3 
TAOK3_HUMAN 
Serine/threonine-protein kinase 
TAO3 
HPCA_HUMAN 
Neuron-specific calcium-binding 
protein hippocalcin 
TAP1_HUMAN Antigen peptide transporter 1 
HPCL1_HUMAN Hippocalcin-like protein 1 TAP2_HUMAN Antigen peptide transporter 2 
HPRT_HUMAN 
Hypoxanthine-guanine 
phosphoribosyltransferase 
TB10C_HUMAN Carabin 
HPSE_HUMAN Heparanase TBA1A_HUMAN Tubulin alpha-1A chain 
HPT_HUMAN Haptoglobin TBA1B_HUMAN Tubulin alpha-1B chain 
HRG_HUMAN Histidine-rich glycoprotein TBA1C_HUMAN Tubulin alpha-1C chain 
HS105_HUMAN Heat shock protein 105 kDa TBA4A_HUMAN Tubulin alpha-4A chain 
HS90A_HUMAN Heat shock protein HSP 90-alpha TBA8_HUMAN Tubulin alpha-8 chain 
HS90B_HUMAN Heat shock protein HSP 90-beta TBB1_HUMAN Tubulin beta-1 chain 
HSDL2_HUMAN 
Hydroxysteroid dehydrogenase-like 
protein 2 
TBB2A_HUMAN Tubulin beta-2A chain 
HSP71_HUMAN Heat shock 70 kDa protein 1A/1B TBB4B_HUMAN Tubulin beta-4B chain 
HSP74_HUMAN Heat shock 70 kDa protein 4 TBB5_HUMAN Tubulin beta chain 
HSP7C_HUMAN Heat shock cognate 71 kDa protein TBB6_HUMAN Tubulin beta-6 chain 
HSPB1_HUMAN Heat shock protein beta-1 TBC13_HUMAN TBC1 domain family member 13 
HUWE1_HUMAN E3 ubiquitin-protein ligase HUWE1 TBC15_HUMAN TBC1 domain family member 15 
HV103_HUMAN Ig heavy chain V-I region V35 TBCA_HUMAN Tubulin-specific chaperone A 
HV303_HUMAN Ig heavy chain V-III region VH26 TBCB_HUMAN Tubulin-folding cofactor B 
HV305_HUMAN Ig heavy chain V-III region BRO TBCD5_HUMAN TBC1 domain family member 5 
HV311_HUMAN Ig heavy chain V-III region KOL TBL1X_HUMAN 
F-box-like/WD repeat-containing 
protein TBL1X 
HV316_HUMAN Ig heavy chain V-III region TEI TBR1_HUMAN T-box brain protein 1 
HXK1_HUMAN Hexokinase-1 TBRG4_HUMAN Protein TBRG4 
HXK3_HUMAN Hexokinase-3 TCEA1_HUMAN 
Transcription elongation factor A 
protein 1 
HYES_HUMAN Bifunctional epoxide hydrolase 2 TCP4_HUMAN 
Activated RNA polymerase II 
transcriptional coactivator p15 
HYOU1_HUMAN Hypoxia up-regulated protein 1 TCPA_HUMAN T-complex protein 1 subunit alpha 
IC1_HUMAN Plasma protease C1 inhibitor TCPB_HUMAN T-complex protein 1 subunit beta 
ICAL_HUMAN Calpastatin TCPD_HUMAN T-complex protein 1 subunit delta 
ICAM2_HUMAN Intercellular adhesion molecule 2 TCPE_HUMAN T-complex protein 1 subunit epsilon 
ICAM3_HUMAN Intercellular adhesion molecule 3 TCPG_HUMAN T-complex protein 1 subunit gamma 
IDH3A_HUMAN 
Isocitrate dehydrogenase [NAD] 
subunit alpha, mitochondrial 
TCPH_HUMAN T-complex protein 1 subunit eta 
IDH3G_HUMAN 
Isocitrate dehydrogenase [NAD] 
subunit gamma, mitochondrial 
TCPQ_HUMAN T-complex protein 1 subunit theta 
IDHC_HUMAN 
Isocitrate dehydrogenase [NADP] 
cytoplasmic 
TCPZ_HUMAN T-complex protein 1 subunit zeta 
IDHP_HUMAN 
Isocitrate dehydrogenase [NADP], 
mitochondrial 
TCTP_HUMAN 
Translationally-controlled tumor 
protein 
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IF16_HUMAN 
Gamma-interferon-inducible protein 
16 
TDRP_HUMAN Testis development-related protein 
IF1AX_HUMAN 
Eukaryotic translation initiation factor 
1A, X-chromosomal 
TEBP_HUMAN Prostaglandin E synthase 3 
IF2A_HUMAN 
Eukaryotic translation initiation factor 
2 subunit 1 
TERA_HUMAN 
Transitional endoplasmic reticulum 
ATPase 
IF2B_HUMAN 
Eukaryotic translation initiation factor 
2 subunit 2 
TES_HUMAN Testin 
IF2B2_HUMAN 
Insulin-like growth factor 2 mRNA-
binding protein 2 
TETN_HUMAN Tetranectin 
IF2GL_HUMAN 
Putative eukaryotic translation 
initiation factor 2 subunit 3-like 
protein 
TF65_HUMAN Transcription factor p65 
IF4A1_HUMAN Eukaryotic initiation factor 4A-I TFAM_HUMAN 
Transcription factor A, 
mitochondrial 
IF4A2_HUMAN Eukaryotic initiation factor 4A-II TFG_HUMAN Protein TFG 
IF4A3_HUMAN Eukaryotic initiation factor 4A-III TFIP8_HUMAN 
Tumor necrosis factor alpha-
induced protein 8 
IF4B_HUMAN 
Eukaryotic translation initiation factor 
4B 
TGFB1_HUMAN Transforming growth factor beta-1 
IF4E_HUMAN 
Eukaryotic translation initiation factor 
4E 
TGFI1_HUMAN 
Transforming growth factor beta-1-
induced transcript 1 protein 
IF4G1_HUMAN 
Eukaryotic translation initiation factor 
4 gamma 1 
THAS_HUMAN Thromboxane-A synthase 
IF4G2_HUMAN 
Eukaryotic translation initiation factor 
4 gamma 2 
THBG_HUMAN Thyroxine-binding globulin 
IF4G3_HUMAN 
Eukaryotic translation initiation factor 
4 gamma 3 
THIC_HUMAN 
Acetyl-CoA acetyltransferase, 
cytosolic 
IF4H_HUMAN 
Eukaryotic translation initiation factor 
4H 
THIK_HUMAN 
3-ketoacyl-CoA thiolase, 
peroxisomal 
IF5_HUMAN 
Eukaryotic translation initiation factor 
5 
THIL_HUMAN 
Acetyl-CoA acetyltransferase, 
mitochondrial 
IF5A1_HUMAN 
Eukaryotic translation initiation factor 
5A-1 
THIM_HUMAN 
3-ketoacyl-CoA thiolase, 
mitochondrial 
IF6_HUMAN 
Eukaryotic translation initiation factor 
6 
THIO_HUMAN Thioredoxin 
IFT27_HUMAN 
Intraflagellar transport protein 27 
homolog 
THOC4_HUMAN THO complex subunit 4 
IFT88_HUMAN 
Intraflagellar transport protein 88 
homolog 
THOP1_HUMAN Thimet oligopeptidase 
IGHA1_HUMAN Ig alpha-1 chain C region THRB_HUMAN Prothrombin 
IGHA2_HUMAN Ig alpha-2 chain C region THTM_HUMAN 
3-mercaptopyruvate 
sulfurtransferase 
IGHG1_HUMAN Ig gamma-1 chain C region THTR_HUMAN Thiosulfate sulfurtransferase 
IGHG2_HUMAN Ig gamma-2 chain C region THUM1_HUMAN 
THUMP domain-containing protein 
1 
IGHM_HUMAN Ig mu chain C region TIAR_HUMAN Nucleolysin TIAR 
IGJ_HUMAN Immunoglobulin J chain TIF1B_HUMAN 
Transcription intermediary factor 1-
beta 
IGKC_HUMAN Ig kappa chain C region TIMP1_HUMAN Metalloproteinase inhibitor 1 
IGLL5_HUMAN 
Immunoglobulin lambda-like 
polypeptide 5 
TITIN_HUMAN Titin 
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IKKB_HUMAN 
Inhibitor of nuclear factor kappa-B 
kinase subunit beta 
TKT_HUMAN Transketolase 
IL16_HUMAN Pro-interleukin-16 TLN1_HUMAN Talin-1 
IL1B_HUMAN Interleukin-1 beta TLN2_HUMAN Talin-2 
ILEU_HUMAN Leukocyte elastase inhibitor TM109_HUMAN Transmembrane protein 109 
ILF2_HUMAN Interleukin enhancer-binding factor 2 TM1L2_HUMAN TOM1-like protein 2 
ILF3_HUMAN Interleukin enhancer-binding factor 3 TM9S2_HUMAN 
Transmembrane 9 superfamily 
member 2 
ILK_HUMAN Integrin-linked protein kinase TMED2_HUMAN 
Transmembrane emp24 domain-
containing protein 2 
IMA3_HUMAN Importin subunit alpha-3 TMED4_HUMAN 
Transmembrane emp24 domain-
containing protein 4 
IMA5_HUMAN Importin subunit alpha-5 TMED5_HUMAN 
Transmembrane emp24 domain-
containing protein 5 
IMB1_HUMAN Importin subunit beta-1 TMED9_HUMAN 
Transmembrane emp24 domain-
containing protein 9 
IMDH2_HUMAN 
Inosine-5'-monophosphate 
dehydrogenase 2 
TMEDA_HUMAN 
Transmembrane emp24 domain-
containing protein 10 
IMPA1_HUMAN Inositol monophosphatase 1 TMM33_HUMAN Transmembrane protein 33 
INF2_HUMAN Inverted formin-2 TMM40_HUMAN Transmembrane protein 40 
INO1_HUMAN Inositol-3-phosphate synthase 1 TMM43_HUMAN Transmembrane protein 43 
INP4B_HUMAN 
Type II inositol 3,4-bisphosphate 4-
phosphatase 
TMOD3_HUMAN Tropomodulin-3 
IP3KB_HUMAN Inositol-trisphosphate 3-kinase B TMX1_HUMAN 
Thioredoxin-related 
transmembrane protein 1 
IPO5_HUMAN Importin-5 TMX3_HUMAN Protein disulfide-isomerase TMX3 
IPO7_HUMAN Importin-7 TMX4_HUMAN 
Thioredoxin-related 
transmembrane protein 4 
IPO9_HUMAN Importin-9 TNG2_HUMAN 
Transport and Golgi organization 
protein 2 homolog 
IPYR_HUMAN Inorganic pyrophosphatase TNIK_HUMAN 
TRAF2 and NCK-interacting protein 
kinase 
IPYR2_HUMAN 
Inorganic pyrophosphatase 2, 
mitochondrial 
TNPO1_HUMAN Transportin-1 
IQGA1_HUMAN 
Ras GTPase-activating-like protein 
IQGAP1 
TNPO2_HUMAN Transportin-2 
IQGA2_HUMAN 
Ras GTPase-activating-like protein 
IQGAP2 
TNPO3_HUMAN Transportin-3 
ISOC1_HUMAN 
Isochorismatase domain-containing 
protein 1 
TOIP1_HUMAN Torsin-1A-interacting protein 1 
IST1_HUMAN IST1 homolog TOLIP_HUMAN Toll-interacting protein 
ITA2_HUMAN Integrin alpha-2 TOM1_HUMAN Target of Myb protein 1 
ITA2B_HUMAN Integrin alpha-IIb TOM70_HUMAN 
Mitochondrial import receptor 
subunit TOM70 
ITA6_HUMAN Integrin alpha-6 TOP1_HUMAN DNA topoisomerase 1 
ITAL_HUMAN Integrin alpha-L TOR1A_HUMAN Torsin-1A 
ITAM_HUMAN Integrin alpha-M TOR4A_HUMAN Torsin-4A 
ITAX_HUMAN Integrin alpha-X TP4A1_HUMAN 
Protein tyrosine phosphatase type 
IVA 1 
ITB1_HUMAN Integrin beta-1 TP8L2_HUMAN 
Tumor necrosis factor alpha-
induced protein 8-like protein 2 
ITB2_HUMAN Integrin beta-2 TPD54_HUMAN Tumor protein D54 
ITB3_HUMAN Integrin beta-3 TPIS_HUMAN Triosephosphate isomerase 
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ITB5_HUMAN Integrin beta-5 TPM1_HUMAN Tropomyosin alpha-1 chain 
ITIH1_HUMAN 
Inter-alpha-trypsin inhibitor heavy 
chain H1 
TPM2_HUMAN Tropomyosin beta chain 
ITIH2_HUMAN 
Inter-alpha-trypsin inhibitor heavy 
chain H2 
TPM3_HUMAN Tropomyosin alpha-3 chain 
ITIH3_HUMAN 
Inter-alpha-trypsin inhibitor heavy 
chain H3 
TPM4_HUMAN Tropomyosin alpha-4 chain 
ITIH4_HUMAN 
Inter-alpha-trypsin inhibitor heavy 
chain H4 
TPP1_HUMAN Tripeptidyl-peptidase 1 
ITPR1_HUMAN 
Inositol 1,4,5-trisphosphate receptor 
type 1 
TPP2_HUMAN Tripeptidyl-peptidase 2 
IVD_HUMAN 
Isovaleryl-CoA dehydrogenase, 
mitochondrial 
TPR_HUMAN Nucleoprotein TPR 
JAM1_HUMAN Junctional adhesion molecule A TPRKB_HUMAN EKC/KEOPS complex subunit TPRKB 
JAM3_HUMAN Junctional adhesion molecule C TPSN_HUMAN Tapasin 
JIP4_HUMAN 
C-Jun-amino-terminal kinase-
interacting protein 4 
TRA2B_HUMAN 
Transformer-2 protein homolog 
beta 
K0513_HUMAN Uncharacterized protein KIAA0513 TRADD_HUMAN 
Tumor necrosis factor receptor type 
1-associated DEATH domain protein 
K1C10_HUMAN Keratin, type I cytoskeletal 10 TRFE_HUMAN Serotransferrin 
K1C14_HUMAN Keratin, type I cytoskeletal 14 TRFL_HUMAN Lactotransferrin 
K1C16_HUMAN Keratin, type I cytoskeletal 16 TRI58_HUMAN E3 ubiquitin-protein ligase TRIM58 
K1C17_HUMAN Keratin, type I cytoskeletal 17 TRML1_HUMAN Trem-like transcript 1 protein 
K1C9_HUMAN Keratin, type I cytoskeletal 9 TRNT1_HUMAN 
CCA tRNA nucleotidyltransferase 1, 
mitochondrial 
K1H1_HUMAN Keratin, type I cuticular Ha1 TRPC6_HUMAN 
Short transient receptor potential 
channel 6 
K22E_HUMAN 
Keratin, type II cytoskeletal 2 
epidermal 
TRUA_HUMAN 
tRNA pseudouridine synthase A, 
mitochondrial 
K2C1_HUMAN Keratin, type II cytoskeletal 1 TRXR1_HUMAN 
Thioredoxin reductase 1, 
cytoplasmic 
K2C5_HUMAN Keratin, type II cytoskeletal 5 TRY1_HUMAN Trypsin-1 
K2C6A_HUMAN Keratin, type II cytoskeletal 6A TS101_HUMAN 
Tumor susceptibility gene 101 
protein 
K2C6B_HUMAN Keratin, type II cytoskeletal 6B TSN_HUMAN Translin 
KAD1_HUMAN Adenylate kinase isoenzyme 1 TSN14_HUMAN Tetraspanin-14 
KAD2_HUMAN Adenylate kinase 2, mitochondrial TSN33_HUMAN Tetraspanin-33 
KAD3_HUMAN 
GTP:AMP phosphotransferase AK3, 
mitochondrial 
TSN9_HUMAN Tetraspanin-9 
KALRN_HUMAN Kalirin TSNAX_HUMAN Translin-associated protein X 
KAP0_HUMAN 
cAMP-dependent protein kinase type 
I-alpha regulatory subunit 
TSP1_HUMAN Thrombospondin-1 
KAP3_HUMAN 
cAMP-dependent protein kinase type 
II-beta regulatory subunit 
TTC1_HUMAN Tetratricopeptide repeat protein 1 
KAPCA_HUMAN 
cAMP-dependent protein kinase 
catalytic subunit alpha 
TTHY_HUMAN Transthyretin 
KAPCB_HUMAN 
cAMP-dependent protein kinase 
catalytic subunit beta 
TTL12_HUMAN 
Tubulin--tyrosine ligase-like protein 
12 
KCAB2_HUMAN 
Voltage-gated potassium channel 
subunit beta-2 
TWF1_HUMAN Twinfilin-1 
KCC1A_HUMAN 
Calcium/calmodulin-dependent 
protein kinase type 1 
TWF2_HUMAN Twinfilin-2 
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KCC2A_HUMAN 
Calcium/calmodulin-dependent 
protein kinase type II subunit alpha 
TXD12_HUMAN 
Thioredoxin domain-containing 
protein 12 
KCD12_HUMAN 
BTB/POZ domain-containing protein 
KCTD12 
TXD17_HUMAN 
Thioredoxin domain-containing 
protein 17 
KCRB_HUMAN Creatine kinase B-type TXND5_HUMAN 
Thioredoxin domain-containing 
protein 5 
KCY_HUMAN UMP-CMP kinase TXNL1_HUMAN Thioredoxin-like protein 1 
KGP1_HUMAN cGMP-dependent protein kinase 1 TXTP_HUMAN 
Tricarboxylate transport protein, 
mitochondrial 
KHDR1_HUMAN 
KH domain-containing, RNA-binding, 
signal transduction-associated protein 
1 
TYPH_HUMAN Thymidine phosphorylase 
KIF2A_HUMAN Kinesin-like protein KIF2A U2AF1_HUMAN Splicing factor U2AF 35 kDa subunit 
KINH_HUMAN Kinesin-1 heavy chain U2AF2_HUMAN Splicing factor U2AF 65 kDa subunit 
KLC1_HUMAN Kinesin light chain 1 U520_HUMAN 
U5 small nuclear ribonucleoprotein 
200 kDa helicase 
KNG1_HUMAN Kininogen-1 U5S1_HUMAN 
116 kDa U5 small nuclear 
ribonucleoprotein component 
KPCA_HUMAN Protein kinase C alpha type UB2D3_HUMAN 
Ubiquitin-conjugating enzyme E2 
D3 
KPCB_HUMAN Protein kinase C beta type UB2L3_HUMAN Ubiquitin-conjugating enzyme E2 L3 
KPCD_HUMAN Protein kinase C delta type UB2V1_HUMAN 
Ubiquitin-conjugating enzyme E2 
variant 1 
KPRA_HUMAN 
Phosphoribosyl pyrophosphate 
synthase-associated protein 1 
UB2V2_HUMAN 
Ubiquitin-conjugating enzyme E2 
variant 2 
KPRB_HUMAN 
Phosphoribosyl pyrophosphate 
synthase-associated protein 2 
UBA1_HUMAN 
Ubiquitin-like modifier-activating 
enzyme 1 
KPYM_HUMAN Pyruvate kinase PKM UBA3_HUMAN 
NEDD8-activating enzyme E1 
catalytic subunit 
KRT81_HUMAN Keratin, type II cuticular Hb1 UBA5_HUMAN 
Ubiquitin-like modifier-activating 
enzyme 5 
KS6A3_HUMAN Ribosomal protein S6 kinase alpha-3 UBA6_HUMAN 
Ubiquitin-like modifier-activating 
enzyme 6 
KSYK_HUMAN Tyrosine-protein kinase SYK UBA7_HUMAN 
Ubiquitin-like modifier-activating 
enzyme 7 
KT3K_HUMAN Ketosamine-3-kinase UBC9_HUMAN SUMO-conjugating enzyme UBC9 
KTHY_HUMAN Thymidylate kinase UBCP1_HUMAN 
Ubiquitin-like domain-containing 
CTD phosphatase 1 
KTN1_HUMAN Kinectin UBE2A_HUMAN Ubiquitin-conjugating enzyme E2 A 
KV110_HUMAN 
Ig kappa chain V-I region HK102 
(Fragment) 
UBE2K_HUMAN Ubiquitin-conjugating enzyme E2 K 
KV125_HUMAN Ig kappa chain V-I region WAT UBE2N_HUMAN Ubiquitin-conjugating enzyme E2 N 
KV205_HUMAN 
Ig kappa chain V-II region GM607 
(Fragment) 
UBE2O_HUMAN 
E2/E3 hybrid ubiquitin-protein 
ligase UBE2O 
KV206_HUMAN Ig kappa chain V-II region RPMI 6410 UBE3C_HUMAN Ubiquitin-protein ligase E3C 
KV303_HUMAN 
Ig kappa chain V-III region NG9 
(Fragment) 
UBF1_HUMAN Nucleolar transcription factor 1 
KV305_HUMAN Ig kappa chain V-III region WOL UBP14_HUMAN 
Ubiquitin carboxyl-terminal 
hydrolase 14 
KV309_HUMAN 
Ig kappa chain V-III region VG 
(Fragment) 
UBP24_HUMAN 
Ubiquitin carboxyl-terminal 
hydrolase 24 
KV313_HUMAN Ig kappa chain V-III region HIC UBP2L_HUMAN Ubiquitin-associated protein 2-like 
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KV404_HUMAN Ig kappa chain V-IV region B17 UBP47_HUMAN 
Ubiquitin carboxyl-terminal 
hydrolase 47 
LA_HUMAN Lupus La protein UBP5_HUMAN 
Ubiquitin carboxyl-terminal 
hydrolase 5 
LAC2_HUMAN Ig lambda-2 chain C regions UBP7_HUMAN 
Ubiquitin carboxyl-terminal 
hydrolase 7 
LAC3_HUMAN Ig lambda-3 chain C regions UBQL1_HUMAN Ubiquilin-1 
LACB2_HUMAN Beta-lactamase-like protein 2 UBR4_HUMAN E3 ubiquitin-protein ligase UBR4 
LACTB_HUMAN 
Serine beta-lactamase-like protein 
LACTB, mitochondrial 
UBS3B_HUMAN 
Ubiquitin-associated and SH3 
domain-containing protein B 
LAMP1_HUMAN 
Lysosome-associated membrane 
glycoprotein 1 
UBXN6_HUMAN UBX domain-containing protein 6 
LAMP2_HUMAN 
Lysosome-associated membrane 
glycoprotein 2 
UCHL5_HUMAN 
Ubiquitin carboxyl-terminal 
hydrolase isozyme L5 
LAP2_HUMAN Protein LAP2 UCRI_HUMAN 
Cytochrome b-c1 complex subunit 
Rieske, mitochondrial 
LAP2B_HUMAN 
Lamina-associated polypeptide 2, 
isoforms beta/gamma 
UFC1_HUMAN 
Ubiquitin-fold modifier-conjugating 
enzyme 1 
LASP1_HUMAN LIM and SH3 domain protein 1 UFD1_HUMAN 
Ubiquitin fusion degradation 
protein 1 homolog 
LAT_HUMAN 
Linker for activation of T-cells family 
member 1 
UFL1_HUMAN E3 UFM1-protein ligase 1 
LBR_HUMAN Lamin-B receptor UGGG1_HUMAN 
UDP-glucose:glycoprotein 
glucosyltransferase 1 
LCP2_HUMAN Lymphocyte cytosolic protein 2 UGPA_HUMAN 
UTP--glucose-1-phosphate 
uridylyltransferase 
LDHA_HUMAN L-lactate dehydrogenase A chain ULA1_HUMAN 
NEDD8-activating enzyme E1 
regulatory subunit 
LDHB_HUMAN L-lactate dehydrogenase B chain UMPS_HUMAN 
Uridine 5'-monophosphate 
synthase 
LEG1_HUMAN Galectin-1 UN13D_HUMAN Protein unc-13 homolog D 
LEG7_HUMAN Galectin-7 UN45A_HUMAN Protein unc-45 homolog A 
LEGL_HUMAN Galectin-related protein UPAR_HUMAN 
Urokinase plasminogen activator 
surface receptor 
LETM1_HUMAN 
LETM1 and EF-hand domain-
containing protein 1, mitochondrial 
UPP1_HUMAN Uridine phosphorylase 1 
LEUK_HUMAN Leukosialin URP2_HUMAN Fermitin family homolog 3 
LFG3_HUMAN Protein lifeguard 3 USMG5_HUMAN 
Up-regulated during skeletal muscle 
growth protein 5 
LG3BP_HUMAN Galectin-3-binding protein USO1_HUMAN 
General vesicular transport factor 
p115 
LGUL_HUMAN Lactoylglutathione lyase USP9X_HUMAN 
Probable ubiquitin carboxyl-
terminal hydrolase FAF-X 
LIMA1_HUMAN 
LIM domain and actin-binding protein 
1 
UTRO_HUMAN Utrophin 
LIMS1_HUMAN 
LIM and senescent cell antigen-like-
containing domain protein 1 
VA0D1_HUMAN V-type proton ATPase subunit d 1 
LIS1_HUMAN 
Platelet-activating factor 
acetylhydrolase IB subunit alpha 
VAC14_HUMAN Protein VAC14 homolog 
LKHA4_HUMAN Leukotriene A-4 hydrolase VAMP3_HUMAN 
Vesicle-associated membrane 
protein 3 
LMAN1_HUMAN Protein ERGIC-53 VAMP7_HUMAN 
Vesicle-associated membrane 
protein 7 
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LMAN2_HUMAN 
Vesicular integral-membrane protein 
VIP36 
VAMP8_HUMAN 
Vesicle-associated membrane 
protein 8 
LMNA_HUMAN Prelamin-A/C VAPA_HUMAN 
Vesicle-associated membrane 
protein-associated protein A 
LMNB1_HUMAN Lamin-B1 VASP_HUMAN 
Vasodilator-stimulated 
phosphoprotein 
LMNB2_HUMAN Lamin-B2 VAT1_HUMAN 
Synaptic vesicle membrane protein 
VAT-1 homolog 
LONM_HUMAN Lon protease homolog, mitochondrial VATA_HUMAN 
V-type proton ATPase catalytic 
subunit A 
LOX12_HUMAN 
Arachidonate 12-lipoxygenase, 12S-
type 
VATB2_HUMAN 
V-type proton ATPase subunit B, 
brain isoform 
LOX5_HUMAN Arachidonate 5-lipoxygenase VATC1_HUMAN V-type proton ATPase subunit C 1 
LPPRC_HUMAN 
Leucine-rich PPR motif-containing 
protein, mitochondrial 
VATE1_HUMAN V-type proton ATPase subunit E 1 
LRBA_HUMAN 
Lipopolysaccharide-responsive and 
beige-like anchor protein 
VATH_HUMAN V-type proton ATPase subunit H 
LRC40_HUMAN 
Leucine-rich repeat-containing protein 
40 
VAV_HUMAN Proto-oncogene vav 
LRC47_HUMAN 
Leucine-rich repeat-containing protein 
47 
VDAC1_HUMAN 
Voltage-dependent anion-selective 
channel protein 1 
LRC59_HUMAN 
Leucine-rich repeat-containing protein 
59 
VDAC2_HUMAN 
Voltage-dependent anion-selective 
channel protein 2 
LRRF1_HUMAN 
Leucine-rich repeat flightless-
interacting protein 1 
VDAC3_HUMAN 
Voltage-dependent anion-selective 
channel protein 3 
LRRF2_HUMAN 
Leucine-rich repeat flightless-
interacting protein 2 
VIME_HUMAN Vimentin 
LSM1_HUMAN 
U6 snRNA-associated Sm-like protein 
LSm1 
VINC_HUMAN Vinculin 
LSM2_HUMAN 
U6 snRNA-associated Sm-like protein 
LSm2 
VP13C_HUMAN 
Vacuolar protein sorting-associated 
protein 13C 
LSM3_HUMAN 
U6 snRNA-associated Sm-like protein 
LSm3 
VP26A_HUMAN 
Vacuolar protein sorting-associated 
protein 26A 
LSP1_HUMAN Lymphocyte-specific protein 1 VPS25_HUMAN 
Vacuolar protein-sorting-associated 
protein 25 
LTBP1_HUMAN 
Latent-transforming growth factor 
beta-binding protein 1 
VPS29_HUMAN 
Vacuolar protein sorting-associated 
protein 29 
LTOR1_HUMAN Ragulator complex protein LAMTOR1 VPS35_HUMAN 
Vacuolar protein sorting-associated 
protein 35 
LTOR2_HUMAN Ragulator complex protein LAMTOR2 VPS4B_HUMAN 
Vacuolar protein sorting-associated 
protein 4B 
LTOR3_HUMAN Ragulator complex protein LAMTOR3 VPS51_HUMAN 
Vacuolar protein sorting-associated 
protein 51 homolog 
LUM_HUMAN Lumican VRK1_HUMAN 
Serine/threonine-protein kinase 
VRK1 
LV105_HUMAN Ig lambda chain V-I region NEWM VTA1_HUMAN 
Vacuolar protein sorting-associated 
protein VTA1 homolog 
LXN_HUMAN Latexin VTDB_HUMAN Vitamin D-binding protein 
LY66F_HUMAN 
Lymphocyte antigen 6 complex locus 
protein G6f 
VTNC_HUMAN Vitronectin 
LYAM3_HUMAN P-selectin VWF_HUMAN von Willebrand factor 
LYN_HUMAN Tyrosine-protein kinase Lyn WASF2_HUMAN 
Wiskott-Aldrich syndrome protein 
family member 2 
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LYPA1_HUMAN Acyl-protein thioesterase 1 WASP_HUMAN Wiskott-Aldrich syndrome protein 
LYPA2_HUMAN Acyl-protein thioesterase 2 WBP2_HUMAN WW domain-binding protein 2 
LYRIC_HUMAN Protein LYRIC WDFY1_HUMAN 
WD repeat and FYVE domain-
containing protein 1 
LYSC_HUMAN Lysozyme C WDR1_HUMAN WD repeat-containing protein 1 
M2OM_HUMAN 
Mitochondrial 2-oxoglutarate/malate 
carrier protein 
WDR37_HUMAN WD repeat-containing protein 37 
M3K5_HUMAN 
Mitogen-activated protein kinase 
kinase kinase 5 
WDR44_HUMAN WD repeat-containing protein 44 
MA2A1_HUMAN Alpha-mannosidase 2 WIPF1_HUMAN 
WAS/WASL-interacting protein 
family member 1 
MACF1_HUMAN 
Microtubule-actin cross-linking factor 
1, isoforms 1/2/3/5 
XPO1_HUMAN Exportin-1 
MAGD2_HUMAN Melanoma-associated antigen D2 XPO2_HUMAN Exportin-2 
MAGT1_HUMAN Magnesium transporter protein 1 XPO7_HUMAN Exportin-7 
MANF_HUMAN 
Mesencephalic astrocyte-derived 
neurotrophic factor 
XPOT_HUMAN Exportin-T 
MAOM_HUMAN 
NAD-dependent malic enzyme, 
mitochondrial 
XPP1_HUMAN Xaa-Pro aminopeptidase 1 
MAOX_HUMAN NADP-dependent malic enzyme XRCC5_HUMAN 
X-ray repair cross-complementing 
protein 5 
MAP11_HUMAN Methionine aminopeptidase 1 XRCC6_HUMAN 
X-ray repair cross-complementing 
protein 6 
MAP2_HUMAN Methionine aminopeptidase 2 YBOX1_HUMAN 
Nuclease-sensitive element-binding 
protein 1 
MAP4_HUMAN Microtubule-associated protein 4 YES_HUMAN Tyrosine-protein kinase Yes 
MARE1_HUMAN 
Microtubule-associated protein RP/EB 
family member 1 
ZA2G_HUMAN Zinc-alpha-2-glycoprotein 
MARE2_HUMAN 
Microtubule-associated protein RP/EB 
family member 2 
ZAP70_HUMAN Tyrosine-protein kinase ZAP-70 
MAT2B_HUMAN 
Methionine adenosyltransferase 2 
subunit beta 
ZCCHV_HUMAN 
Zinc finger CCCH-type antiviral 
protein 1 
MATR3_HUMAN Matrin-3 ZN185_HUMAN Zinc finger protein 185 
MAVS_HUMAN 
Mitochondrial antiviral-signaling 
protein 
ZO2_HUMAN Tight junction protein ZO-2 
MBNL3_HUMAN Muscleblind-like protein 3 ZYX_HUMAN Zyxin 
MCA3_HUMAN 
Eukaryotic translation elongation 
factor 1 epsilon-1 
ZZEF1_HUMAN 
Zinc finger ZZ-type and EF-hand 
domain-containing protein 1 
MCAT_HUMAN 
Mitochondrial carnitine/acylcarnitine 
carrier protein 
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Supplementary Table VII.7. Common quantified proteins in the six biological samples. For each protein it is 
shown its entry name in UniProt database. 
Entry name Protein name Entry name Protein name 
1433B_HUMAN 14-3-3 protein beta/alpha LYAM3_HUMAN P-selectin 
1433E_HUMAN 14-3-3 protein epsilon LYRIC_HUMAN Protein LYRIC 
1433F_HUMAN 14-3-3 protein eta LYSC_HUMAN Lysozyme C 
1433G_HUMAN 14-3-3 protein gamma MARE2_HUMAN 
Microtubule-associated protein 
RP/EB family member 2 
1433T_HUMAN 14-3-3 protein theta MDHC_HUMAN 
Malate dehydrogenase, 
cytoplasmic 
1433Z_HUMAN 14-3-3 protein zeta/delta MDHM_HUMAN 
Malate dehydrogenase, 
mitochondrial 
1A03_HUMAN 
HLA class I histocompatibility antigen, 
A-3 alpha chain 
MGLL_HUMAN Monoglyceride lipase 
3BP1_HUMAN SH3 domain-binding protein 1 ML12A_HUMAN Myosin regulatory light chain 12A 
6PGD_HUMAN 
6-phosphogluconate dehydrogenase, 
decarboxylating 
MMRN1_HUMAN Multimerin-1 
6PGL_HUMAN 6-phosphogluconolactonase MOES_HUMAN Moesin 
A1AT_HUMAN Alpha-1-antitrypsin MYH9_HUMAN Myosin-9 
ACON_HUMAN Aconitate hydratase, mitochondrial MYL6_HUMAN Myosin light polypeptide 6 
ACTG_HUMAN Actin, cytoplasmic 2 MYL9_HUMAN 
Myosin regulatory light 
polypeptide 9 
ACTN1_HUMAN Alpha-actinin-1 NB5R3_HUMAN 
NADH-cytochrome b5 reductase 
3 
ACTN4_HUMAN Alpha-actinin-4 NDKB_HUMAN Nucleoside diphosphate kinase B 
ADT2_HUMAN ADP/ATP translocase 2 NDUS8_HUMAN NADH dehydrogenase 
AHNK_HUMAN 
Neuroblast differentiation-associated 
protein AHNAK 
NHRF1_HUMAN 
Na(+)/H(+) exchange regulatory 
cofactor NHE-RF1 
AK1A1_HUMAN Alcohol dehydrogenase NP1L1_HUMAN 
Nucleosome assembly protein 1-
like 1 
ALBU_HUMAN Serum albumin NPM_HUMAN Nucleophosmin 
ALDOA_HUMAN Fructose-bisphosphate aldolase A NTF2_HUMAN Nuclear transport factor 2 
AMPD2_HUMAN AMP deaminase 2 NUCL_HUMAN Nucleolin 
AMPL_HUMAN Cytosol aminopeptidase OSTF1_HUMAN Osteoclast-stimulating factor 1 
AN32A_HUMAN 
Acidic leucine-rich nuclear 
phosphoprotein 32 family member A 
PA1B2_HUMAN 
Platelet-activating factor 
acetylhydrolase IB subunit beta 
ANX11_HUMAN Annexin A11 PABP3_HUMAN Polyadenylate-binding protein 3 
ANXA1_HUMAN Annexin A1 PARK7_HUMAN Protein deglycase DJ-1 
ANXA2_HUMAN Annexin A2 PARVB_HUMAN Beta-parvin 
ANXA5_HUMAN Annexin A5 PCBP1_HUMAN Poly(rC)-binding protein 1 
ANXA6_HUMAN Annexin A6 PCBP2_HUMAN Poly(rC)-binding protein 2 
ANXA7_HUMAN Annexin A7 PDC6I_HUMAN 
Programmed cell death 6-
interacting protein 
AP2A1_HUMAN AP-2 complex subunit alpha-1 PDE5A_HUMAN 
cGMP-specific 3',5'-cyclic 
phosphodiesterase 
AP2B1_HUMAN AP-2 complex subunit beta PDIA1_HUMAN Protein disulfide-isomerase 
APMAP_HUMAN 
Adipocyte plasma membrane-
associated protein 
PDIA3_HUMAN Protein disulfide-isomerase A3 
APOA1_HUMAN Apolipoprotein A-I PDIA4_HUMAN Protein disulfide-isomerase A4 
APT_HUMAN Adenine phosphoribosyltransferase PDIA6_HUMAN Protein disulfide-isomerase A6 
ARC1B_HUMAN 
Actin-related protein 2/3 complex 
subunit 1B 
PDLI1_HUMAN PDZ and LIM domain protein 1 
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ARF1_HUMAN ADP-ribosylation factor 1 PEBP1_HUMAN 
Phosphatidylethanolamine-
binding protein 1 
ARF4_HUMAN ADP-ribosylation factor 4 PERM_HUMAN Myeloperoxidase 
ARK72_HUMAN 
Aflatoxin B1 aldehyde reductase 
member 2 
PFKAP_HUMAN 
ATP-dependent 6-
phosphofructokinase, platelet 
type 
ARP2_HUMAN Actin-related protein 2 PGAM1_HUMAN Phosphoglycerate mutase 1 
ARP3_HUMAN Actin-related protein 3 PGH1_HUMAN Prostaglandin G/H synthase 1 
ARPC2_HUMAN 
Actin-related protein 2/3 complex 
subunit 2 
PGK1_HUMAN Phosphoglycerate kinase 1 
ARPC3_HUMAN 
Actin-related protein 2/3 complex 
subunit 3 
PGM2_HUMAN Phosphoglucomutase-2 
ARPC4_HUMAN 
Actin-related protein 2/3 complex 
subunit 4 
PHB_HUMAN Prohibitin 
ARPC5_HUMAN 
Actin-related protein 2/3 complex 
subunit 5 
PHB2_HUMAN Prohibitin-2 
AT2A3_HUMAN 
Sarcoplasmic/endoplasmic reticulum 
calcium ATPase 3 
PI42A_HUMAN 
Phosphatidylinositol 5-phosphate 
4-kinase type-2 alpha 
ATPA_HUMAN 
ATP synthase subunit alpha, 
mitochondrial 
PLEC_HUMAN Plectin 
ATPB_HUMAN 
ATP synthase subunit beta, 
mitochondrial 
PLEK_HUMAN Pleckstrin 
ATPO_HUMAN ATP synthase subunit O, mitochondrial PLF4_HUMAN Platelet factor 4 
B2MG_HUMAN Beta-2-microglobulin PLSL_HUMAN Plastin-2 
BAX_HUMAN Apoptosis regulator BAX PNCB_HUMAN 
Nicotinate 
phosphoribosyltransferase 
BIN2_HUMAN Bridging integrator 2 PNPH_HUMAN Purine nucleoside phosphorylase 
C1QBP_HUMAN 
Complement component 1 Q 
subcomponent-binding protein, 
mitochondrial 
PP1A_HUMAN 
Serine/threonine-protein 
phosphatase PP1-alpha catalytic 
subunit 
C1TC_HUMAN 
C-1-tetrahydrofolate synthase, 
cytoplasmic 
PP1R7_HUMAN 
Protein phosphatase 1 regulatory 
subunit 7 
CAB39_HUMAN Calcium-binding protein 39 PPIA_HUMAN 
Peptidyl-prolyl cis-trans 
isomerase A 
CAH2_HUMAN Carbonic anhydrase 2 PPIB_HUMAN 
Peptidyl-prolyl cis-trans 
isomerase B 
CALD1_HUMAN Caldesmon PRAF3_HUMAN PRA1 family protein 3 
CALR_HUMAN Calreticulin PRDX1_HUMAN Peroxiredoxin-1 
CALX_HUMAN Calnexin PRDX2_HUMAN Peroxiredoxin-2 
CAN1_HUMAN Calpain-1 catalytic subunit PRDX3_HUMAN 
Thioredoxin-dependent peroxide 
reductase, mitochondrial 
CAN2_HUMAN Calpain-2 catalytic subunit PRDX5_HUMAN Peroxiredoxin-5, mitochondrial 
CAND1_HUMAN 
Cullin-associated NEDD8-dissociated 
protein 1 
PRDX6_HUMAN Peroxiredoxin-6 
CAP1_HUMAN Adenylyl cyclase-associated protein 1 PROF1_HUMAN Profilin-1 
CAPG_HUMAN Macrophage-capping protein PRTN3_HUMAN Myeloblastin 
CAPZB_HUMAN F-actin-capping protein subunit beta PSA_HUMAN 
Puromycin-sensitive 
aminopeptidase 
CATA_HUMAN Catalase PSA4_HUMAN Proteasome subunit alpha type-4 
CATD_HUMAN Cathepsin D PSA6_HUMAN Proteasome subunit alpha type-6 
CAZA1_HUMAN 
F-actin-capping protein subunit alpha-
1 
PSA7_HUMAN Proteasome subunit alpha type-7 
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CAZA2_HUMAN 
F-actin-capping protein subunit alpha-
2 
PSB1_HUMAN Proteasome subunit beta type-1 
CCL5_HUMAN C-C motif chemokine 5 PSB2_HUMAN Proteasome subunit beta type-2 
CD14_HUMAN 
Monocyte differentiation antigen 
CD14 
PSB3_HUMAN Proteasome subunit beta type-3 
CD36_HUMAN Platelet glycoprotein 4 PSB8_HUMAN Proteasome subunit beta type-8 
CD9_HUMAN CD9 antigen PSMD1_HUMAN 
26S proteasome non-ATPase 
regulatory subunit 1 
CDC42_HUMAN 
Cell division control protein 42 
homolog 
PSMD5_HUMAN 
26S proteasome non-ATPase 
regulatory subunit 5 
CH10_HUMAN 
10 kDa heat shock protein, 
mitochondrial 
PSME1_HUMAN 
Proteasome activator complex 
subunit 1 
CH60_HUMAN 
60 kDa heat shock protein, 
mitochondrial 
PSME2_HUMAN 
Proteasome activator complex 
subunit 2 
CISY_HUMAN Citrate synthase, mitochondrial PTBP1_HUMAN 
Polypyrimidine tract-binding 
protein 1 
CLH1_HUMAN Clathrin heavy chain 1 PTCA_HUMAN 
Protein tyrosine phosphatase 
receptor type C-associated 
protein 
CLIC1_HUMAN 
Chloride intracellular channel protein 
1 
PTN6_HUMAN 
Tyrosine-protein phosphatase 
non-receptor type 6 
CNDP2_HUMAN Cytosolic non-specific dipeptidase PTPRC_HUMAN 
Receptor-type tyrosine-protein 
phosphatase C 
CNN2_HUMAN Calponin-2 PUR9_HUMAN 
Bifunctional purine biosynthesis 
protein PURH 
COF1_HUMAN Cofilin-1 PYGB_HUMAN 
Glycogen phosphorylase, brain 
form 
COPB_HUMAN Coatomer subunit beta QCR1_HUMAN 
Cytochrome b-c1 complex 
subunit 1, mitochondrial 
COR1A_HUMAN Coronin-1A QCR2_HUMAN 
Cytochrome b-c1 complex 
subunit 2, mitochondrial 
COR1C_HUMAN Coronin-1C RAB14_HUMAN Ras-related protein Rab-14 
COTL1_HUMAN Coactosin-like protein RAB1B_HUMAN Ras-related protein Rab-1B 
COX2_HUMAN Cytochrome c oxidase subunit 2 RAB6B_HUMAN Ras-related protein Rab-6B 
COX41_HUMAN 
Cytochrome c oxidase subunit 4 
isoform 1, mitochondrial 
RAB7A_HUMAN Ras-related protein Rab-7a 
CPNS1_HUMAN Calpain small subunit 1 RALB_HUMAN Ras-related protein Ral-B 
CSK_HUMAN Tyrosine-protein kinase CSK RAN_HUMAN GTP-binding nuclear protein Ran 
CXCL7_HUMAN Platelet basic protein RAP1B_HUMAN Ras-related protein Rap-1b 
CYC_HUMAN Cytochrome c RB11B_HUMAN Ras-related protein Rab-11B 
DBNL_HUMAN Drebrin-like protein RB27B_HUMAN Ras-related protein Rab-27B 
DDX17_HUMAN 
Probable ATP-dependent RNA helicase 
DDX17 
RBBP7_HUMAN Histone-binding protein RBBP7 
DDX3Y_HUMAN ATP-dependent RNA helicase DDX3Y RHG01_HUMAN Rho GTPase-activating protein 1 
DHE3_HUMAN 
Glutamate dehydrogenase 1, 
mitochondrial 
RHG18_HUMAN Rho GTPase-activating protein 18 
DHX9_HUMAN ATP-dependent RNA helicase A RHOA_HUMAN Transforming protein RhoA 
DIAP1_HUMAN Protein diaphanous homolog 1 RINI_HUMAN Ribonuclease inhibitor 
DJB11_HUMAN DnaJ homolog subfamily B member 11 RL11_HUMAN 60S ribosomal protein L11 
DNM1L_HUMAN Dynamin-1-like protein RL12_HUMAN 60S ribosomal protein L12 
DPYL2_HUMAN Dihydropyrimidinase-related protein 2 RL17_HUMAN 60S ribosomal protein L17 
DX39B_HUMAN Spliceosome RNA helicase DDX39B RL18_HUMAN 60S ribosomal protein L18 
DYN2_HUMAN Dynamin-2 RL24_HUMAN 60S ribosomal protein L24 
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EDEM1_HUMAN 
ER degradation-enhancing alpha-
mannosidase-like protein 1 
RL6_HUMAN 60S ribosomal protein L6 
EF1A3_HUMAN 
Putative elongation factor 1-alpha-like 
3 
RL7_HUMAN 60S ribosomal protein L7 
EF1D_HUMAN Elongation factor 1-delta RL8_HUMAN 60S ribosomal protein L8 
EF1G_HUMAN Elongation factor 1-gamma RLA0_HUMAN 60S acidic ribosomal protein P0 
EF2_HUMAN Elongation factor 2 ROA1_HUMAN 
Heterogeneous nuclear 
ribonucleoprotein A1 
EFHD2_HUMAN EF-hand domain-containing protein D2 ROA2_HUMAN 
Heterogeneous nuclear 
ribonucleoproteins A2/B1 
EHD1_HUMAN EH domain-containing protein 1 ROA3_HUMAN 
Heterogeneous nuclear 
ribonucleoprotein A3 
EHD3_HUMAN EH domain-containing protein 3 RS10_HUMAN 40S ribosomal protein S10 
EIF3C_HUMAN 
Eukaryotic translation initiation factor 
3 subunit C 
RS13_HUMAN 40S ribosomal protein S13 
ENOA_HUMAN Alpha-enolase RS14_HUMAN 40S ribosomal protein S14 
ENPL_HUMAN Endoplasmin RS15A_HUMAN 40S ribosomal protein S15a 
ESYT1_HUMAN Extended synaptotagmin-1 RS18_HUMAN 40S ribosomal protein S18 
ETFB_HUMAN 
Electron transfer flavoprotein subunit 
beta 
RS19_HUMAN 40S ribosomal protein S19 
EZRI_HUMAN Ezrin RS20_HUMAN 40S ribosomal protein S20 
F13A_HUMAN Coagulation factor XIII A chain RS25_HUMAN 40S ribosomal protein S25 
FA49B_HUMAN Protein FAM49B RS27A_HUMAN 
Ubiquitin-40S ribosomal protein 
S27a 
FA5_HUMAN Coagulation factor V RS3A_HUMAN 40S ribosomal protein S3a 
FCN1_HUMAN Ficolin-1 RS4X_HUMAN 
40S ribosomal protein S4, X 
isoform 
FIBA_HUMAN Fibrinogen alpha chain RSSA_HUMAN 40S ribosomal protein SA 
FIBB_HUMAN Fibrinogen beta chain RSU1_HUMAN Ras suppressor protein 1 
FIBG_HUMAN Fibrinogen gamma chain RTN4_HUMAN Reticulon-4 
FKB1A_HUMAN 
Peptidyl-prolyl cis-trans isomerase 
FKBP1A 
RUXE_HUMAN Small nuclear ribonucleoprotein E 
FLNA_HUMAN Filamin-A S10A4_HUMAN Protein S100-A4 
G3P_HUMAN 
Glyceraldehyde-3-phosphate 
dehydrogenase 
S10A8_HUMAN Protein S100-A8 
G6PD_HUMAN 
Glucose-6-phosphate 1-
dehydrogenase 
S10A9_HUMAN Protein S100-A9 
G6PI_HUMAN Glucose-6-phosphate isomerase SAMH1_HUMAN 
Deoxynucleoside triphosphate 
triphosphohydrolase SAMHD1 
GANAB_HUMAN Neutral alpha-glucosidase AB SAR1A_HUMAN GTP-binding protein SAR1a 
GBB1_HUMAN Guanine nucleotide-binding protein G SC22B_HUMAN Vesicle-trafficking protein SEC22b 
GBLP_HUMAN 
Guanine nucleotide-binding protein 
subunit beta-2-like 1 
SDPR_HUMAN 
Serum deprivation-response 
protein 
GBP1_HUMAN 
Interferon-induced guanylate-binding 
protein 1 
SEPT6_HUMAN Septin-6 
GDIB_HUMAN Rab GDP dissociation inhibitor beta SEPT7_HUMAN Septin-7 
GDIR1_HUMAN Rho GDP-dissociation inhibitor 1 SEPT9_HUMAN Septin-9 
GDIR2_HUMAN Rho GDP-dissociation inhibitor 2 SET_HUMAN Protein SET 
GELS_HUMAN Gelsolin SH3L2_HUMAN 
SH3 domain-binding glutamic 
acid-rich-like protein 2 
GIMA1_HUMAN GTPase IMAP family member 1 SH3L3_HUMAN 
SH3 domain-binding glutamic 
acid-rich-like protein 3 
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GMFG_HUMAN Glia maturation factor gamma SKAP2_HUMAN 
Src kinase-associated 
phosphoprotein 2 
GNAI2_HUMAN Guanine nucleotide-binding protein G SMD2_HUMAN 
Small nuclear ribonucleoprotein 
Sm D2 
GP1BA_HUMAN Platelet glycoprotein Ib alpha chain SMD3_HUMAN 
Small nuclear ribonucleoprotein 
Sm D3 
GP1BB_HUMAN Platelet glycoprotein Ib beta chain SNP23_HUMAN 
Synaptosomal-associated protein 
23 
GPDM_HUMAN 
Glycerol-3-phosphate dehydrogenase, 
mitochondrial 
SODM_HUMAN Superoxide dismutase 
GPIX_HUMAN Platelet glycoprotein IX SPB6_HUMAN Serpin B6 
GPV_HUMAN Platelet glycoprotein V SPB9_HUMAN Serpin B9 
GPX1_HUMAN Glutathione peroxidase 1 SPRC_HUMAN SPARC 
GRAN_HUMAN Grancalcin SPTB1_HUMAN Spectrin beta chain, erythrocytic 
GRP75_HUMAN Stress-70 protein, mitochondrial SQRD_HUMAN 
Sulfide:quinone oxidoreductase, 
mitochondrial 
GRP78_HUMAN 78 kDa glucose-regulated protein SRC_HUMAN 
Proto-oncogene tyrosine-protein 
kinase Src 
GSHR_HUMAN Glutathione reductase, mitochondrial SRC8_HUMAN Src substrate cortactin 
GSTK1_HUMAN Glutathione S-transferase kappa 1 SRP14_HUMAN 
Signal recognition particle 14 kDa 
protein 
GSTO1_HUMAN Glutathione S-transferase omega-1 SRSF2_HUMAN 
Serine/arginine-rich splicing 
factor 2 
GSTP1_HUMAN Glutathione S-transferase P SRSF7_HUMAN 
Serine/arginine-rich splicing 
factor 7 
GTR14_HUMAN 
Solute carrier family 2, facilitated 
glucose transporter member 14 
ST134_HUMAN Putative protein FAM10A4 
H12_HUMAN Histone H1.2 ST1A4_HUMAN Sulfotransferase 1A4 
H15_HUMAN Histone H1.5 STIP1_HUMAN Stress-induced-phosphoprotein 1 
H2A2B_HUMAN Histone H2A type 2-B STK4_HUMAN 
Serine/threonine-protein kinase 
4 
H2AV_HUMAN Histone H2A.V STOM_HUMAN 
Erythrocyte band 7 integral 
membrane protein 
H2AY_HUMAN Core histone macro-H2A.1 STX7_HUMAN Syntaxin-7 
H2B1C_HUMAN Histone H2B type 1-C/E/F/G/I STXB2_HUMAN Syntaxin-binding protein 2 
H2B2D_HUMAN Putative histone H2B type 2-D SYHC_HUMAN 
Histidine--tRNA ligase, 
cytoplasmic 
H31_HUMAN Histone H3.1 SYSC_HUMAN Serine--tRNA ligase, cytoplasmic 
H4_HUMAN Histone H4 SYUA_HUMAN Alpha-synuclein 
HBA_HUMAN Hemoglobin subunit alpha TAGL2_HUMAN Transgelin-2 
HBB_HUMAN Hemoglobin subunit beta TALDO_HUMAN Transaldolase 
HCD2_HUMAN 
3-hydroxyacyl-CoA dehydrogenase 
type-2 
TBA1A_HUMAN Tubulin alpha-1A chain 
HEM2_HUMAN Delta-aminolevulinic acid dehydratase TBA4A_HUMAN Tubulin alpha-4A chain 
HMGB1_HUMAN High mobility group protein B1 TBA8_HUMAN Tubulin alpha-8 chain 
HMGB2_HUMAN High mobility group protein B2 TBB1_HUMAN Tubulin beta-1 chain 
HMHA1_HUMAN Minor histocompatibility protein HA-1 TBB4B_HUMAN Tubulin beta-4B chain 
HNRL2_HUMAN 
Heterogeneous nuclear 
ribonucleoprotein U-like protein 2 
TBB5_HUMAN Tubulin beta chain 
HNRPC_HUMAN 
Heterogeneous nuclear 
ribonucleoproteins C1/C2 
TCP4_HUMAN 
Activated RNA polymerase II 
transcriptional coactivator p15 
HNRPD_HUMAN 
Heterogeneous nuclear 
ribonucleoprotein D0 
TCPA_HUMAN 
T-complex protein 1 subunit 
alpha 
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HNRPK_HUMAN 
Heterogeneous nuclear 
ribonucleoprotein K 
TCPB_HUMAN T-complex protein 1 subunit beta 
HNRPM_HUMAN 
Heterogeneous nuclear 
ribonucleoprotein M 
TCPD_HUMAN T-complex protein 1 subunit delta 
HNRPU_HUMAN 
Heterogeneous nuclear 
ribonucleoprotein U 
TCPE_HUMAN 
T-complex protein 1 subunit 
epsilon 
HP1B3_HUMAN 
Heterochromatin protein 1-binding 
protein 3 
TCPG_HUMAN 
T-complex protein 1 subunit 
gamma 
HPRT_HUMAN 
Hypoxanthine-guanine 
phosphoribosyltransferase 
TCPH_HUMAN T-complex protein 1 subunit eta 
HPT_HUMAN Haptoglobin TCPQ_HUMAN 
T-complex protein 1 subunit 
theta 
HS90A_HUMAN Heat shock protein HSP 90-alpha TCPZ_HUMAN T-complex protein 1 subunit zeta 
HS90B_HUMAN Heat shock protein HSP 90-beta TERA_HUMAN 
Transitional endoplasmic 
reticulum ATPase 
HSP71_HUMAN Demerged into P0DMV8 and P0DMV9. TGFB1_HUMAN 
Transforming growth factor beta-
1 
HSP7C_HUMAN Heat shock cognate 71 kDa protein TGFI1_HUMAN 
Transforming growth factor beta-
1-induced transcript 1 protein 
HSPB1_HUMAN Heat shock protein beta-1 THAS_HUMAN Thromboxane-A synthase 
HXK1_HUMAN Hexokinase-1 THIM_HUMAN 
3-ketoacyl-CoA thiolase, 
mitochondrial 
IDHP_HUMAN Isocitrate dehydrogenase TIMP1_HUMAN Metalloproteinase inhibitor 1 
IGHG1_HUMAN Ig gamma-1 chain C region TKT_HUMAN Transketolase 
IGHG2_HUMAN Ig gamma-2 chain C region TLN1_HUMAN Talin-1 
IGKC_HUMAN Ig kappa chain C region TM109_HUMAN Transmembrane protein 109 
IL16_HUMAN Pro-interleukin-16 TMOD3_HUMAN Tropomodulin-3 
ILEU_HUMAN Leukocyte elastase inhibitor TPIS_HUMAN Triosephosphate isomerase 
ILF2_HUMAN Interleukin enhancer-binding factor 2 TPM1_HUMAN Tropomyosin alpha-1 chain 
ILK_HUMAN Integrin-linked protein kinase TPM3_HUMAN Tropomyosin alpha-3 chain 
IMA3_HUMAN Importin subunit alpha-3 TPM4_HUMAN Tropomyosin alpha-4 chain 
IMB1_HUMAN Importin subunit beta-1 TRFE_HUMAN Serotransferrin 
INF2_HUMAN Inverted formin-2 TSP1_HUMAN Thrombospondin-1 
IQGA1_HUMAN 
Ras GTPase-activating-like protein 
IQGAP1 
TWF2_HUMAN Twinfilin-2 
ITA2B_HUMAN Integrin alpha-IIb TXND5_HUMAN 
Thioredoxin domain-containing 
protein 5 
ITA6_HUMAN Integrin alpha-6 TYPH_HUMAN Thymidine phosphorylase 
ITB1_HUMAN Integrin beta-1 U2AF2_HUMAN 
Splicing factor U2AF 65 kDa 
subunit 
ITB2_HUMAN Integrin beta-2 UB2V1_HUMAN 
Ubiquitin-conjugating enzyme E2 
variant 1 
ITB3_HUMAN Integrin beta-3 UBA1_HUMAN 
Ubiquitin-like modifier-activating 
enzyme 1 
JAM1_HUMAN Junctional adhesion molecule A UBE2N_HUMAN 
Ubiquitin-conjugating enzyme E2 
N 
K1C10_HUMAN Keratin, type I cytoskeletal 10 UBP5_HUMAN 
Ubiquitin carboxyl-terminal 
hydrolase 5 
K1C9_HUMAN Keratin, type I cytoskeletal 9 UN13D_HUMAN Protein unc-13 homolog D 
K22E_HUMAN 
Keratin, type II cytoskeletal 2 
epidermal 
URP2_HUMAN Fermitin family homolog 3 
K2C1_HUMAN Keratin, type II cytoskeletal 1 USO1_HUMAN 
General vesicular transport factor 
p115 
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KAD2_HUMAN Adenylate kinase 2, mitochondrial VASP_HUMAN 
Vasodilator-stimulated 
phosphoprotein 
KAP0_HUMAN 
cAMP-dependent protein kinase type 
I-alpha regulatory subunit 
VATA_HUMAN 
V-type proton ATPase catalytic 
subunit A 
KCC1A_HUMAN 
Calcium/calmodulin-dependent 
protein kinase type 1 
VATE1_HUMAN V-type proton ATPase subunit E 1 
KPYM_HUMAN Pyruvate kinase PKM VDAC1_HUMAN 
Voltage-dependent anion-
selective channel protein 1 
LAP2B_HUMAN 
Lamina-associated polypeptide 2, 
isoforms beta/gamma 
VDAC2_HUMAN 
Voltage-dependent anion-
selective channel protein 2 
LASP1_HUMAN LIM and SH3 domain protein 1 VDAC3_HUMAN 
Voltage-dependent anion-
selective channel protein 3 
LCP2_HUMAN Lymphocyte cytosolic protein 2 VIME_HUMAN Vimentin 
LDHA_HUMAN L-lactate dehydrogenase A chain VINC_HUMAN Vinculin 
LDHB_HUMAN L-lactate dehydrogenase B chain VPS35_HUMAN 
Vacuolar protein sorting-
associated protein 35 
LEG1_HUMAN Galectin-1 VTNC_HUMAN Vitronectin 
LEGL_HUMAN Galectin-related protein VWF_HUMAN von Willebrand factor 
LGUL_HUMAN Lactoylglutathione lyase WDR1_HUMAN WD repeat-containing protein 1 
LIMS1_HUMAN 
LIM and senescent cell antigen-like-
containing domain protein 1 
XRCC5_HUMAN 
X-ray repair cross-
complementing protein 5 
LMNB1_HUMAN Lamin-B1 XRCC6_HUMAN 
X-ray repair cross-
complementing protein 6 
LMNB2_HUMAN Lamin-B2 ZAP70_HUMAN Tyrosine-protein kinase ZAP-70 
LTBP1_HUMAN 
Latent-transforming growth factor 
beta-binding protein 1 
ZYX_HUMAN Zyxin 
LY66F_HUMAN 
Lymphocyte antigen 6 complex locus 
protein G6f 
  
Supplementary Table VII.8. Cell count of PBMCs samples from six healthy individuals. 
Cells #1 #2 #3 #4 #5 #6 
WBC 8.5 11.9 13.6 8.6 5.8 16.1 
RBC 0.01 0.02 0.02 0.01 0.01 0.04 
WBC are presented in millions of cells per mL; RBC are presented in millions of cells per µL; RBC = red blood cells; WBC 
= white blood cells; #1, #2, #3, #4, #5, #6 = biological samples of the six different donors. 
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Supplementary Figure VII.1. KEGG atlas mapping of metabolic pathways of PBMCs. (A) Global view of all metabolic 
pathways where PBMCs proteins are involved in (blue). (B), (C), (D), (E), (F), (G), and (H) display diverse immune-system 
pathways. The identified proteins are highlighted in dark grey boxes. 
 
Complement and coagulation cascades 
Chemokine signaling pathway H 
G 
